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It's the neoplastic lesions 
which are called the adenomas 
They're the ones that have the risk 
of going on to carcinoma. 
 
Now these chances are related 
to their number, size and site 
Their degree of cell dysplasia 
and their histologic type. 
 
In the stomach in the colon 
duodenum and the rectum 
They are tubular or villous 
or a mixture of this spectrum. 
 
Adenomas by the hundred 
mean familial polyposis 
A colectomy will help prevent 
a carcinomatosis. 
 
 
 
Tales of the Ampulla of Vater, 
 Leslie H. Sobin, M.D. 1994  
 
 
 
 
 
 
 
 
 Contents 
 
 
Chapter 1 Introduction.         9
    
Chapter 2 Detoxification enzymes in the duodenal mucosa     
of patients with familial adenomatous polyposis.   27 
 
Chapter 3 Polymorphisms in detoxification enzymes are not involved  
in duodenal adenomatosis in patients with familial  
adenomatous polyposis.       41 
 
Chapter 4 Loss of extracellular E-cadherin in the normal mucosa of   
duodenum and colon of patients with familial adenomatous  
polyposis.         65 
 
Chapter 5 Chromosomal and methylation alterations in sporadic and   
 familial adenomatous polyposis-related duodenal carcinomas.  91 
 
Chapter 6 Ursodeoxycholic acid intervention in patients with     
familial adenomatous polyposis: a pilot study.    117 
 
Summary           139 
Samenvatting                                                                                                          147 
Dankwoord           155 
List of publications                                                                                                  159 
Colour figures                                                                                                         163 
 
  
 
 
Chapter 1 
 
 
 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 Introduction 
 
 10 
Familial adenomatous polyposis 
Familial adenomatous polyposis (FAP) is an autosomal dominant disorder 
caused by germline mutations in the tumour suppressor gene adenomatous 
polyposis coli (APC) 1. Patients develop hundreds to thousands of colorectal 
adenomas during the second and third decade of life. The risk of colorectal 
cancer at the age of 40-50 years is almost 100 per cent unless prophylactic 
colectomy is performed. The incidence of FAP is estimated at birth to be 
approximately one in 10,000 2. In about 10% of the patients, the disease is 
less severe with < 100 colorectal adenomas and a later onset of the disease. 
This variant is called attenuated FAP (AFAP) 3. In addition to colorectal 
adenomas, several extra-colonic manifestations are observed, including 
desmoid tumours, osteomas, dental abnormalities, congenital hypertrophy of 
the retinal epithelium, lipomas, epidermoid cysts and upper gastrointestinal 
adenomas 4.  
 
Adenomatous polyposis coli gene 
In 1987, the adenomatous polyposis coli (APC) gene was identified and found 
to have mutated in patients with FAP 1. This gene is located on chromosome 
5q21-22 and the coding region of this gene consists of 15 exons, encoding a 
protein of 2,842 amino acids. This large gene has a tumour suppressor 
function. The germline mutations found in patients with FAP often lead to a 
truncated non-functional protein 5. The APC protein has a broad spectrum of 
functions, ranging from affecting cell adhesion and migration, to apoptosis, 
chromosomal segregation at mitosis and control of the Wnt signal transduction 
pathway. The Wnt signalling pathway regulates the phosphorylation and 
degradation of -catenin 6.  β-catenin is a bi-functional protein which has a 
crucial role in cell-cell adhesion 7 and in the Wnt signalling pathway 8. Loss of 
functional APC in tumourigenesis deregulates the signalling properties of β-
catenin leading to cytosolic accumulation and nuclear translocation of the 
protein. In the nucleus, it activates transcriptional targets such as c-MYC 9 and 
cyclin D1 10. In cell adhesion, β-catenin is crucial to the normal functioning of 
E-cadherin 11. Inactivation of APC function seems to underlie both tumour 
initiation and promotion 12. In 30-50% of patients with FAP or AFAP, no 
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germline mutation is detected 13, 14. However, 10-30% of these patients have a 
mutation in the MYH gene, another recently identified polyposis gene. 
Mutations in this gene cause a recessive form of colonic polyposis 15.  
 
Genotype-phenotype correlation 
The site of the APC mutations can be associated with the severity of the 
colonic phenotype. In the attenuated phenotype (< 100 colorectal adenomas), 
the mutations are found before codon 157, after codon 1595 and in the 
alternative spliced region of exon 9. The phenotypes with severe polyposis (> 
1000 colorectal adenomas) are associated with mutations between the codons 
1250 to 1464. An intermediate phenotype (100 – 1000 adenomas) is linked to 
the rest of the gene. Upper gastrointestinal tumours are seen both in patients 
with FAP as well as those with AFAP and several locations at the APC gene 
have been related to the development of duodenal adenomas. However, no 
large study has been performed to establish an association between germline 
APC genotype and the severity of duodenal polyposis 16.   
 
 Figure 1: The localisation of mutations in the APC gene are associated with the colonic 
phenotype and several locations have been related to duodenal adenomas.   
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Duodenal adenomas and carcinomas 
As early as 1904, duodenal adenomas were reported by Funkestein 17 and the 
first published report of an FAP-related duodenal carcinoma appeared in 1935 
18
. Duodenal adenomas are observed in 50-90% of patients with FAP 19-21. 
Duodenal adenomatosis can be graded according to Spigelman stage, which 
is a semi-quantitive scoring system, expressing the severity of duodenal 
polyposis according to number, size, histology and degree of dysplasia of the 
duodenal lesions (Table 1) 22.  
 
 
 
 
 
 
 
 
 
 
 
 
 
The Spigelman stage increases with age, probably due to the increasing 
number and size of adenomas 23. The duodenal adenomas are most often 
located around the ampulla of Vater. As a consequence of the localisation of 
these adenomas, the risk of pancreatitis seems higher in patients with FAP 24. 
Furthermore, the clustering of the duodenal adenomas around the ampulla of 
Vater suggests that bile plays a role in the formation and/or progression of 
these adenomas.  
 
The progression of duodenal adenomatosis is slow in patients with early 
disease 23, 25-27. In two large studies, no malignant progression was present 
after 10 years in patients with Spigelman stage 0 or I duodenal adenomatosis 
23, 26
. The cumulative incidence of malignancy in patients with Spigelman IV is 
estimated at between 7% 23 and 36% 26. In patients surviving to the age of 75, 
Table 1:  Spigelman stage represents the severity in duodenal polyposis. 
     
 
Category 
 
 
1 
Points 
2 
 
 
3 
 
Number of adenomas                                        
 
1-4
 
5-20 
 
> 20 
Size of adenomas (mm)                                    1-4 5-10 > 20 
Histology            Tubular Tubulovillous Villous 
Degree of dysplasia                                          Mild Moderate Severe 
 
Within each category, 1 to 3 points can be scored, and the sum of the score in the 4 categories results in the  
Spigelman stage. Stage 0, 0 points; Stage I, 1-4 points; Stage II, 5-6 points; Stage III, 7-8 points; Stage IV, 9-12  
points.                                                                        
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between 20-52% are likely to have developed Spigelman IV duodenal 
adenomatosis with an estimated cumulative incidence of duodenal carcinoma 
between 4 and 10% 23, 28, 29. In general, duodenal carcinomas will develop in 
only 2-5% of the patients with FAP 19, 23, 26, 30 and their postoperative outcome 
is poor 31. Considering the natural course of duodenal adenomatosis in 
patients with FAP, strategies for each Spigelman stage are summarised in 
Table 2 32.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Developmental aspects of duodenal adenomas and carcinomas 
In comparison to colorectal and gastric cancer, little is known about the 
carcinogenesis of the small intestine. In the small intestine, the most frequent 
site for the development of adenocarcinomas is the duodenum (± 50%), 
followed by the jejunum (± 25%) and the ileum (± 13%), whereas the 
localisation of the rest of the tumours is not specified 33-35. The duodenum is 
also the main site for malignant extra-colonic manifestations in patients with 
FAP. Thus far, only a few reports have been published with regard to the 
Table 2: Recommended strategies in the managment of duodenal adenomatosis in patients 
 with FAP, according to their Spigelman stage. 
 
 
Spigelman 
Stage 
 
 
Strategy 
 
0 
 
Side-viewing endoscopy including biopsy at intervals of 5 years. 
 
I Side-viewing endoscopy including biopsy at intervals of 5 years. 
 
II Side-viewing endoscopy including biopsy at intervals of 2-3 
years. 
 
III Side-viewing endoscopy including biopsies at intervals of 1-2 years, 
chemoprevention with celecoxib and possibly endoscopic therapy. 
 
IV Pre-operative imaging, referral for consideration for prophylactic  
pylorus preserving pancreaticoduodenectomy, continued 
chemoprevention and surveillance and endoscopic resection in 
inoperable cases. 
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underlying mechanism of the development of adenomas and carcinomas in 
the duodenum of patients with FAP. Figure 2 summarises the publications 
describing abnormalities and possible mechanisms leading to the 
development of adenomas and carcinomas in the duodenum of patients with 
FAP. 
 
Figure 2: Abnormalities observed in the normal duodenum, duodenal adenomas or duodenal 
carcinomas in patients with FAP. 
 
 
 
 
 
 
 
 
 
In the normal duodenal mucosa of patients with FAP, several cellular 
abnormalities have been described; higher proliferation index 36, 37, increased 
expression of cyclooxgenase-2 (COX-2) 38, telomerase activity (43%) 39, 
increased number of Paneth and endocrine cells in the crypts 40. In addition, in 
this thesis loss of extracellular E-cadherin is also described 41. In duodenal 
adenomas of patients with FAP, somatic APC mutations are observed in 5%, 
22% and 67% of the adenomas 42, 43. K-ras mutations have been observed in 
7% and 33% of the duodenal adenomas of patients with FAP 42, 44. 
Telomerase activity (63%) 39 was also observed in the adenoma stage, as was 
overexpression of p53 45. In this thesis both loss of extracellular E-cadherin 
and SMAD4 was demonstrated in duodenal adenomas 41. In addition, 
expression of transforming growth factor-alpha (TGF-alpha, 100%) 46 and 
epidermal growth factor receptor (EGF-R, 63%) expression 47 have also been 
described in duodenal adenomas of patients with FAP. In duodenal 
carcinomas, overexpression of p53 45 was seen and K-ras mutations were 
detected in 12.5% of the ampullary carcinomas 44. In analogy with the 
adenoma stage, TGF-alpha (100%) and EGF expression (67%) 46 was also 
Duodenal adenomas Duodenal carcinomasNormal duodenum
Proliferation
Cyclooxygenase 2
Telomerase activity 
Paneth & endocrine cells
Somatic APC mutations 
K-ras mutations 
P53    in severity of adenomas
Telomerase activity 
TGF-alpha and EGF-R expression 
EGF immunoreactivity in Paneth cells
K-ras mutations
P53 overexpression  
TGF-alpha and EGF-R expression
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seen in the duodenal carcinomas. In Chapter 5 of this thesis, a comparison of 
chromosomal abnormalities and alterations in methylation of DNA is made 
between sporadic and FAP-related duodenal carcinomas. This comparison 
shows similarities as well as differences between duodenal tumours of 
hereditary and non-hereditary origin. 
 
Bile acids 
Since the duodenal adenomas in patients with FAP are mostly clustered 
around the ampulla of Vater, it has been suggested that bile acids may play a 
role in their initiation and/or progression. Primary bile acids are synthesised in 
the liver and are excreted into the gall bladder, from which they are released 
into the small intestine after stimulation of the gall bladder. Bile acids are then 
re-absorbed in the terminal ileum and only approximately 5% of the bile acid 
pool enters the large intestine. Bacteria in the large intestine are responsible 
for the transformation of primary bile acids into secondary bile acids. The 
secondary bile acids specifically are known tumour promoters in the 
gastrointestinal tract 48-50. 
 
There is some evidence for an excess of DNA adducts (chemical modifications 
of DNA, that are implicated in the initiation of carcinogenesis) in the bile of 
patients with FAP 51-53. The levels of DNA adducts seem to be pH dependent, 
indicating that a therapy increasing the duodenal pH may reduce damage of 
DNA caused by bile 54. The findings that patients with FAP showing gastric 
adenomas have more severe reflux, may confirm the role of bile in 
adenomatosis 55. Additionally, dysplasia is observed in the gall bladder of 
patients with FAP 56.  
 
Biotransformation enzymes 
The detoxification enzyme families, glutathione S-transferases (GSTs) and 
UDP-glucuronosyltransferases (UGTs), play an important role in the mucosal 
protection against potential toxins, mutagens or carcinogens. These enzyme 
families are responsible for the metabolism and excretion of many toxic, 
mutagenic or carcinogenic compounds, both of exogenous and endogenous 
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sources. UGTs catalyse the conjugation of mainly lipophilic compounds with 
glucuronic acid, while GSTs catalyse conjugation with glutathione of 
electrophiles and products of oxidative stress 57-59. In general, the conjugates 
are more water soluble and less biologically active, and can be readily 
excreted. A significant inverse correlation between GST or UGT activity in the 
normal mucosa of the gastrointestinal tract and the corresponding tumour 
incidence has been observed 60, suggesting an important role for these 
enzymes in cancer prevention.  
 
The human GSTs are a family of cytosolic enzymes, compried of four main 
classes: alpha, pi, mu and theta, each consisting of one or more isoforms 57. 
The expression of the GSTs isoforms differs in the various tissues and large 
inter-individual differences in tissue levels have been reported 60-62. The 
human UGTs are localised in the endoplasmic reticulum and are divided into 
the UGT1 and UGT2 subfamilies, consisting of 9 and 7 functional genes, 
respectively 63, 64. Several UGT isoforms may be expressed in the duodenum 
as well as in the colon 65, 66, however the UGT enzyme activity in the 
duodenum was reported to be much higher compared to that of the colon 67.  
 
In patients with FAP, a significantly lower GST activity was observed in the 
colonic mucosa as compared to healthy controls 68 . Furthermore, Spigelman 
et al. 69 reported lower GST mu levels in the blood of patients with FAP 
compared to controls. In addition, by phenotyping with caffeine 70 or 
genotyping 71, lower N-acetyltransferase (generally inactivating carcinogens) 
and higher cytochrome P-450 (generally activating carcinogens) enzyme 
activity was demonstrated in patients with FAP when compared to controls. 
Functional polymorphisms in the genes of detoxification enzymes may result in 
enzymes with reduced activity, or even in a complete absence of enzyme 
activity 72, 73. Therefore, such functional polymorphisms could potentially 
modulate individual susceptibility for the development of duodenal adenomas 
and carcinomas in patients with FAP.  
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Chemoprevention 
Several studies have been performed in regard to chemoprevention of 
duodenal adenomatosis in patients with FAP. Reduction of duodenal 
proliferation was observed after administration of the non-selective 
cyclooxygenase inhibitor sulindac 74. However, Richard et al. 75 found no effect 
of sulindac on the reduction of ampullary adenomas, whereas Debinski et al. 
76
 only found an effect in small adenomas. By video endoscopic scoring, a 
statistically significant reduction of duodenal adenomatis was observed after 6 
month’s administration of 2x400 mg daily of the selective cyclooxygenase–2 
inhibitor celecoxib 77. In addition, celecoxib showed a significant reduction of 
colorectal adenomas, with concomittant change in relevant biomarkers in 
patients with FAP 78. Gastric acid lowering therapy with ranitidine 79 or 
administration of calcium with calciferol 80 were not found to be effective in the 
reduction of duodenal adenomatosis. Recently, a reduction in the number and 
size of ileal adenomas was found after the combination of curcumin and 
quercetin 81. Promising gene therapy, in which normal copies of the APC gene 
are supplied to the duodenum, has only been described in vivo 82. 
 
Outline and objectives of this thesis 
Duodenal carcinomas and desmoid tumours are now the leading causes of 
cancer–related mortality in patients with FAP. Therefore, the treatment of 
duodenal adenomas in patients with FAP is a clinical challenge. Since both the 
incidence and severity of the duodenal adenomatosis increase with age, and 
due to the colectomy the FAP population is aging, the problems with respect to 
the development of duodenal adenomas and malignancies will increase. So 
far, the treatment of duodenal adenomas in FAP has been mainly restricted to 
surgical intervention, with concomitant high morbidity and mortality, and 
therefore new therapies, such as chemoprevention, would be preferable. 
Although it is known that FAP is caused by mutations in the APC gene, the 
relation between the duodenal phenotype and the site of the APC mutations is 
not clear. Other factors could contribute to the variety seen in the age of onset, 
number of adenomas or severity of the duodenal adenomatosis. The studies 
described in the first part of this thesis focus on the role of biotransformation 
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enzymes in duodenal adenomatosis in patients with FAP. After the general 
introduction of Chapter 1, in Chapter 2, the detoxification capacity of UGT 
and GST in the duodenal mucosa of patients with FAP is compared with that 
of healthy controls. Chapter 3 compares the genotype distribution of several 
important GST and UGT detoxification enzymes present in the duodenum in 
patients with FAP with the corresponding genotypes found in healthy controls. 
The following chapters of this thesis are focussed on the mechanisms 
underlying the development of duodenal adenomas and carcinomas in FAP. In 
Chapter 4, normal mucosa and adenoma tissues of the duodenum and colon 
of patients with FAP are compared with corresponding non-FAP samples for 
the distribution of E-cadherin, -catenin and SMAD4. Chapter 5 describes the 
chromosomal abnormalities and alterations in DNA methylation, as found in 
duodenal sporadic and FAP-related carcinomas. These findings are also 
compared to literature data for gastric and colorectal tumours. Finally, a pilot 
intervention study as described in Chapter 6, explores the possibility for the 
use of ursodeoxycholic acid as a future chemopreventive agent for duodenal 
adenomas/carcinomas in patients with FAP.  
 
 
The main objectives of this thesis are to: 
1. investigate factors that may influence the individual variety in duodenal 
adenomatosis in patients with FAP.  
2. further elucidate the mechanisms underlying the development of 
duodenal adenomas and carcinomas in patients with FAP. 
3. explore the possibility of chemoprevention of duodenal adenomas/ 
carcinomas in patients with FAP. 
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Patients with familial adenomatous polyposis (FAP) are at risk of duodenal 
adenomas and carcinomas. Besides the germline mutations in the APC gene, 
which are responsible for the severity of the FAP phenotype, the disease may 
be modulated by other genes of low penetrance. The detoxifying enzymes 
glutathione S-transferases (GSTs) and UDP-glucuronosyltransferases (UGTs) 
are involved in the mucosal protection against toxins and carcinogens. A low 
GST activity has been observed in the colon and blood of patients with FAP 
compared to that of controls. This suggests that these enzymes may be risk 
modulators in patients with FAP. The aim of this study is to compare the 
detoxification capacity of GST and UGT in duodenal mucosa of patients with 
FAP with that of healthy controls. Normal appearing duodenal biopsies were 
obtained from 18 patients with FAP and 18 controls. GST isoforms were 
quantified by immunoblotting. GST and UGT enzyme activities were measured 
spectrophotometrically and spectrofluorometrically respectively. No 
differences were observed in the GST isoform levels or in the GST and UGT 
enzyme activities, in the duodenal mucosa of patients with FAP compared to 
healthy duodenal mucosa. The detoxification enzymes GST and UGT studied 
here do not seem to be involved in the duodenal adenomatosis in patients with 
FAP. 
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Introduction 
Familial adenomatous polyposis (FAP) is an autosomal dominant disorder 
characterised by numerous adenomatous colorectal polyps that have a 
tendency to progress to adenocarcinoma. It is caused by germline mutations 
in the Adenomatous Polyposis Coli (APC) gene 1. The treatment of choice is 
prophylactic colectomy since untreated FAP will inevitably lead to colorectal 
cancer at a relatively young age 2. Patients with FAP are also at risk of 
developing extra-colonic manifestations, although the duodenum is the main 
site for these malignant manifestations 3,4. The prevalence of the mainly peri-
ampullary adenomas varies from 50% to greater than 90% 7-9. The cumulative 
incidence of duodenal adenomatosis at the age of 70 years is 90%, and 52% 
of these adenomas are graded as Spigelman stage IV 10, which is associated 
with a high risk of a malignant course of the adenomas 11-13. The prevalence of 
duodenal carcinoma in patients with FAP is 2-5% 4,5,8,10,12 and compared to the 
general population, the relative risk of duodenal adenocarcinoma is 
exceptionally high 3. However, since the FAP populations investigated so far 
are relatively young, the prevalence rates will increase further 12. Since the 
incidence and severity of the duodenal adenomatosis increases with age 
regular endoscopic surveillance is recommended. The current treatment of 
choice for patients with Spigelman stage IV adenomas is a pylorus-preserving 
pancreaticoduodenectomy 10. However the choice between continued 
surveillance and this procedure, which is associated with considerably 
morbidity and mortality, is delicately balanced 14.  Therefore chemoprevention 
would be a much more preferable treatment 15, mainly since celecoxib, a 
selective cyclooxygenase-2 inhibitor, showed a beneficial effect in the 
prevention or even regression of duodenal adenomatosis 16. 
 
Although mutations in the APC gene are the main cause of FAP, modifier 
genes of low penetrance are likely to contribute to the FAP phenotype, and 
carcinogen metabolising enzymes may be good candidates 17. The detoxifying 
enzymes glutathione S-transferases (GSTs) and UDP-
glucuronosyltransferases (UGTs) are involved in the detoxification of 
carcinogens and have a pivotal function in mucosal protection against 
carcinogens. The human GSTs are a family of enzymes, compried of four 
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main classes: alpha, pi, mu and theta, each consisting of one or more isoforms 
18
. GSTs catalyse the conjugation of a wide variety of toxic or carcinogenic 
electrophiles to the tripeptide glutathione. The majority of these GST 
substrates are xenobiotics or products of oxidative stress. The conjugation of 
electrophiles with the sulfhydryl group of glutathione generally results in more 
water soluble and less toxic molecules, which are subsequently excreted via 
bile or urine, and thus GSTs are almost exclusively involved in detoxification 
18,19
. The expression of the GSTs isoforms differs in the various tissues and 
large inter-individual differences in tissue levels have also been reported 20-23. 
A significant inverse correlation between GST activity in normal mucosa along 
the gastrointestinal tract and the tumour incidence at these sites has been 
observed 22, suggesting an important role for GST in cancer prevention. 
 
The UGTs are endoplasmic reticulum resident enzymes, which catalyse the 
transfer of glucuronic acid from the donor UDP-glucuronic acid to a wide range 
of potentially hazardous molecules. This glucuronidation is responsible for the 
transformation of lipophilic substrates into more easily renal or biliary excreted, 
hydrophilic glucuronides, which in general are less toxic compared to the 
parent compound 24. Human UGTs are divided into the UGT1 and UGT2 
subfamilies, consisting of 9 and 7 functional genes respectively 25,26. Several 
UGT isoforms may be expressed in the duodenum as well as in the colon 27,28, 
however the UGT enzyme activity in the duodenum was reported to be much 
higher compared to that of the colon 21,27,29. 
  
Recently, we noticed a significantly lower GST activity in the colonic mucosa 
of patients with FAP compared to healthy controls 30, whereas lower GST mu 
levels were measured in the blood of patients with FAP compared to controls 
by Spigelman et al. 31. In addition, via caffeine phenotyping 32 or genotyping 33, 
lower N-acetyltransferase (NAT; generally inactivating carcinogens) and 
higher cytochrome P-450 (generally activating carcinogens) activity was 
demonstrated in patients with FAP compared to controls. Lower levels of NAT, 
GST or UGT activity in the intestine may enhance the risk of developing 
intestinal carcinoma 21. Therefore, it is suggested that reduced detoxification 
activity may to some extent modulate the risk of (extra)-colonic adenomas or 
Chapter 2 Duodenal GST and UGT in FAP 
 
 31 
carcinomas in patients with FAP. The aim of this study is to compare the 
detoxification capacity of GST and UGT in the duodenal mucosa of patients 
with FAP with that of healthy controls. 
 
Material & Methods 
 
Patients and controls 
Duodenal biopsies were obtained from 18 patients (average age 49 ± 15 yrs, 
10 males/ 8 females) with FAP, who underwent routine duodenoscopy at the 
Radboud University Nijmegen Medical Centre, the Netherlands. The 
specimens were taken from normal appearing mucosa. Severity of duodenal 
adenomatosis was classified according to Spigelman stage 34. Spigelman 0, I, 
II, III and IV was found in 4, 4, 4, 5 and 1 patients respectively. In the period 
from 1957-1997, 17 patients underwent colectomy. Control duodenal biopsies 
were obtained from 18 subjects (average age 50 ± 13 yrs, 8 males / 10 
females) who underwent duodenoscopy for suspected coeliac disease, 
however no abnormalities were found by the pathologist. Informed consent 
was given by the individuals participating in this study. 
 
Tissue samples 
Immediately after endoscopy, three biopsy specimens were frozen in liquid 
nitrogen and stored at – 80° C until use. The biopsy specimens were weighed 
and homogenised on ice in 5 parts homogenising buffer (100 mM Tris/HCL, 
1mM EDTA, pH 7.4). A part of the homogenates were immediately frozen in 
liquid nitrogen and stored at – 800 C for the UGT activity assay, and the rest of 
the homogenates was centrifuged at 150,000 g at 4° C for 1 hour (cytosolic 
fractions) for the GST assays. Immediately after centrifugation, the cytosolic 
fractions were frozen in liquid nitrogen and stored in small aliquots at – 80° C 
until further analysis. 
 
Glutathione S-transferase assays 
Protein concentrations were determined in duplicate by the method of Lowry et 
al. 35 using bovine serum albumin as a standard. The cytosolic glutathione S-
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transferase activity was assayed in duplicate with 1-chloro, 2,4-dinitrobenzene 
as substrate by using the method of Habig et al. 36. Concentrations of the GST 
alpha, mu, pi and theta isoforms were determined by immunoblots previously 
as described 22,37,38. In short, cytosolic fractions were subjected to sodium 
dodecylsulfate-polyacrylamide 13% (w/v) gel electrophoresis (SDS-PAGE). 
Subsequently, proteins were electroblotted to nitrocellulose membranes which 
were then blocked with 1% gelatine in PBS-buffer also containing 0.05% (v/v) 
Tween-20 (PBS-T) for 15 min. Next, the membranes were incubated overnight 
with monoclonal antibodies (dilution 1:5000 in PBS-T/ gelatine) against human 
GST class alpha (A1 + A2) 37, pi (P1) 39, mu (M1 + M2) 40 or theta (T1) 41. After 
washing and incubating with the secondary antibody, peroxidase-conjugated 
rabbit anti-mouse immunoglobulin (Dakopatts Glostrup, Denmark), 
immunoreactive proteins were visualized with 0.1% (w/v) 3,3’-
diaminobenzidine, 5 mM imidazole, 2 mM cobalt chloride 6H2O and 16 l 30% 
H2O2 in PBS. Intensity of the staining was measured using a laser 
densitometer (Ultrascan XL; LKB, Bromma, Sweden). Known amounts of the 
corresponding GST isoforms, which were run in parallel with the samples, 
were used as standards for the quantification of the GST isoforms.  
 
UDP- glucuronosyltransferase enzyme activity measurement 
UGT activity was assayed with 4-methylumbelliferone (4-MUB) as substrate 42. 
Duodenum homogenates were preincubated for 2 mins at 37˚ C in the 
presence of 10 mM MgCl2, 1 mM saccharic aicd-1,4-lactone and 0.1 mM 4-
MUB in a final volume of 110 l Tris/HCl (20 mM), pH 7.4. The substrate 4-
MUB was dissolved in ethanol (50 mM) and diluted with assay medium just 
before use. Subsequently, UDP-glucuronic acid (UDPGA; Sigma, Zwijndrecht, 
the Netherlands) was added (concentration during incubation: 4 mM) and the 
samples were incubated for 30 mins at 37˚ C. After the addition of 1 ml 0.5 M 
glycine/ NaOH, pH 10.35, the conjugation reaction was ended. Next the 
samples were centrifuged at 10,000 g for 10 min and 4-MUB was determined 
fluorometrically (excitation 375 nm, emission 450 nm). 
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Statistical analysis 
The Wilcoxon-Mann-Whitney test was used to compare enzyme activities and 
GST isoenzyme levels of patients and controls. The Kruskal-Wallis test was 
performed to examine the relation between the enzyme activities, GST 
isoenzyme levels and the categorical variable Spigelman classification. P < 
0.05 was considered to be statistically significant (SPSS 11.0 for Windows, 
2001). 
 
Results 
Duodenal biopsies from 18 patients with FAP and 18 patients with normal 
duodenal mucosa (controls) were analysed in this study. Patients with FAP 
and controls were matched with respect to age and gender. Data on the levels 
of glutathione S-transferase alpha (A1 + A2), pi (P1), mu (M1) and theta (T1), 
the GST and UGT enzyme activities in the duodenal mucosa of patients with 
FAP and healthy controls is presented in Table 1. Seven patients with FAP 
and 7 controls were of the GSTM1 null genotype and showed no expression of 
the GSTM1 protein, whereas 6 patients with FAP and 2 controls were of the 
GSTT1 null genotype.   
 
  
 
 
 
 
 
 
 
                                                                                               
 
 
 
 
 
 
 
      
 
 
 
 
Table 1:  Glutathione S-transferase (GST) isoenzyme content, GST and UDP-  
glucuronosyltransferase (UGT) enzyme activity in duodenal mucosa of patients with FAP  
and controls 
 
 
FAP 
n = 18 
 
Controls 
n = 18 
 
 
GSTA1 + A2 
in ng / mg protein 
 
7138 
(5830 - 7917) 
 
6166 
(5128-7975) 
 
GSTP1   
in ng / mg protein 
 
4617 
(2644-5830) 
 
4463 
(3175-5294) 
 
GSTM1 
in ng / mg protein 
 
325 
(0-429) 
 
344 
(0-426) 
 
GSTT1 
in ng / mg protein 
 
2376 
(1937-5320) 
 
2383 
(1675-4567) 
 
GST enzyme activity 
in nmol min -1 mg –1 protein 
 
619 
(586-689) 
 
576 
(531-697) 
 
UGT enzyme activity  
in nmol min -1 mg –1 protein 
 
0.45 
(0.27-0.59) 
 
0.47 
(0.28-0.65) 
 
 
Data are presented as medians (25th -75th percentiles). 
GSTM1 negative: 7 patients and 7 controls 
GSTT1 negative: 6 patients and 2 controls 
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GST A1 + A2 levels were highest (7138 vs. 6166 ng/mg protein p = 0.372), 
followed by GSTP1 (4617 vs. 4463 ng/mg protein p = 0.501), GSTT1 (2376 
vs. 2383 ng/mg protein p = 0.377) and GSTM1 (325 vs. 344 ng/mg protein p = 
0.748) in duodenum of patients with FAP compared to controls. No differences 
were observed in the GST levels in the duodenal mucosa of patients with FAP 
compared to healthy duodenal mucosa. Furthermore no differences in the 
enzyme activity of GST (p = 0.606) or UGT (p = 0.935) in the duodenal 
mucosa of the patients with FAP compared to values in control mucosa could 
be noticed. 
 
The Spigelman stage is a measure for the severity of the duodenal 
adenomatosis in patients with FAP. In this study no relation was found 
between the Spigelman stages and the GST and UGT enzyme activities (p = 
0.353 and p = 0.700 respectively). Nor did the GST isoform levels show a 
relation with the Spigelman stages. 
 
Discussion  
Patients with the autosomal dominant disease FAP develop hundreds of 
adenomas in their colon. Without prophylactic colectomy, these will inevitable 
lead to colon cancer at a relatively young age. Nowadays, with an increased 
life expectancy for patients with FAP because of this prophylactic colectomy, 
the problems of the extra-colonic manifestations in these patients become 
apparent 8,10-12. Adenomas are also formed in the upper gastrointestinal tract, 
most notably in the duodenum around the ampulla. 5,6. This process, although 
mainly driven by APC mutations, may be modulated to some extent by other 
factors, such as levels and functioning of detoxification enzymes.  
 
The GST and UGT detoxification enzymes are involved in the mucosal 
protection against carcinogens. GSTs and UGTs are widely distributed along 
the gastrointestinal tract and both enzyme systems significantly contribute to 
the prevention of carcinogenesis at these sites 21,22,23. A lower detoxification 
capacity, however, could contribute to an enhanced cancer risk. For example, 
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a low UGT and GST enzyme activity is present in the colon compared to the 
small intestine, whereas the cancer incidence in the colon is much higher  
compared to that in the small intestine 21,22,27,29. Furthermore, a significantly 
lower GST enzyme activity was observed in the colonic mucosa and blood of 
patients with FAP compared to corresponding values in controls 30,31. 
However, direct measurement of detoxification enzyme values at sites other 
than the colon 30 in the gastrointestinal tract of patients with FAP has never 
been performed and therefore we investigated UGTs and GSTs in the 
duodenum, a site where adenomas and carcinomas also develop.   
 
This study, however, reveals no differences between the levels of GST 
isoforms and GST and UGT enzyme activity in the duodenal mucosa of 
patients with FAP compared to normal duodenal mucosa of age and sex 
matched controls. Thus, in contrast to our earlier observation in the colon, a 
lowered detoxification capacity does not seem to be present in the duodenal 
mucosa of patients with FAP. The much higher detoxification capacity in the 
upper-gastrointestinal tract compared to that of the colon may play a role in 
the differences in the prevalence of adenomas and carcinomas seen at these 
sites in patients with FAP. The prevalence of duodenal adenomas and 
carcinomas is 50-90% and 2-5% 4,5,8,10,12 compared to corresponding values of 
100% and 90% respectively in the colon 43. 
 
A lower detoxification capacity is associated with a higher risk of 
carcinogenesis 20,21,22. Genetic polymorphisms in genes encoding for GST and 
UGT isoforms can lead to an absence or decrease in enzyme activity 18,44.  
Crabtree et al. reported an association between N-acetyltransferase (NAT) 
polymorphisms and more severe disease in FAP, although no associations 
with other polymorphisms leading to reduced enzyme activity, such as GST 
M1 or GSTT1 null polymorphisms, were found 17. The latter is in accordance 
with the results of Lamberti et al., who found no association between GSTM1 
null genotype and age at first diagnosis of colorectal adenomas or extra-
colonic manifestations 45. Although there is some evidence of a modulating 
role of genes of low penetrance in the severity and distribution of adenomas 
and carcinoma in the duodenum of patients with FAP, direct enzyme activity 
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measurements in the target organ have not so far been performed. No 
evidence was found however that lower levels or enzyme activity of potential 
modifying enzymes were present in the duodenum of patients with FAP. 
 
Since there are mainly peri-ampullary adenomas present in the duodenum of 
patients with FAP, it seems that bile may be a strong tumour promoter, or that 
otherwise the peri-ampullary mucosa may be more sensitive towards 
adenomatosis compared to the more distant mucosa. This was difficult to test 
however, as normal peri-ampullary mucosa of patients with FAP could not be 
obtained. 
 
In summary, the detoxification capacity of GSTs and UGTs in the duodenum is 
not lower in patients with FAP compared to healthy duodenal mucosa. 
Therefore, these detoxification enzymes do not seem to be involved in the 
duodenal adenomatosis in FAP. 
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Patients with familial adenomatous polyposis (FAP) are at high risk of 
duodenal adenomas and carcinomas. Besides germline mutations in the APC 
gene, the age of onset and the number of duodenal adenomas may be 
modulated to some extent by additional factors, such as the detoxification 
enzymes glutathione S-transferases (GSTs) and UDP-glucuronosyltransferases 
(UGTs), which are involved in the mucosal protection against toxins and 
carcinogens. This study compares the genotype distributions of duodenal 
isoforms of UGTs and GSTs in patients with FAP and controls. Genotyping of 
85 patients with FAP and 218 healthy controls was performed for 
polymorphisms in the detoxification enzymes UGT1A1, UGT1A3, UGT1A4, 
UGT1A6, UGT1A10, UGT2B4, UGT2B7, UGT2B15, GSTA1, GSTP1, GSTM1 and 
GSTT1.  
The variant genotypes of UGT1A3 were found significantly less common in 
patients with FAP (OR 0.39, 95% CI 0.22-0.67) compared with controls, whereas 
no associations were found between FAP and the other polymorphic genes. 
The polymorphisms investigated here had no predictive value for the severity 
of the duodenal adenomatosis in the patients with FAP. The variant genotype 
of UGT1A3 is less present in patients with FAP, however this variant genotype 
does not modulate the severity of duodenal adenomatosis. 
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Introduction 
FAP is an autosomal dominant disorder caused by germline mutations in the 
tumour suppressor gene adenomatous polyposis coli (APC) 1. Patients with 
FAP develop hundreds to thousands of colorectal adenomas which without 
prophylactic colectomy will inevitably lead to colorectal cancer at a relatively 
young age 2. Nowadays, with increased survival due to prophylactic 
colectomy, problems of extra-colonic manifestations become apparent in these 
patients 3. The prevalence of the mainly peri-ampullary adenomas in patients 
with FAP varies from 50-90% 4-6 and the prevalence of duodenal carcinoma is 
2-5% 3, 7. Together with desmoid tumours, duodenal carcinomas are now the 
leading causes of cancer-related mortality in patients with FAP 8.  
 
The severity of the colonic phenotype can be associated with the site of the 
APC mutations. In contrast, the development of duodenal adenomas can only 
be partly explained by the location of the APC mutations 9. Furthermore, there 
is a large variety in the age of onset as well as in the number of duodenal 
adenomas in patients with FAP. This suggests that, in addition to the APC 
mutations, other genes of low penetrance could play a modulating role in the 
inter-individual differences in the development of duodenal adenomas and 
carcinomas. Genes of biotransformation enzymes could be good candidate 
genes 10. The detoxification enzyme families glutathione S-transferases 
(GSTs) and UDP-glucuronosyltransferases (UGTs) especially, which play an 
important role in the mucosal protection against potential mutagens and 
carcinogens. These enzyme families are responsible for the metabolism and 
excretion of many toxic, mutagenic or carcinogenic compounds, both of 
exogenous and endogenous sources. UGTs catalyse the conjugation of 
mainly lipophilic compounds with glucuronic acid, while GSTs catalyse 
conjugation with glutathione of electrophiles and products of oxidative stress 
11-13
. After conjugation, the compounds are generally more water soluble and 
less biologically active, and can be readily excreted. A significant inverse 
correlation has been observed between GST or UGT activity in the normal 
mucosa of the gastrointestinal tract and the corresponding tumour incidence 
14
, suggesting an important role for these enzymes in cancer prevention. 
Several isoforms of the UGT and GST detoxification enzyme families may be 
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expressed in the duodenal mucosa (GSTM1, GSTP1, GSTT1, GSTA1, 
UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A10, UGT2B4, UGT2B7 and 
UGT2B15) 15-19. Functional polymorphisms in the genes of these detoxification 
enzymes may result in reduced enzyme activity, or even in a complete 
absence of enzyme activity 20, 21. Therefore, such functional polymorphisms 
could result in deficient duodenal detoxification, leading to increased levels of 
harmful compounds, and could thus potentially modulate individual 
susceptibility to the development of duodenal adenomas and carcinomas in 
patients with FAP. 
 
Until now, there have been several reports on biotransformation enzymes in 
patients with FAP. Spigelman et al. 22 reported a lower activity of GSTM in the 
peripheral blood of patients with FAP compared with that of controls. However, 
in duodenal mucosa of patients with FAP we were not able to demonstrate 
lower UGT and GST enzyme activity compared to controls 23. By caffeine 
phenotyping, lower N-acetyltransferase (NAT; generally inactivating 
carcinogens) and higher cytochrome P4501A2 (generally activating 
carcinogens) activity was demonstrated in patients with FAP compared to 
controls 23. Furthermore, slow acetylation phenotypes were shown to increase 
the risk of extra-colonic manifestations in patients with FAP 24 . Genetic 
polymorphisms in NAT, but not in GSTT or GSTM, were shown to modulate 
the severity of disease in patients with FAP 10, 25 .  
 
The GST and UGT enzyme activity measurements in duodenal mucosa of 
patients with FAP and controls, performed by us in an earlier study 15 cover 
only part of the GST and UGT isoenzymes present in the duodenum. In 
addition, activity measurements were performed only on a limited number of 
patients. Therefore in the current study, the genotypes of the most important 
duodenal isoforms of the UGT and GST family were determined in a large 
number of patients with FAP and compared with those of controls. 
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Materials & Methods 
 
Patients and controls 
A total of 85 patients with FAP (average age 42 ± 16 yrs, 38 males/ 47 
females) were included in this study; 59 patients were recruited at the 
Department of Gastroenterology, Radboud University Nijmegen Medical 
Centre, and 26 patients were recruited at the Department of Gastroenterology 
and Hepatology, Academic Medical Centre, Amsterdam, the Netherlands. All 
patients with FAP were unrelated, meaning that only one patient per family 
name was included. Fifty-nine patients with FAP were diagnosed based on the 
presence of APC mutations and 26 of the patients on the specific clinical 
characteristics; namely the presence of hundreds of adenomas in their colon. 
Age and gender matched healthy subjects (218 in total, average age 42 ± 16 
yrs, 103 males/ 115 females) served as controls and were recruited by an 
advertisement in a local paper in the area of Nijmegen. All subjects were of 
Caucasian origin. This study was approved by the local medical ethical review 
committee. 
 
Spigelman stage 
Of 50 patients with FAP (59%), age as well as the Spigelman stage was 
registered at first duodenoscopy. Spigelman’s stage is a semi-quantitive 
scoring system, expressing the severity of duodenal polyposis according to 
number, size, histology and degree of dysplasia of duodenal lesions, as 
outlined in Table 1   26.   
 
 
 
 
 
 
 
 
 
Table 1:  Spigelman stage represents the severity in duodenal polyposis. 
 
Category 
 
 
1 
Points 
2 
 
 
3 
 
Number of adenomas                 
 
1-4 
 
5-20 
 
> 20 
Size of adenomas (mm)                                    1-4 5-10 > 20 
Histology            Tubular Tubulovillous Villous 
Degree of dysplasia                                          Mild Moderate Severe 
                                                                                   
Within each category, 1 to 3 points can be scored, and the sum of the score in the 4 categories results in the  
Spigelman stage. Stage 0, 0 points; Stage I, 1-4 points; Stage II, 5-6 points; Stage III, 7-8 points; Stage IV, 9-12  
points. 
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DNA isolation 
The Puregene DNA purification kit (Gentra Systems, Minneapolis, MN) was 
used to isolate DNA from whole blood of 64 patients with FAP and 218 healthy 
controls. The isolation was performed according to the instructions of the 
manufacturer. From 21 patients with FAP, no blood samples were available 
and here DNA was isolated from resected colonic tissue by using the phenol-
chloroform-isoamylalcohol extraction method according to Maniatis et al. 27.  
 
Genotyping  
UGT1A1. The number of TA repeats in the promoter region of the UGT1A1 
gene was analysed using the polymerase chain reaction (PCR) conditions and 
primers (Table 2) according to Monaghan et al. 28. After confirmation of the 
amplification by agarose electrophoresis, the fragments were subjected to 
10% polyacrylamide gels (19:1 acrylamide / bisacrylamide) in Tris – Borate - 
EDTA buffer. Gels (20 x 20 x 0.075 cm) were run at 400V for 3 hrs and stained 
with ethidium bromide for 30 mins 29. Fragments of 98 bp indicate the 
UGT1A1*1 allele, which contains six TA repeats, and fragments of 100 bp 
indicate the UGT1A1*28 allele with seven TA repeats.  
 
UGT1A3 and UGT1A4. Polymorphic variants of the UGT1A3 and UGT1A4 
genes were identified by PCR-restricted fragment length polymorphism 
(RFLP) methods developed in our laboratory. To detect the variations at 
UGT1A3 codons 11 and 47, the forward and reverse primers, as shown in 
Table 2, were used in the presence of 1.5 mM MgCl2. The PCR conditions 
were: 5 mins at 95°C, then 40 cycles of 30 secs at 95°C, 30 secs at 50°C, 1 
min at 72°C and finally an elongation step of 7 mins at 72°C. A 427 bp product 
was amplified and aliquots of 5 l of the PCR mixture were digested for at 
least 1 h at 37 ˚ C with the appropriate restriction enzyme, followed by 
electrophoresis on 3% agarose gel, containing ethidium bromide. 
Electrophoresis patterns of DNA fragments after digestion with SstII for codon 
11 are: a 427 bp product (homozygous common genotype), 427 + 319 + 108 
bp products (heterozygous genotype) and 319 + 108 bp products 
(homozygous variant genotype). For codon 47, digestion occured with the 
restriction enzyme StuI, resulting in an electrophoresis pattern of a 427 bp 
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product (homozygous most common), 427 + 217 + 210 bp products 
(heterozygous genotype) and 217 + 210 bp products (homozygous variant 
genotype).  
 
Table 2: Primers and restriction enzymes used for genotyping 
 
 
Genes 
 
Primers/beacons (5’- 3’; F = forward, R = reverse) *  
 
Restriction enzymes 
 
 
UGT1A1 
 
F : GTC ACG TGA CAC AGT CAA AC    
R : TTT GCT CCT GCC AGA GGT T 
 
 
- 
UGT1A3 F : AGG TAA TTA AGA TGA AGA AAG  
R : ACA TTG CCA TAC TTC TGA 
  
W11R : SstII 
V47A : StuI 
 
UGT1A4 F : GCC CAT AAC GAA AGG CAG T 
R : CAC ACA ACA CCT ATG AAG GG   
P24T : Hpy188III 
L48V : StuI 
 
UGT1A6 F : GGA AAA TAC CTA GGA GCC CTG TGA 
R : AGG AGC CAA ATG AGT GAG GGA G 
T181A : NSiI 
R184S : Fnu4HI 
 
UGT1A10
  
F : CTC TTT CCT ATG TCC CCA ATG  
R : CTG GAA AGA AAT CTG AAA TGC AAC AAA C 
 
T240M : NlaIII 
L244I : EcoRV 
 
UGT2B4 
  
F : CCA AAT TAA CTT ACT TTC AAT GTT  
R : AGG CCC AGC AGG AAC CCA G 
 
Fam-CGC GAT AGC CCC TTG ATC GAG CAG TCA TCG CG-
BHQ1 
Hex-CGC GAT AGC CCC TTG AAA GAG CAG TCA TCG CG-
BHQ1 
 
- 
UGT2B7 F : GTA TGG CTT ATT CGA AAC TC   
R : CAA ACA CTC TGA AAG AAG AC 
 
Fam-TTT CAG TTT CCA TAT CCA CTC TTA CC-BHQ1 
Hex-TTT CAG TTT CCT CAT CCA CTC TTA CC-BHQ1 
 
 
- 
UGT2B15 F : TTG ACA TCT TCG GCT TCT AC    
R : CTG CCA GAA TGA CAT CAA AC 
 
Fam-CGC TGC CAT CTT TAA CTA AAA ATG ATT TGG AAG 
ATT CTC TGC AGC G-BHQ1 
Hex-CGC TGC CAT CTT TAA CTA AAA ATT ATT TGG AAG 
ATT CTC TGC AGC G-BHQ1 
 
 
GSTA1  F : TGT TGA TTG TTT GCC TGA AAT T 
R : GTT AAA CGC TGT CAC CGT CC 
 
EarI 
 
GSTP1  F: GTA GTT TGC CCA AGG TCA AG    
R: AGC CAC CTG AGG GGT AAG 
 
Alw261 
 
GSTM1  F : CTC CTG ATT ATG ACA GAA GCC    
R : CTG GAT TGT AGC AGA TCA TGC 
 
- 
GSTT1  F : TTC CTT ACT GGT CCT CAC ATC TC   
R : TCA CCG GAT CAT GGC CAG CA 
 
- 
ß-Globin  F : CAA CTT CAT CCA  CGT TCA CC 
R : GAA GAG CCA AGG ACA GGT AC 
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The polymorphic variants of UGT1A4 codons 24 and 48 were detected using 
the forward and reverse primers, as shown in Table 2, with 2.0 mM MgCl2. 
The PCR conditions were: 5 mins at 95°C, then 40 cycles of 30 secs at 95°C, 
30 secs at 54°C, 1 min at 72°C and finally an elongation step of 7 mins at 
72°C. Aliquots (5 l) of the PCR product were digested with the restriction 
enzyme Hpy188III (codon 24) or StuI (codon 48) for at least 1 h at 37˚C. For 
codon 24, this digestion resulted in 513 + 54 bp products (homozygous most 
common), 513 + 266 + 247 + 54 bp products (heterozygous genotype), 266 + 
247 + 54 bp products (homozygous variant genotype). The digestion with StuI 
leads to electrophoresis patterns of 319 + 248 bp products (homozygous most 
common), 567 + 319 + 248 bp products (heterozygous genotype) and a 567 
bp product (homozygous variant genotype). 
 
UGT1A6 and UGT1A10. The polymorphisms in the UGT1A6 and UGT1A10 
genes were studied using PCRs followed by RFLP analyses as previously 
described 30-32. Table 2 shows the primers and restriction enzymes used in 
these studies.  
 
UGT2B4, UGT2B7 and UGT2B15. A dual-colour allele-specific assay was 
used for genotyping the polymorphism at codon 458 of the UGT2B4 gene. 
PCR was performed on the iCycler iQ Multicolour Real-Time Detection System 
(Bio-Rad Laboratories, Hercules, CA) using forward and reverse primers in the 
presence of the FAM-labelled wild-type beacon and the HEX-labelled mutant 
beacon (Sigma-Aldrich, Zwijndrecht, the Netherlands), as described in Table 
2. The 25 microliter reaction mixture contained 200 ng of genomic DNA, 10 
mM Tris/HCl (pH 9.0), 50 mM KCl, 0.1% Triton X-100, 4 mM MgCl2, 0.25 mM 
dNTPs, 5 pmol of each primer, 200 nM of each beacon and 2.5 U Taq-DNA-
polymerase. The PCR conditions were 3 mins at 95°C, then 40 cycles of 30 
secs at 95°C, 30 secs at 56°C and 30 secs at 72°C. Fluorescent signals were 
measured at 56°C. Genotypes were assigned using the iCycler iQ Optical 
System Software version 3.1. At each PCR run (in 96 wells plates), sterile H2O 
rather than genomic DNA, was added to several wells as negative controls for 
amplification. For the genotyping of the exon 1 polymorphism at codon 268 of 
the UGT2B7 gene, a similar method was used as described above for 
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UGT2B4. For UGT2B7, the PCR conditions were 3 mins at 95°C, then 40 
cycles of 30 secs at 95°C, 30 secs at 57°C and 30 secs at 72°C. Table 2 
describes primers and probes (Sigma-Aldrich) used for UGT2B7. For the 
genotyping of the exon 1 polymorphism at codon 85 of the UGT2B15 gene, 
the same method was used as described above for UGT2B4 but with a 
magnesium concentration of 3 mM . For this polymorphism, the PCR 
conditions were 3 mins at 95°C, then 40 cycles of 30 secs at 95°C, 30 secs at 
60°C and 30 s at 72°C. 
 
GSTM1 and GSTT1. The GSTM1 polymorphism was determined by PCR 
according to the method of Brockmöller et al. 33. The -globin gene was used 
as an internal positive control and sterile H2O, as substitute for genomic DNA, 
served as a negative control. PCR primers are given in Table 2. PCR 
amplification was followed by 1% agarose gel electrophoresis of the PCR 
products. The presence of a 650 bp product represents at least one functional 
GSTM1 allele, whereas absence of an amplification product is consistent with 
the null genotype. The detection procedure of the GSTT1 null polymorphism 
based on the method of Pemble et al. 34 is similar to that of GSTM1. Here the 
visualization of a 480 bp product indicates the presence of at least one 
functional GSTT1 allele. 
 
GSTA1 and GSTP1. The polymorphisms in the GSTA1 and GSTP1 genes 
were studied by using PCR, followed by RFLP analyses exactly as described 
before 35,36. Table 2 shows the primers and restriction enzymes used for these 
polymorphisms. All genotypes investigated in this study are summarised in 
Table 3. 
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Table 3: Summary of the polymorphic variants of the detoxification enzymes. 
 
Nomenclature polymorphic genes  
  
 
Nucleotide or amino acid changes * 
 
UGT1A1*1 
UGT1A1*28 
 
(TA)6TAA 
(TA)7TAA 
 
UGT1A3*1    
UGT1A3*2    
UGT1A3*3    
UGT1A3*6   
W11V47 
R11A47 
R11V47 
W11A47 
 
UGT1A4*1    
UGT1A4*2    
UGT1A4*3    
 
P24L48 
T24L48 
P24V48 
UGT1A6*1    
UGT1A6*2    
UGT1A6*3    
 
T181R184 
A181S184 
T181S184 
 
UGT1A10*1    
UGT1A10*3    
UGT1A10*4    
 
T240L244 
M240L244 
T240I244 
 
UGT2B4*1    
UGT2B4*2    
 
D458 
E458 
UGT2B7*1    
UGT2B7*2    
 
H268 
Y268 
 
UGT2B15*1    
UGT2B15*2    
 
D85 
Y85 
GSTA1*A    
GSTA1*B    
 
-69C 
-69T 
GSTP1 Ile 105    
GSTP1 Val 105    
 
 
I 105 
V 105 
 
GSTM1+    
GSTM1null    
 
At least one functioning allele 
Deletion in both alleles  
 
GSTT1+    
GSTT1 null    
At least one functioning allele 
Deletion in both alleles 
 
*
 Bold characters indicate nucleotide or amino acid changes as compared to the most  
common allele. 
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Statistical analysis 
The differences between characteristics of patients with FAP and controls 
were analysed with the Student’s t-test. All genotypes investigated among 
controls and patients were tested as to whether they were distributed 
according to the Hardy-Weinberg equilibrium. Furthermore, the chi-square was 
used to test for differences in the distribution of genotypes between the two 
study groups, or to estimate differences in allele frequencies. Odds ratios (OR) 
with 95% confidence interval (95% CI) were calculated for genotypes 
associated with predicted normal enzyme activity versus genotypes with 
predicted altered enzyme activities (variant genotypes). The predictive value of 
the various polymorphisms for the Spigelman stage at the first duodenoscopy 
of the patients with FAP was determined by logistic regression. In total, five 
different genetic polymorphisms of the UGT1A family were analysed. Because 
genetic polymorphisms were only detected in four of these UGT1A genes that 
are all derived from one combined gene locus, we corrected for multiple 
testing with Bonferroni here, implying that a p-value of 0.0125 was considered 
to be statistically significant. In all other cases, a P < 0.05 was considered to 
be statistically significant (SPSS 12.0.1 for Windows 2003, SPSS Inc, 
Chicago, USA). 
 
Results 
 
Characteristics of patients and controls 
Table 4 lists the characteristics of the patients with FAP and controls. In 34% 
of the patients with FAP, a Spigelman stage 0 was observed at first 
duodenoscopy. Only 4% showed Spigelman stage I compared with 24%, 22% 
and 16% for the stages II, III and IV, respectively.  
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Genotyping 
Genotype distributions of the UGT and GST biotransformation enzymes 
investigated here are summarised in Table 5, and corresponding allele 
frequencies are shown in Table 6. All polymorphisms tested here were 
distributed according to the Hardy-Weinberg criteria, except for two genotypes, 
which did not fit these criteria: the UGT1A4 polymorphism in the control group 
and the UGT2B7 polymorphism in the patient group. Chi-square analyses 
revealed no significant differences in the investigated polymorphisms between 
patients with FAP and controls. The difference observed between patients with 
FAP and the control group for the UGT1A3 gene (p = 0.013), lost significance 
after the Bonferroni correction for multiple testing (p < 0.0125). 
Table 4: Characteristics of patients with FAP and controls. 
 
 
Characteristics  
 
Patients with FAP 
 
Controls 
 
 
Number  
 
 
85 
 
218 
Age (years; mean ± SD) 
 
42 ± 16 42 ± 16 
Gender: 
             Female             
             Male  
 
 
47 (55.3) 
38 (44.7) 
 
115 (52.8) 
103 (47.2) 
Spigelman stage at first duodenoscopy  A
   
Stage 0    
Stage I     
Stage II    
Stage III   
            Stage IV    
 
 
 
 
17 (34.0) 
2 (4.0) 
12 (24.0) 
11 (22.0) 
8 (16.0) 
 
 
 
Age at first duodenoscopy 
(years; mean ± SD) 
 
Stage 0    
Stage I      
Stage II    
Stage III    
Stage IV    
 
 
 
 
39.6 ± 11.8 
63.0 
43.0 ± 12.2 
38.3 ± 10.0 
48.5 ± 10.2 
 
 
A
 For 35 patients with FAP, no information on Spigelman stage at first duodenoscopy was available. 
Percentages are given in parenthesis 
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Calculation of the odds ratio of genotypes associated with predicted normal 
enzyme activity versus genotypes associated with predicted altered enzyme 
activities (variant genotypes) showed that the variant genotypes of UGT1A3 
are significantly less common in patients with FAP (OR 0.39, 95% CI 0.22-
0.67). The observed lower frequency of the variant genotypes of UGT1A1 in 
patients with FAP (p = 0.021) was no longer significant after the Bonferroni 
correction for multiple testing (p < 0.0125). 
 
Chi-square analyses revealed no significant differences in the presence of 
variant alleles between patients with FAP and controls. When combining 
alleles that may provide normal enzyme activities versus alleles that may yield 
altered enzymes activities, a significantly lower number of the variant UGT1A3 
alleles were observed in the patients with FAP (OR 0.60, 95% CI 0.41-0.88).  
 
Spigelman stage 
No associations between genotype patterns and the Spigelman stages were 
observed in patients with FAP. Furthermore, the polymorphisms investigated 
here had no predictive value for the Spigelman stage at first duodenoscopy in 
patients with FAP. 
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Table 5: Distribution of UGT and GST genotypes in patients with FAP and controls. 
 
Genes  
 
Genotypes 
 
Patients with FAP (%) A  
 
Controls (%) A  
 
OR (95% CI) B 
 
UGT1A1 
 
*1*1   
*1*28 
*28*28  
 
 
49/85 (57.7) 
28 (32.9) 
8 (9.4)  
 
94/216 (43.5)  
98 (45.4) 
24 (11.1)  
 
0.57 (0.34-0.94)  
 
UGT1A3 *1*1  
*1*2 
*2*2  
*3*1  
*3*2  
*3*3 
*6*6  
*1*6  
 
35/79 (44.3) 
26 (32.9) 
7 (8.9)  
5 (6.3)  
5 (6.3)  
1 (1.3)  
45/192 (23.4) 
83 (43.2) 
31 (16.1) 
24 (12.5) 
4 (2.1) 
3 (1.6) 
1 (0.5) 
1 (0.5) 
0.39 (0.22-0.67) C 
 
UGT1A4 *1*1  
*1*2  
*2*2  
*1*3  
*2*3  
 
55/79 (69.6) 
6 (7.6)  
 
16 (20.3) 
2 (2.5) 
131/181 (72.4) 
16 (8.8) 
3 (1.7) 
30 (16.5) 
1 (0.6) 
1.14  (0.64-2.04) 
 
UGT1A6 *1*1 
*1*2  
*2*2  
*1*3  
*2*3 
 
45/85 (52.9) 
28 (32.9) 
8 (9.4) 
2 (2.4)  
2 (2.4)  
98/218 (45.0) 
94 (43.1)  
20 (9.2)  
4 (1.8) 
2 (0.9) 
0.76 (0.46-1.26) 
 
UGT1A10 *1*1  85/85 (100) 
 
217/217 (100)  
- 
 
UGT2B4 *1*1  
*1*2  
*2*2 
  
49/83 (59.0) 
25 (30.1) 
9 (10.9)  
105/217 (48.4) 
93 (42.9) 
19 (8.7) 
  
0.65 (0.39-1.09) 
 
UGT2B7 *1*1  
*1*2  
*2*2 
28/85 (32.9) 
32 (37.6) 
25 (29.5)  
57/217 (26.2) 
108 (49.8) 
52 (24.0) 
 
0.73 (0.42-1.25) 
 
UGT2B15 *1*1  
*1*2  
*2*2 
13/78 (16.6) 
41 (52.6) 
24 (30.8) 
 
44/211 (20.9) 
92 (43.6) 
75 (35.5) 
 
1.3 (0.67-2.61) 
 
GSTA1  *A*A  
*A*B  
*B*B 
  
37/85 (43.5) 
38 (44.7) 
10 (11.8)  
88/211 (41.7) 
89 (42.2) 
34 (16.1) 
 
0.93  (0.56-1.54) 
 
GSTP1   Ile/ Ile  
Ile/Val 
Val/Val  
 
31/85 (36.5) 
39 (45.9) 
15 (17.6) 
90/209 (43.1) 
86 (41.1) 
33 (15.8) 
 
1.32 (0.78-2.22) 
 
GSTM1  +  
null 
38/85 (44.7) 
47 (55.3) 
  
100/215 (46.5) 
115 (53.5) 
 
1.08 (0.65-1.78) 
 
GSTT1  +  
null 
60/85 (70.6)  
25 (29.4) 
165/214 (77.1) 
49 (22.9) 
 
1.40 (0.80-2.47) 
 
 
A
 In both the FAP and control group, there is some missing data because of insufficient amount  
of DNA or unsuccessful PCR 
B
 Genotypes were combined on the basis of an expected phenotype-genotype relationship  
(variant genotypes with expected altered enzyme activities versus genotypes with expected  
normal enzyme activities).  
C
 Statistically significant 
 
 
Chapter 3 GST and UGT polymorphisms in FAP 
 
 55 
Table 6: Allele frequencies of UGT and GST polymorphisms in patients with FAP and controls. 
 
 
Alleles  
 
 
Patients with FAP A 
(number/total)  
 
Controls A 
(number/total)   
 
OR (95% CI) B 
 
 
UGT1A1*1  
UGT1A1*28  
 
 
0.74 (126/170) 
0.26 
 
0.66 (286/432) 
0.34  
 
0.68 (0.46-1.02) 
 
UGT1A3*1  
UGT1A3*2   
UGT1A3*3 
UGT1A3*6  
0.64 (101/158) 
0.28 
0.08    
0.52 (198/384)  
0.38 
0.09 
0.01 
 
0.60 (0.41-0.88) C 
 
UGT1A4*1  
UGT1A4*2  
UGT1A4*3 
0.84 (132/158)  
0.05  
0.11 
0.85 (308/362)  
0.06 
0.09 
 
1.12 (0.67-1.87) 
 
UGT1A6*1 
UGT1A6*2  
UGT1A6*3 
0.71 (120/170) 
0.27 
0.02  
  
0.67 (294/436) 
0.31 
0.02 
  
0.86 (0.59-1.27) 
 
UGT1A10*1  
UGT1A10*3 
UGT1A10*4 
 
1.0 (170/170)  1.0 (434/434) - 
 
UGT2B4*1 
UGT2B4*2 
0.74 (123/166)  
0.26  
0.70 (303/434) 
0.30 
  
0.81 (0.54-1.21) 
 
UGT2B7*1   
UGT2B7*2 
0.52 (88/170)  
0.48 
0.51 (222/434) 
0.49 
  
0.98 (0.68-1.39) 
 
UGT2B15*1   
UGT2B15*2 
0.57 (89/156) 
0.43   
0.57 (242/422) 
0.43 
  
0.99 (0.68-1.43) 
 
GSTA1*A   
GSTA1*B 
0.66 (112/170)  
0.34  
0.63 (265/422) 
0.37 
   
0.87 (0.60-1.27) 
 
GSTP1*Ile   
GSTP1*Val  
0.59 (101/170)  
0.41  
0.64 (266/418) 
0.36 
  
1.20 (0.83-1.72) 
 
GSTM1+  
GSTM1null  
0.45 (76/170) 
0.55   
0.47 (200/430) 
0.53 
  
1.08 (0.75-1.54) 
 
GSTT1+   
GSTT1null 
0.71 (120/170) 
0.29  
  
0.77 (330/428)  
0.23 
1.40 (0.94-2.09) 
 
A
 In both the FAP and control group, there is some missing data because of insufficient amount of DNA 
or unsuccessful PCR 
B
 Genotypes were combined on the basis of an expected phenotype-genotype relationship (variant 
genotypes with expected altered enzyme activities versus genotypes withexpected normal enzyme 
activities). 
C
 Statistically significant 
 
 
Chapter 3 GST and UGT polymorphisms in FAP 
 
 56 
Discussion 
Without prophylactic colectomy, almost 100% of the patients with FAP will 
develop colorectal cancer by the age of forty 2. In addition, these patients 
frequently develop duodenal adenomas and the prevalence of duodenal 
carcinomas is 2-5% 3, 7. This process, although mainly driven by APC 
mutations, may be modulated to some extent by other factors, such as the 
enzymes involved in detoxification. Detoxification is pivotal in reducing the 
load of toxins and carcinogens entering the body via food, medication or 
lifestyle habits such as smoking and drinking alcohol. In addition to the 
germline APC mutations, an extra pressure of toxins or carcinogens may 
introduce additional somatic mutations, which can accelerate the processes of 
adenomatosis and carcinogenesis in patients with FAP. Several functional 
genetic polymorphisms with concomitant loss of enzyme activity have been 
described in the important detoxification enzymes of the GST and UGT 
families, which are mainly involved in the mucosal protection against 
carcinogens 11, 13. We therefore investigated whether the polymorphisms in 
GST and UGT genes, which are associated with functional changes in the 
enzyme activity and may be involved in modulation of the phenotype, are 
differently distributed in patients with FAP versus age and gender matched 
controls.   
 
A significantly different distribution was found for the genotypes of UGT1A3 in 
patients with FAP compared with controls. UGT1A3 is expressed in the liver, 
biliary and gastric tissues and in the intestine 18, 37, 38. It catalyses the 
glucuronidation of important endogenous substances such as the steroid 
hormones estrone and 2-hydroxyestrone, the bile acid chenodexoycholic acid, 
as well as many exogenous compounds like primary amines, tertiary amines, 
hydroxylated benzo(a)yrenes, 2-acetylaminofluorenes, flavonoids, 7-
hydroxycoumarins, opiods, anthraquinones and commonly prescribed drugs 37, 
39, 40
.  Iwai et al. 41 studied the different genotypes of UGT1A3 present in a 
Japanese population and measured the in vitro enzyme activity towards the 
substrate estrone, of the polymorphic variants of UGT1A3 expressed in COS 
cells. The UGT1A3*2 variant enzyme showed a significantly higher (269%) 
enzyme activity towards estrone compared to the most common UGT1A3*1 
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form, whereas the enzyme activity of the UGT1A3*3 variant was 21% higher 
compared to UGT1A3*1 (not significant). The variant allele UGT1A3*6 was not 
detected in either patients or controls under study here. Estrone is an 
endogenous female steroid hormone. Epidemiological and experimental 
evidence suggests an inverse association between ever use of oral 
contraceptives and the risk of colorectal cancer 42. Interestingly, a recent case 
report showed complete adenoma regression in the colon of a patient with 
FAP, after the use of oral contraceptives 43.  Since UGTs including UGT1A3, 
are involved in the metabolism of female steroid hormones, the low UGT1A3 
enzyme activity associated genotypes, more often present in patients with 
FAP, may possibly be a factor of importance in the modulation of 
adenomatosis. The current study revealed no difference between females and 
males in their UGT1A3 genotype distribution, although these subgroups are 
very small. 
 
Polymorphisms in the UGT1A3 gene may also result in a decreased activity 
towards flavonoids. Flavonoids are dietary antioxidants widely found in fruits, 
vegetables, cereals, pulses, chocolate, and beverages 44. The flavonoids such 
as quercetin, kaempferol and luteolin may play an important role in cancer 
prevention 45, 46. Compared to the control group, patients with FAP more often 
have a genotype associated with a high conjugating enzyme activity towards 
the flavonoids. This may result in higher rates of inactivating and excretion of 
flavonoids in patients with FAP compared to controls, which could mean that 
the patients with FAP in general have less benefit from the dietary flavonoids. 
There are only two studies so far describing the effect of polymorphisms in the 
UGT1A3 gene 41, 46. A better understanding of the effect of polymorphisms on 
different substrates could give new insights into the relationship between these 
polymorphisms and FAP.   
 
In accordance with the results of Crabtree et al. 10 and Lamberti et al. 25, we 
found no differences between the genotype distribution of GSTT1 and GSTM1 
in patients with FAP versus controls. In contrast, Spigelman et al. 22 found 
lower GSTM levels in the peripheral blood of patients with FAP.  
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The two genotype distributions tested here did not fit the Hardy-Weinberg 
criteria: the UGT1A4 (control group) and the UGT2B7 genotype (patient 
group). If genotype frequencies differ from the expected Hardy-Weinberg 
values, one or more of the assumptions of this model are being compromised. 
One assumption is that the population is large; the relatively small numbers of 
patients in this study may be an explanation for the above-cited disequilibrium 
in the two groups.   
 
Although the difference in genotype distribution of UGT1A1 (patients with FAP 
vs. controls) lost significance after correction for multiple testing, it is tempting 
to speculate on the possible consequence of this observation. UGT1A1 is the 
only UGT involved in the breakdown of billirubin. The presence of one or two 
variant alleles of UGT1A1*28 was associated with lower bilirubin conjugating 
enzyme activity and higher serum levels of unconjugated billirubin 47, which is 
an established antioxidant. Higher levels of serum billirubin were associated 
with a lower risk of cardiovascular disease 48. Furthermore, it has been 
suggested that higher serum levels of billirubin can reduce the risk of cancer 
49
. Since the patients with FAP more frequently show the genotype with the 
normal UGT1A1 enzyme activity associated with lower serum billirubin levels, 
this could also contribute to an increased risk of (early) colorectal as well as 
duodenal tumours. 
 
In conclusion, although the genotype distribution of UGT1A3 is different in 
patients with FAP compared with controls, some critical remarks should be 
made. The number of patients included in this study is relatively small, only 
one out of the twelve polymorphisms investigated differs between patients with 
FAP and controls and there is no correlation with the polymorphisms and the 
Spigelman stage. Therefore the polymorphisms in UGTs and GSTs 
investigated here do not play an important modulating role in the inter-
individual differences in the development of duodenal adenomas as noted in 
patients with FAP. Therefore, we conclude that the findings of this study can 
not be used in the clinical management of duodenal adenomas  in patients 
with FAP.   
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The duodenum is the main site for (pre-)malignant extra-colonic manifestations 
in patients with familial adenomatous polyposis. Changes in the E-cadherin / -
catenin complex play a pivotal role in the development of malignancies. Loss 
of E-cadherin has been described in association with loss of SMAD4. In order 
to elucidate the pathways leading to the development of duodenal adenomas in 
patients with FAP, the distributions of E-cadherin, SMAD4 and -catenin were 
analysed. Furthermore, differences between the duodenum and colon were 
evaluated. Normal FAP duodenum (n=13) and FAP duodenal adenomas (n=50, 
total 21 patients) were compared with non-FAP duodenal adenomas (n=7) and 
normal non-FAP duodenum (n=15) by immunohistochemical staining for 
extracellular and intracellular E-cadherin, -catenin and SMAD4. Colonic 
biopsies of 10 patients with FAP were also studied, as well as non-FAP colonic 
adenomas (n=26) and non-FAP normal colon (n=12). Compared to the 
intracellular component of E-cadherin that was present in all cases, a 
significant loss of extracellular E-cadherin was observed in both duodenal and 
colonic adenomas and in normal tissue of patients with FAP. Nuclear 
localisation of -catenin was more often observed in duodenal FAP adenomas 
compared with non-FAP adenomas. Loss of nuclear SMAD4 was seen in the 
duodenum and to a larger extent in the colon of patients with FAP, as well as 
non-FAP patients.The loss of extracellular E-cadherin in the normal duodenal 
and colonic mucosa of patients with FAP might play a role in the high 
susceptibility of these tissues to (pre-)malignant transformation.  
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Introduction 
Germline mutations in the tumour suppressor gene Adenomatous polyposis 
coli (APC) cause familial adenomatous polyposis (FAP) 1. This autosomal 
dominant disorder is characterised by numerous colorectal adenomas, which 
will eventually progress to adenocarcinoma. Without prophylactic colectomy, 
FAP will inevitably lead to colorectal cancer at a relatively young age 2.  
Additionally, patients with FAP run the risk of developing extra-colonic 
manifestations and the duodenum is the main site for these (pre-)malignant 
developments 2,3. The prevalence of the mainly peri-ampullary located 
adenomas varies from 50% to over 90% 4-6. The prevalence of duodenal 
carcinoma in patients with FAP is 2-5% 6-9 and, compared to the general 
population, the relative risk of duodenal adenocarcinoma is exceptionally high 
3
. Together with desmoid tumours, duodenal carcinomas are now the leading 
causes of cancer-related mortality in FAP 10.  
The mutations in the APC gene found in FAP lead to a disturbed function of 
the APC protein. The key tumour suppressor function of APC is to regulate the 
stability and cellular localisation of β-catenin 11.  β-catenin is a bifunctional 
protein; it has a crucial role in cell-cell adhesion 12 and a signalling role in the 
Wnt pathway 13. Loss of functional APC in tumourigenesis deregulates the 
signalling properties of β-catenin leading to cytosolic accumulation and nuclear 
translocation. In the nucleus, it activates transcriptional targets such as c-MYC 
14
 and cyclin D1 15. In cell adhesion, β-catenin is crucial to the normal 
functioning of E-cadherin 16. E-cadherin, the main adhesion molecule of 
epithelial cells, is a calcium-dependent transmembrane glycoprotein which 
mediates cell-cell adhesion 17. Intracellular β-catenin binds to the cytoplasmic 
tail of E-cadherin forming an adhesion complex with the actin cytoskeleton 18. 
E-cadherin/catenin complexes are also involved in differentiation, polarity, 
migration, proliferation, and survival of epithelial cells, which are all 
fundamental processes for the maintenance of normal intestinal epithelial 
architecture and function 19.  Mutations in the E-cadherin gene are associated 
with diffuse-type gastric cancer 20 and lobular breast carcinomas 21, and down 
regulation of E-cadherin expression has been described in many types of 
cancer. Moreover, loss or absence of E-cadherin is associated with aggressive 
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histopathological characteristics such as tumour invasiveness and metastasis 
22
. In primary colorectal tumours, loss of E-cadherin is strongly linked to the 
loss of SMAD4 23. The tumour suppressor function of SMAD4 lies in its 
capacity to mediate the effects of TGF- signalling superfamily 24. 
Furthermore, in small intestinal adenocarcinomas, inactivating mutations of the 
SMAD4 gene have been observed 25. Recently, loss of E-cadherin was shown 
in colonic adenomas of patients with FAP, which suggests that it is an early 
event in the colonic adenoma-carcinoma sequence in FAP 26.  
 
The aim of the current study is to evaluate the distribution of E-cadherin, -
catenin and SMAD4 in adenomas and normal duodenum of patients with FAP 
and to compare it with the patterns in non-FAP duodenal adenomas and 
normal non-FAP duodenum. In addition, the above-mentioned parameters are 
compared in the duodenum and colon of patients with FAP.  
 
Materials & Methods 
 
Patients and controls 
In the period 1996-2004 duodenal specimens of patients with FAP were 
retrieved from the files of the Department of Pathology (Radboud University 
Nijmegen Medical Centre, the Netherlands). A total of 63 specimens including 
normal duodenal mucosa (n=13) and adenomas (n=50) of 21 patients were 
included. In addition, normal non-FAP duodenum (n=15) and non-FAP 
adenomas (n=7) from the same period were selected. No ampullary 
adenomas were included. To exclude HNPCC in the non-FAP patients with 
duodenal adenomas, immunohistochemical staining for the DNA mismatch 
repair proteins: MLH-1 MSH-2 and MSH-6 (see immunohistochemistry) was 
performed, for which all stainings were positive. Colonic specimens, both 
normal mucosa (n=3) and adenomas (n=22) of 10 of the patients with FAP, as 
well as non-FAP colonic adenomas (n=26) and normal non-FAP colon (n=12) 
specimens were included in the study. In 41% of the patients with FAP, the 
APC mutation was not known. Mutations in exons 12, 13, 14 and 15 were 
respectively observed in 5%, 27%, 5% and 17% of the patients with FAP. One 
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patient (5%) showed a MYH mutation. This study was approved by the local 
medical ethical review committee. 
 
Histological evaluation 
Adenomas were graded and classified according to histological type and 
degree of dysplasia by the method of Morson 27. The slides were reviewed by 
two pathologists (JHJMvK & IDN). 
 
Spigelman stage 
All duodenal specimens of patients with FAP were graded according to 
Spigelman’s stage, which is a semi-quantitive scoring system, expressing the 
severity of duodenal polyposis according to number, size, histology and 
degree of dysplasia of duodenal lesions (Table 1) 28.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunohistochemistry 
Table 2 summarises the antibodies used in this study. In short, the paraffin–
embedded tissues were cut into 4 µm sections. These sections were 
deparaffinised in xylene, rehydrated and incubated with 3% hydrogen 
peroxide/ PBS to block endogenous peroxidase. Antigen retrieval was 
performed by microwave exposure for 10 min in 10 mM citrate buffer (pH 6.0). 
The slides were allowed to cool down for at least 90 mins. After pre-incubation 
with 20% normal horse serum, sections were incubated overnight at 4° C with 
Table 1:  Spigelman stage represents the severity in duodenal polyposis. 
 
Category 
 
 
1 
Points 
2 
 
 
3 
 
Number of adenomas                                        
 
1-4
 
5-20 
 
> 20 
Size of adenomas (mm)                                    1-4 5-10 > 20 
Histology            Tubular Tubulovillous Villous 
Degree of dysplasia                                          Mild Moderate Severe 
 
Within each category, 1 to 3 points can be scored, and the sum of the score in the 4 categories results in the  
Spigelman stage. Stage 0, 0 points; Stage I, 1-4 points; Stage II, 5-6 points; Stage III, 7-8 points; Stage IV, 9-12  
points.                                                                
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the primary antibodies in PBS/ 1% Bovine Serum Albumin (BSA), followed by 
the incubations with a biotinylated secondary antibody and the avidin-biotin-
peroxidase complex (Vector Laboratories Inc, Burlingame) respectively. 
Finally, 3,3’-diaminobenzidene (DAB) was used as the chromagen with 
haematoxylin counterstaining. Negative controls were constructed by omitting 
the primary antibody. For the DNA mismatch repair proteins the following 
antibodies (and antigen retrieval) were used: 
• MLH1: 1:500, BD Biosciences, Europe, microwave exposure for 10 
mins in 10 mM Tris/ 1 mM EDTA, pH 9.0; 
• MSH2: 1:140, Merck Biosciences, Europe, microwave exposure for 10 
mins in 10 mM Tris/ 1 mM EDTA, pH 9.0; 
• MSH6: 1:1000, BD Biosciences, Europe, microwave exposure for 20 
mins in 10mM citrate buffer, pH 6.0. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunofluorescent double staining  
Immunofluorescent double staining was used to confirm light microscope 
findings and illustrative representation. Immunofluorescent double staining 
was performed, using antibodies against the extracellular and intracellular 
epitopes of E-cadherin. In short, after deparaffinising and rehydrating, the 
sections were washed overnight in PBS. Antigen retrieval was performed by 
microwave exposure for 10 mins in 10 mM citrate buffer (pH 6.0). The slides 
were allowed to cool down for at least 90 mins. Incubation with normal goat 
Table 2: Primary antibodies used for immunohistochemistry. 
 
 
Antigen 
 
Antibody  
 
Duodenum  
dilution
  
 
Colon 
dilution 
 
 
Animal 
source 
 
E-cadherin 
extracellular 
 
 
HECD-1, Takara Bio Inc., Japan 
 
1:400 
 
1:200 
 
mouse 
E-cadherin 
intracellular 
 
Clone 36, BD Biosciences, Europe
  
1:1500 1:2000 mouse 
B-catenin Clone 14, BD Transduction 
Laboratories, Europe 
 
1:8000 1:8000 mouse 
SMAD4
  
B-8, Santa Cruz Biotechnology, USA 1:500 1:500 mouse 
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serum (20%) in PBS for 10 mins blocked background staining. The sections 
were incubated with the first primary antibody (mouse anti-human HECD-1, 
Takara Bio Inc, Japan) at a dilution of 1:50 in PBS/ 1% BSA at 4˚ C overnight. 
The slides were incubated with a goat anti-mouse IgG antibody conjugated 
with alexa 594 (1:200, Molecular Probes, Inc, Eugene, USA) for 30 mins at 
room temperature. From this moment the sections were handled in the dark. 
After a second incubation with normal goat serum, the slides were incubated 
with the second primary antibody (mouse anti-human E-cadherin Clone 36, 
BD Biosciences, Europe) at a dilution of 1:1500 in PBS/ 1% BSA at 4º C 
overnight. The sections were then incubated with a goat anti-mouse IgG2a 
antibody conjugated with alexa 488 (1:200, Molecular Probes) for 30 mins at 
room temperature. The nuclei were stained with 4’-6-diamino-2-phenylindole 
(DAPI) for 20 secs. The slides were enclosed in Fluorteck (Euro-Diagnostica, 
Arnhem, the Netherlands) and examined with a fluorescence microscope 
(Leica, Solms, Germany).  
 
Scoring method 
Two categories for loss of membranous staining of E-cadherin were used: 1 = 
normal expression with maximal 5% loss and 2 = 50-90% loss of E-cadherin, a 
self-designed scoring method. This scoring method was derived from the first 
scoring into four categories: 1, no loss; 2, low loss; 3, moderate loss; and 4, 
high loss. After this scoring, it was evident that all samples could be classified 
into the two categories: no to low loss (1 & 2) and moderate to high loss (3 & 
4). These categories represent the percentages of loss observed, namely: 1= 
normal with maximal 5% loss and 2 = 50 – 90% loss, as described above. 
Nuclear loss of SMAD4 could also be put into the categories 1 and 2 and focal 
loss of nuclear SMAD4 staining was noted. Beta-catenin was scored for 
membranous, cytoplasmic or nuclear expression, should any part of the 
specimen show this expression. Localisation was considered cytoplasmic if 
membranous staining was totally absent. The slides were independently 
reviewed by two of the authors (MB & MJEMG). In less than 5% of the slides 
differences between the two observers occurred, these specimens were re-
evaluated by the two observers together and consensus was obtained.  
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Statistical analysis 
Fisher’s exact test was used to compare the loss of E-cadherin and SMAD4 
between the different groups. One-way ANOVA was performed to examine the 
relation between the age of the subjects and other categorical parameters. 
Associations between the categorical parameters were tested with the Chi-
square test. For statistical correctness, analyses were also performed with one 
randomly chosen sample for each patient. These analyses gave the same 
results as with multiple sampling of one patient. P < 0.05 was considered to be 
statistically significant (SSPS 12.0.1 for Windows 2003, SPSS Inc., Chicago, 
USA) 
 
Results 
 
Patient characteristics 
Specimens were collected at several time points from almost all patients with 
FAP. Table 3 lists the duodenal and colonic biopsies of the patients with FAP 
included in this study and summarises data on age, histological type and 
degree of dysplasia. The average age of the non-FAP patients is 62 ± 7 years. 
Patients with FAP and duodenal adenomas were significantly younger 
compared with the non-FAP patients (average age 50 ± 13 vs. 62 ± 7 years, p 
= 0.03). The age of patients with FAP with a normal duodenum did not differ 
from that of the non-FAP patients with a normal duodenum (p = 0.174). 
 
At an average age of 28 ± 11 years at the moment of surgery, all patients with 
FAP underwent colectomy; 52.4% with an ileal-rectal anastomosis, 33.3% with 
an ileal pouch-anal anastomosis and 14.3% with an ileal stoma. The average 
interval between colectomy and the sampling of duodenal specimens used for 
this study was 15.9 ± 7 years.  
 
The Spigelman stages classify the severity of duodenal polyposis into five 
categories (0- IV). Samples in this study were classified as stage 0: 20.6%, 
stage I: 6.3%, stage II: 36.5%, stage III: 28.6% and stage IV: 8%. The 
Spigelman’s stage increased with the increasing age of the patients with FAP 
(Spigelman I: 39 ± 5 years versus Spigelman III: 56 ± 12 years, p = 0. 04).  
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Characteristics of the colonic biopsies of the patients with FAP are also listed 
in Table 3. The average age of the non-FAP patients with normal colon or 
colonic adenomas is 54 ± 19 years and 67 ± 11 years respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histological evaluation of patients with FAP 
In 21% of the duodenal biopsies from patients with FAP, the duodenum 
showed no abnormalities. Tubular adenomas were observed in 42% of the 
biopsies, 27% showed tubulovillous adenomas and 10% villous adenomas. 
The age of the patients with tubular adenoma was significantly lower 
compared with patients with tubulovillous and villous adenomas (45 ± 13 vs. 
Table 3: Characteristics of patients with FAP for both duodenal and colonic biopsies. 
 
    
 
 
ID  
 
Normal 
duodenum 
 
 
Age 
 
Duodenal adenomas 
 
 
 
Age                Type     Dysplasia                
 
 
Normal 
colon 
 
 
Age 
 
Colonic adenomas 
 
 
 
Age            Type           Dysplasia 
 
F1 
     
21 
 
21 
 
TA 
 
II 
F2 57 (2x) 44, 51, 52 
(2x), 53 (2x) 
54 (3x), 55, 
58 
TA (2x) 
TV (5x) 
VA (4x) 
I (2x) 
II (9x) 
 34, 42, 49 TA (3x) 
 
I (2x), II 
 
F3  35, 39 TA, TV I (2x)  29 TA I 
F4  31 TA I  48 (2x), 56 TA (3x) I, II (2x) 
F5  26, 28 TA (2x) I (2x)  17 (3x), 23 TA  (4x) I (4x) 
F6  40 TA II  28 (2x) TA (2x) I (2x) 
F7  41, 43 (2x) TA (3x) I (3x)     
F8 55, 60     14, 15 (2x), 
17 (2x) 
TA (5x) I (2x), II 
(2x), III 
F9 56    34 (2x)    
F10 45 48 TA I  26 (2x) TA, TV I, II 
F11  73 TA I  36 TA I 
F12  31 TA I     
F13 43, 44, 45 41 (3x), 43 
(3x), 44 
TA (7x) I (7x)     
F14  67 (3x), 68 
(3x), 69 
TA  
TV (6x) 
I 
II (6x) 
    
F15  38 TA II     
F16 29, 32        
F17  48, 50 TA, TV I, II     
F18  65 (2x) TA (2x) I (2x)     
F19 24        
F20  59, 60, 61, 
62, 63 
TA 
TV (2x) 
VA (2x) 
II (5x)     
F21  36, 37 TA, TV I, II     
F22 30 31 TV I     
 
Type: TA = Tubular adenoma, TV = Tubulovillous adenoma, VA = Villous adenoma 
Dysplasia: I = mild, II = moderate, III = severe 
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55 ± 13 and 55 ± 5 years respectively; p = 0.04). Tubular adenomas were 
observed earlier after colectomy (17 ± 10 years) compared with tubulovillous 
adenomas (29 ± 14 years, p = 0.01) and villous adenomas (22 ± 7 years). 
Moderately graded dysplasia was present in only 15% of all tubular adenomas 
compared to 100% of all villous adenomas (p < 0.0001). Moderately graded 
dysplasia was more often observed in older patients compared with mildly 
graded dysplasia (56 ± 9 vs. 44 ± 13 years, respectively; p = 0.001). In 
addition, mildly graded dysplasia was observed earlier after colectomy 
compared with moderately graded dysplasia (16 ± 10 vs. 28 ± 11 years, p = 
0.001).  
 
The colonic adenomas were tubular in 95% and tubulovillous in 5% of the 
cases. Mild dysplasia was seen in 64% of the cases, moderate dysplasia in 
32% and severe dysplasia in 4%. 
 
Histological evaluation of non-FAP patients 
The non-FAP patients with duodenal adenomas showed tubular adenomas 
with mild graded dysplasia in 71% of the cases. Due to the small number of 
patients (n=7), statistical analyses were not performed. 
 
Colonic adenomas were tubular in 73% and tubulovillous in 27% of the cases. 
Mild dysplasia was seen in 67% of the cases, moderate dysplasia in 27% and 
severe dysplasia in 6%. 
 
Loss of E-cadherin  
All specimens used in this study showed membranous staining for E-cadherin. 
For the extracellular component of E-cadherin only two categories were 
observed: normal staining with a maximum of 5% loss and specimens showing 
50–90% loss. Compared to the intracellular component of E-cadherin that was 
present in all cases a significant loss of extracellular E-cadherin was observed 
in FAP duodenal adenomas (0% and 54% respectively, p < 0.001). In 43% of 
the non-FAP adenomas, loss of extracellular E-cadherin was observed 
compared with 0% loss of the intracellular component. Loss of extracellular E-
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cadherin was also seen in the morphologically normal duodenum of patients 
with FAP (54% versus 7% in normal non-FAP duodenum, p = 0.01).   
 
Patients with FAP and adenomas showing normal staining of E-cadherin were 
older at the moment of colectomy (31 ± 9 years) compared with patients with 
50 – 90% loss (26 ± 9 years, p = 0.03). Loss of E-cadherin was not associated 
with the age of the patients, Spigelman stage, APC mutation, type of adenoma 
or degree of dysplasia. Furthermore, no intra-individual changes in loss of 
extracellular E-cadherin could be observed in the multiple samples of the 
patients. Immunofluorescent double staining of the extracellular and 
intracellular epitopes of E-cadherin in normal FAP duodenum and normal non-
FAP duodenum is depicted in Figure 1. Figure 2 shows light microscopic 
images of the extracellular and intracellular epitopes of E-cadherin in FAP and 
non-FAP duodenum. 
 
Similar to the duodenum, loss of extracellular E-cadherin was observed in FAP 
colonic adenomas; however, this loss was not seen in the non-FAP colonic 
adenomas (64% and 4% respectively; p < 0.001).  In addition, the normal 
colon of patients with FAP showed loss of extracellular E-cadherin (100% 
versus 0% in normal non-FAP colon, p < 0.001). The intracellular E-cadherin 
was present in the colon in all cases, as it was in the duodenum. Table 4 
summarises the results of the immunohistochemical findings in the duodenum 
compared to these findings in the colon. 
 
Beta-catenin localisation 
Membranous localisation of -catenin was seen in 96% of the FAP duodenal 
adenomas, 86% of the non-FAP duodenal adenomas and 100% of normal 
FAP and non-FAP duodenum. Cytoplasmic localisation was not present in 
normal non-FAP duodenum. Cytoplasmic localisation was observed in 8% of 
normal FAP mucosa, 32% of FAP adenomas and 14% of non-FAP adenomas. 
Nuclear localisation was more often observed in the FAP adenomas compared 
to the non-FAP duodenal adenomas (84% and 14%, respectively; p = 0.001). 
There were no differences in nuclear localisation between normal FAP and 
non-FAP duodenum. Membranous, cytoplasmic and nuclear localisation of -
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catenin is depicted in Figures 3A & B. Distribution of -catenin was not 
associated with degree of dysplasia. However, these observations of -catenin 
in relation to dysplasia are based on the general estimation of dysplasia in the 
whole biopsy. If observed in more detail, in a slide-by-slide comparison, the 
localisation of -catenin seems to be directly related to the type of dysplasia. 
In focal areas with mild dysplasia, -catenin is located membranous, 
compared to cytoplasmic and nuclear localisation in areas with moderate to 
severe dysplasia (p = 0.004).  
 
Membranous localisation of -catenin was visible in all normal FAP and non-
FAP colon. Nuclear localisation was observed in 73% and 85% of the FAP 
adenomas and non-FAP adenomas respectively. Cytoplasmic localisation was 
observed in 32% and 27% of the FAP and non-FAP adenomas respectively. 
The distribution of -catenin was associated with the degree of dysplasia: 
adenomas with a high degree of dysplasia more frequently showed 
cytoplasmic localisation of -catenin (mild dysplasia vs. severe dysplasia, 21% 
and 50% respectively; p = 0.02).  
 
Loss of SMAD4 
In the FAP duodenal adenomas, 42% of the cases showed loss and the loss 
was seen focally in 21% of the cases. There was no difference between FAP 
adenomas and non-FAP adenomas. In normal FAP and non-FAP duodenum, 
92% respectively 93% of the cases showed no loss of SMAD4 and there was 
no focal reduction of nuclear SMAD4. In the FAP adenomas, loss of nuclear 
SMAD4 was associated with loss of extracellular E-cadherin (p = 0.05). Loss 
of SMAD4 was correlated with a high Spigelman’s stage (p = 0.015). Normal 
staining, focal appearance and loss of SMAD4 is depicted in Figures 3C-F. 
Loss of nuclear SMAD4 was observed in both FAP and non-FAP colonic 
adenomas (82% and 85% respectively). In the normal colon 100% (FAP) and 
92% (non-FAP) of the samples showed loss of nuclear SMAD4.  
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Figure 1: Immunofluorescent double staining of E-cadherin in normal FAP duodenum 
 and normal non-FAP duodenum, magnification 400x. A: intracellular epitope of  
E-cadherin in normal FAP duodenum, B: extracellular epitope of E-cadherin in  
normal FAP duodenum, C: merge colour of both intracellular and extracellular epitopes  
of E-cadherin in normal FAP duodenum, D: intracellular epitope of E-cadherin in  
normal non-FAP duodenum, E: extracellular epitope of E-cadherin in normal  
non-FAP duodenum, F: merge coulour of both intracellular and extracellular epitopes  
of E-cadherin in normal non-FAP duodenum. 
 
 
Figure 2: Immunohistochemical staining for the extracellular and intracellular epitopes of  
E-cadherin in FAP and non-FAP duodenum, magnification 400x. A: extracellular  
E-cadherin loss in normal FAP duodenum, B: normal staining of extracellular  
E-cadherin in normal non-FAP duodenum , C:  extracellular E-cadherin loss in adenoma 
of FAP duodenum, D: extracellular E-cadherin loss in adenoma of non-FAP duodenum,   
E: normal staining of intracellular E-cadherin in normal FAP duodenum, F: normal  
staining of intracellular E-cadherin in normal non-FAP duodenum, G: normal staining  
of intracellular E-cadherin in adenoma of FAP duodenum, H: normal staining of  
intracellular E-cadherin in adenoma of non-FAP duodenum. Staining results shown here,  
are also representative for the FAP and non-FAP colon. 
Chapter 4 E-cadherin, -catenin and SMAD4 in FAP 
 
 78 
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Figure 3 Immunohistochemical staining for -catenin and SMAD4 in FAP duodenum,  
magnification 400x.  A: membranous and nuclear localisation of -catenin in adenoma,  
B: cytoplasmic localisation of -catenin in adenoma, C: nuclear staining of SMAD4 in 
normal mucosa, D: loss of nuclear SMAD4 in adenoma, E: focal appearance of  
SMAD4 in adenoma 200x, F: focal appearance of SMAD4 in adenoma . Staining  
results shown here, are also representative for non-FAP duodenum and FAP and  
non-FAP colon. 
 
 
 
Chapter 4 E-cadherin, -catenin and SMAD4 in FAP 
 
 80 
Duodenum versus colon  
In patients with FAP, loss of extracellular E-cadherin was observed in 
morphologically normal mucosa of the duodenum (54%) and colon (100%), as 
well as in the adenomas (duodenum: 52%, colon: 64%). In the non-FAP 
patients, there was extracellular loss of E-cadherin in the duodenal adenomas 
(43%) but not in the colonic adenomas (4%). Almost no loss of extracellular E-
cadherin was found in the morphologically normal mucosa of non-FAP 
patients. Intracellular E-cadherin was found to be present in all cases in the 
duodenum and colon (Table 4).  
 
In normal FAP colon, cytoplasmic localisation of -catenin was observed far 
more often (100%) compared to normal FAP duodenum (8%). Nuclear 
localisation of -catenin was often present in both normal non-FAP and FAP 
duodenum (47% and 54%), whereas it was absent in normal non-FAP colon 
(0%) and only present in one of the FAP colons. In non-FAP adenomas, 
nuclear localisation is more often seen in the colon (85%) compared to the 
duodenum (14%) (Table 4).  
 
With the exception of non-FAP adenomas, the loss of nuclear SMAD4 was 
observed significantly more often in the colon than in the duodenum (Table 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 E-cadherin, -catenin and SMAD4 in FAP 
 
 81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4:  Results of immunohistochemical staining for extracellular and intracellular  
E-cadherin, -catenin and SMAD4 in normal mucosa of patients with FAP,  
normal non-FAP, FAP adenomas and non-FAP adenomas in the duodenum and colon.   
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FAP normal  
 
Duodenum 
(n=13) 
 
Colon 
(n=3) 
 
 
0 
 
0 
 
54 
 
100 
 
100 
 
100 
 
8 
 
100 
 
  54 
 
  33 
 
8 
 
100 
P value  ns ns ns  0.009   ns 0.007 
 
 
Non-FAP normal  
 
Duodenum 
(n=15) 
 
Colon  
(n=12) 
 
 
0 
 
0 
 
 
7 
 
0 
 
100 
 
100 
 
0 
 
0 
 
  47 
 
  0 
 
7 
 
92 
P value  ns ns ns ns   0.01 0.001 
 
 
FAP adenomas  
 
Duodenum 
(n=50) 
 
Colon 
(n=22) 
 
 
0 
 
 
0 
 
52 
 
64 
 
96 
 
100 
 
32 
 
32 
 
  84 
 
  73 
 
42 
 
82 
P value  ns ns ns ns   ns 0.004 
 
 
Non-FAP 
adenomas  
 
Duodenum 
(n=7) 
 
Colon 
(n=26) 
 
 
0 
 
0 
 
43 
 
4 
 
86 
 
100 
 
14 
 
27 
 
  14 
 
   85 
 
57 
 
85 
P value 
 
ns 0.006 ns ns    0.005  
      
ns 
 
 
Ns: not significant 
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Discussion 
In this study, loss of extracellular E-cadherin has already been observed in the 
normal duodenum of patients with FAP, whereas this loss in non-FAP patients 
is first observed in the adenoma stage, suggesting that loss of extracellular E-
cadherin is an early event in the (pre-)malignant transformation of the FAP 
duodenum. These findings are in accordance with the results of Biasco et al., 
who observed changes in the adherens junctions in normal duodenal mucosa 
of patients with FAP 29. Other cellular abnormalities were also observed in the 
normal duodenum of patients with FAP, such as a higher proliferation index 29-
30
, increased numbers of Paneth cells, endocrine cells in the crypts of normal 
FAP duodenum 31 and increased levels of cyclooxygenase-2 32.  Although loss 
of extracellular E-cadherin was observed in the normal mucosa of both 
duodenum and colon of patients with FAP, the morphology showed no 
abnormalities. The morphological integrity is possibly maintained by other 
adhesion molecules, such as Ep-CAM, which showed no loss in this study 
(data not shown). 
 
The prevalence of non-FAP duodenal adenomas is low 33; the number of 
patients included in this study is therefore small. Similar to the duodenal 
adenomas of patients with FAP, loss of extracellular E-cadherin in non-FAP 
adenomas was found. Although presumably the duodenal mucosa out of 
which the adenomas develop from the beginning differs with respect to 
proliferation and other cell kinetics 29-31, the mechanism of loss of extracellular 
E-cadherin in adenomas seems similar.   
 
In contrast to the duodenal adenomas, almost no loss of extracellular E-
cadherin was observed in non-FAP colonic adenomas. However, differences 
in carcinogenesis pathways in the small intestine and colon have already been 
described. APC mutations, which play a pivotal role in the initiation phase of 
colorectal tumourigenesis, are hardly present in small intestinal 
adenocarcinoma 34-36, suggesting a possible different genetic pathway. 
Because the loss of extracellular E-cadherin is seen in the duodenal 
adenomas of patients with FAP as well as non-FAP patients, the direct role of 
the APC mutations in these observations is also questionable. 
Chapter 4 E-cadherin, -catenin and SMAD4 in FAP 
 
 83 
 
Indirect evidence for the non-involvement of APC mutations is derived from 
the fact that mutations in the APC gene, as are present in FAP, could shift the 
cellular equilibrium of β-catenin away from the adherens junctions towards the 
pool of free β-catenin. However, we found no evidence of disturbance in the 
expression of the intracellular part of E-cadherin to which β-catenin is bound. 
Apparently, the deregulation of β-catenin by APC mutations does not 
necessarily lead to a disturbance in the cell adhesion complex. In addition, in 
vitro experiments demonstrated that E-cadherin-mediated cell adhesion is 
maintained after elimination of β-catenin. This suggests a regulatory role for β-
catenin instead of a mechanical role in cell adhesion 37.  
 
In patients with FAP, differences between the duodenum and the colon are 
evident: the prevalence of duodenal adenomas and carcinomas is 50-90% 
and 2-5% 2, 6-9, compared to corresponding values of 100% and 90% 
respectively in the colon 38. Moreover, in contrast to the colon, the correlation 
between the severity of duodenal polyposis and mutations in the APC gene is 
less well understood 39. These differences point to the possibility of a different 
mechanism underlying the development of adenoma and carcinoma in the 
small intestine compared to the large intestine. The difference between the 
duodenum and the colon was also outlined in the loss of SMAD4. Loss of 
nuclear SMAD4 was seen in almost every colonic sample in contrast to the 
duodenum. These observations are very difficult to explain, although it should 
be taken into consideration that the number of normal non-FAP colonic 
samples is very small. 
 
Reduced or absent staining of the extracellular part of E-cadherin, is also seen 
in diffuse gastric cancer 20 and lobular breast cancer 21, diseases both 
associated with mutations in the extracellular domain of the E-cadherin gene. 
One single amino acid substitution in the extracellular domain of E-cadherin 
has been shown to result in functional consequences for cell adhesion 40.  
However, in colorectal carcinomas a reduced staining of extracellular E-
cadherin was also observed which was not related to any mutation in the E-
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cadherin gene 41. Other possible explanations for the loss of E-cadherin are: 
steric hindrance by episialin 42 or proteoglycans 43 or the involvement of matrix 
metalloproteinase-7 (MMP-7). In vitro, this enzyme is capable of the 
ectodomain cleavage of E-cadherin 44, 45.  
 
MMP-7 mRNA has been detected in adenomas and carcinomas of the colon 
46, 47
. In FAP, the expression of MMP-7 in normal colon mucosa was 25 times 
higher and in colon adenomas as much as 700 times higher, compared to the 
levels in normal colon mucosa of controls 48. Furthermore, MMP-7 is a target 
gene for β-catenin 49. Since MMP–7 is often increased in the development of 
tumours, the non-FAP adenomas could also show loss of extracellular E-
cadherin. However, since MMP-7 may be over expressed in normal tissue of 
patients with FAP, the loss of extracellular E-cadherin can also occur in the 
normal mucosa of patients with FAP. In addition, APC mutations were linked 
to an increased secretion of MMP-7 from Paneth cells 50, which are present in 
higher numbers in the normal duodenum of patients with FAP 31. We did not 
include MMP-7 immunohistochemistry results in this study, as staining with a 
commercial antibody (clone 6A4, R&D systems, USA) produced inconsistent 
results. 
 
In this study, no loss of the intracellular epitope of E-cadherin was observed 
using the clone 36 antibody. This antibody has been described to show cross-
reactivity with P-cadherin 51. However, E-cadherin is the main cadherin protein 
expressed on the cell membranes of healthy epithelial cells, whereas P-
cadherin is not expressed in a normal colon 52. We found no loss of E-
cadherin staining in the normal colon using the clone 36 antibody for E-
cadherin and since P-cadherin is not present in normal colon 52, we still 
conclude that E-cadherin is present.  
 
Loss of extracellular E-cadherin is associated with the development of diffuse 
gastric cancer 20 and lobular breast cancer 21, which suggests a direct role of 
E-cadherin loss in the development of malignancies. Furthermore, in this study 
loss of duodenal extracellular E-cadherin is associated with a younger age of 
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the patients with FAP at the moment of colectomy, suggesting a more severe 
course of the disease. 
 
In conclusion, a significant loss of extracellular E-cadherin was demonstrated 
in normal mucosa and corresponding adenomas of the duodenum and colon 
of patients with FAP. This loss may play a role in the high susceptibility of both 
duodenum and colon for (pre-)malignant transformation in these patients.  
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Primary carcinomas of the small intestine are rare and the mechanism of their 
pathogenesis is poorly understood. Patients with familial adenomatous polyposis 
(FAP) have a high risk of developing duodenal carcinomas. The aim of this study 
is to gain more insight into the development of duodenal carcinomas. Therefore, 
five FAP-related duodenal carcinomas were characterized for chromosomal and 
methylation alterations, which were compared to those observed in sporadic 
duodenal carcinomas. Comparative genomic hybridization (CGH) and 
methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) 
was performed in ten primary sporadic and five primary FAP-related duodenal 
carcinomas. In the FAP-related carcinomas, frequent gains were observed on 
chromosomes 8, 17 and 19, whereas in sporadic carcinomas they occurred on 
chromosomes 8, 12, 13 and 20. In 60% of the sporadic carcinomas, gains in the 
regions of chromosome 12 were observed which were absent in the FAP-related 
carcinomas (p = 0.04). Hypermethylation was observed in the immunoglobulin 
superfamily genes member 4 (IGSF4), TIMP metallopeptidase inhibitor 3 (TIMP3), 
Estrogen receptor 1 (ESR1), adenomatous polyposis coli (APC), H-cadherin 
(CDH13) and paired box gene 6 (PAX6) genes. Hypermethylation of PAX6 was 
only observed in FAP-related carcinomas (3/5) and not in sporadic carcinomas 
(p=0.02). In conclusion, in contrast to sporadic duodenal carcinomas, gains on 
chromosome 12 were not observed in duodenal carcinomas of patients with FAP. 
Identification of the genes in these regions of chromosome 12 could lead to a 
better understanding of the carcinogenesis pathways leading to sporadic and 
FAP-related duodenal carcinomas. Furthermore, hypermethylation seems to be a 
general feature of both FAP-related duodenal carcinomas as well as sporadic 
duodenal carcinomas with the exception of the PAX6 gene, which is methylated 
only in FAP-related carcinomas. 
Chapter 5 (Epi-)genetic changes in duodenal carcinomas 
 
 93 
 
Introduction 
Although the small intestine is located between the stomach and the colon, both 
regions with a high cancer risk, carcinomas of the small bowel are surprisingly 
rare. In the Netherlands, the average annual incidence rate of small bowel 
carcinomas is approximately 1 case per 100,000 inhabitants, compared to 49 for 
colorectal cancer and 14 for gastric cancer 1. In contrast to colorectal cancer, the 
molecular pathogenesis of small bowel tumours is rarely the subject of research. 
In the small bowel, the most frequent site for the development of 
adenocarcinomas is the duodenum (± 50%), followed by the jejunum (± 25%) 
and the ileum (± 13%) (rest is not specified) 2-4. Patients with familial 
adenomatous polyposis (FAP) 5, Crohn’s disease 6, coeliac disease 7 or 
hereditary nonpolyposis colorectal cancer (HNPCC) 8 are known to have a higher 
risk of developing small bowel carcinomas.  
 
In patients with FAP, the duodenum is the main site for malignant transformation 
of mucosal cells in the small intestine. FAP is an autosomal dominant disorder 
caused by germline mutations in the tumour suppressor gene adenomatous 
polyposis coli (APC) 9. Patients initially develop hundreds to thousands of 
colorectal adenomas. Without prophylactic colectomy, FAP will inevitably lead to 
colorectal cancer at a relatively young age 10. Nowadays, with increased survival 
due to prophylactic colectomy, problems of extra-colonic manifestations in these 
patients become apparent 11. At present, the prevalence of duodenal carcinoma 
in patients with FAP is 2-5% 11-14. Compared to the general population, the 
relative risk of duodenal adenocarcinoma is exceptionally high (relative risk, 331; 
95% confidence limits: 133 -681) 15. Together with desmoid tumours, duodenal 
carcinomas are now the leading causes of cancer-related mortality in patients 
with FAP 16. 
 
DNA changes are crucial steps in tumour initiation and progression 17. Next to 
mutations in oncogenes and tumour suppressor genes, alterations in DNA copy 
numbers and DNA methylation patterns have been observed as common 
changes in colorectal and gastric cancer. Copy number changes can lead to 
increased or decreased gene expression whereas mutations can have an 
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activating or inactivating effect. Besides these genetic changes, epigenetic 
changes, such as DNA-methylation, may result in altered gene expression levels. 
Usually, aberrant methylation of normally unmethylated CpG-rich areas, also 
known as CpG-islands, which are located in the promoter regions of genes, have 
been associated with transcriptional inactivation of important tumour suppressor 
genes, DNA repair genes or metastasis inhibitor genes 18, 19.  
 
Until now, only a few reports have been published on chromosomal changes or 
methylation of DNA with respect to the carcinogenesis of the small intestine 20-23, 
which lead us to use global screening methods in this study. Comparative 
genomic hybridization (CGH) enables detection of chromosomal gains and loses, 
and can be applied to fixed tissue samples. Major advantages of CGH are that is 
does not require pre-knowledge about the genetic constitution of the tumour 
tissue and the entire genome is analysed in one single experiment 24. Multiplex 
ligation-dependent probe amplification (MLPA) has been accepted as a simple 
and reliable method for detection of copy number changes in paraffin-embedded 
tumour tissue 25. Recently, this technique was adjusted allowing methylation 
specific analysis (MS-MLPA) 26. A major advantage over the conventionally used 
techniques analysing the methylation status is that multiple loci can be analysed 
simultaneously using formalin-fixed and paraffin-embedded tissue.  
 
So far, no comparison has been made between chromosomal and methylation 
alterations in sporadic versus FAP-related duodenal carcinomas. The aim of this 
study is to gain more insight into the development of duodenal carcinomas. FAP-
related duodenal carcinomas were therefore characterised for chromosomal and 
methylation alterations, which were compared to those observed in sporadic 
duodenal carcinomas.  
 
Materials & Methods 
 
Patients 
In the period 1991-2004, five primary duodenal carcinomas of patients with FAP 
(average age 54 ± 9 years) and ten primary sporadic duodenal carcinomas 
(average age 63 ± 19 years) were retrieved from the files of the Departments of 
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Pathology (Radboud University Nijmegen Medical Centre, Nijmegen and 
Rijnstate Hospital, Alysis, Arnhem, the Netherlands). Non-neoplastic duodenal 
tissue was included to serve as control DNA in the comparative genomic 
hybridization. The patients with FAP were diagnosed on their clinical 
characteristics: namely the presence of hundreds of adenomas in their colon. 
The local medical ethical review committee approved this study. 
 
Histological evaluation of the carcinomas 
Classification of the carcinomas was performed using the WHO guidelines; a 
tumour was considered mucinous when over 50% of the adenocarcinoma was 
mucinous 27. Histological differentiation was categorised into well, moderately, 
poorly, or undifferentiated adenocarcinomas based on the part of poorest 
differentiation in the tumour, excluding the invasive front 28. Growth pattern and 
peritumoural inflammation was assessed according to Jass et al. 29 Fibroblastic 
reaction and intratumoural inflammation were scored as none, little, moderate or 
extensive.  
 
DNA isolation 
At least 10 sections (20 µm) of macro-dissected (>80% tumour cells) formalin-
fixed and paraffin-embedded tumour tissue were collected and incubated in 125 
µl P-buffer (50 mM Tris/HCl  pH 8.2, 100 mM NaCl, 1 mM EDTA, 0.5% (v/v) 
Tween-20, 0.5% (v/v) NP40, 20 mM DTT) for 15 min at 90 °C. Protein digestion 
was performed by adding proteinase K (Roche Diagnostics GBMH, Mannheim, 
Germany) with a final concentration of 0.5 mg/ml. The samples were incubated at 
55° C for 24 hrs, followed by incubation at 37° C for 48 hrs with addition of 5 µl 
fresh proteinase K (20 mg/ml) every 24 hrs. Subsequently, DNA was purified 
using the DNeasy tissue kit (Qiagen, Venlo, the Netherlands). The isolation was 
performed according to the instructions of the manufacturer with the 
modifications of adding 250 µl ethanol in step 4 and repeating step 7 with buffer 
AW2. The DNA concentration was measured by using a NanoDrop 
spectrophotometer (Nanodrop Technologies, Wilmington, USA). 
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Comparative genomic hybridization: CGH 
All carcinomas were genetically characterised by conventional comparative 
genomic hybridization (CGH) detecting copy number changes > 2 Mb as 
described previously 30-32. In short, all DNA samples isolated from control- and 
tumour tissues were labeled by nick-translation with digoxigenin-dUTP and 
biotin-dUTP, respectively (Roche Molecular Biochemicals, Almere, the 
Netherlands), and precipitated in the presence of 50X human COT-1 DNA (Gibco 
BRL Life Technologies Inc., Gaitherburg, USA) and herring sperm DNA 
(Invitrogen, Carlsbad, USA). The probe and the metaphase slides were 
denatured simultaneously. After hybridisation and post-hybridisation washes, 
biotin and digoxigenin were detected using streptavidin-FITC and sheep-anti-
digoxigenin-TRITC (Roche Molecular Biochemicals). The chromosomes were 
counterstained with 4,6’-diamino-2-phenylindole-dihydrochloride (DAPI) (Merck, 
Darmstadt, Germany) and the slides were mounted in Fluoroguard (Biorad, 
Veenendaal, The Netherlands). For CGH analysis, Quips CGH software (Applied 
Imaging, Newcastle upon Tyne, United Kingdom) was used. Detection thresholds 
for losses and gains were set at 0.8 and 1.2, respectively. For clear copy number 
changes, the thresholds were 0.6 and 1.4 and a ratio larger than 1.6 indicated 
high copy number amplifications. The average of approximately ten metaphases 
was used to calculate the ratio profiles of the chromosomes. 
 
Methylation–specific multiplex ligation-dependent probe amplification: MS-
MLPA 
This technique uses multiple probe sets each consisting of 2 oligonucleotides, 
both containing a sequence-specific region used for hybridisation to the genomic 
test DNA, tagged with common tails complementary to an universal primer set. 
One of both oligonucleotides additionally contains a stuffer sequence of a 
characteristic length, allowing separation of the individual loci (probe sets) 
analysed. The probe mix, containing multiple probe sets is hybridised onto the 
genomic test DNA. In one part of the sample adjacently hybridised 
oligonucleotides are joint through ligation, whereas for the other half of the 
sample ligation is combined with a methylation sensitive restriction enzyme HhaI 
(recognition site GCGC) digesting the unmethylated fragments, ligation and 
ligation-digestion sample, respectively. Ligated probe sets are amplified by PCR 
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and subjected to capillary electrophoresis. By comparison of the ligated sample 
(indicative for the amount of total DNA, methylated as well as unmethylated, with 
the ligation-digestion sample (indicative for the amount of methylated DNA), the 
amount of methylation can be calculated. For methylation analysis, probe mixes 
ME001 and ME002 were purchased from MRC-Holland (Amsterdam, the 
Netherlands). The probe mix contains 25 probe sequences of which 15 
sequences (control probes) are not influenced by HhaI digestion. All MLPA probe 
pairs code for unique human single copy DNA sequences and were designed 
and prepared as described by Schouten et al. 33. Probe sequences, gene loci and 
chromosome locations can be found at www.mlpa.com. MLPA was performed as 
described by the manufacturer with minor modifications. In short, DNA (100-200 
ng) was dissolved in 5 µl TE-buffer (10 mM Tris pH 8.2, 1 mM EDTA pH 8.0), 
denatured and subsequently cooled down to 25° C. After adding the probe mix, 
the sample was denatured and the probes were allowed to hybridise (16 hrs at 
60° C). Subsequently, the samples were divided in two and one half of the 
samples was ligated, whereas for the other part of the samples ligation was 
combined with the HhaI digestion enzyme. This digestion resulted in ligation of 
only the methylated sequences. PCR was performed on both parts of the 
samples in a volume of 50 µl containing 10 µl of the ligation reaction mixture 
using the PTC 200 thermal cycler (MJ Research Inc., Waltham, USA) 33 cycles 
of denaturation at 95° C for 20 secs, annealing at 60° C for 30 secs and 
extension at 72° C for 1 min with a final extension of 20 mins at 72° C. An 
additional agarose gel electrophoresis was used to check MLPA efficiency 34. 
Aliquots of 1 µl of the PCR reaction were combined with 0.3 µl LIZ-labeled 
internal size standard (Applied Biosystems, Foster City, USA) and 8.7 µl 
deionised formamide. After denaturation, fragments were separated and 
quantified by electrophoresis on an ABI 3730 capillary sequencer and 
Genemapper analysis (both Applied Biosystems). Peak identification was 
checked visually and values corresponding to peak size in base pairs (bp) and 
peak heights were used for further data processing. Instead of peak height, peak 
area can also be used 25. The validity of the probes was checked by the analysis 
of normal DNA 43. Furthermore, the sensitivity of ME001 and ME002 was 
established in a titration experiment in which normal DNA isolated from 
lymphocytes, which then was methylated in vitro using SSSI (New England 
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Biolabs, Ipswich, USA) as described by the manufacturer. Methylated samples 
were diluted to 75% methylated (M), 50% M and 25% M using the original 
unmethylated DNA 43. Data analysis was performed in Excel as described by the 
manufacturer of the MLPA kits. First, the fraction of each peak is calculated by 
dividing the peak value of each probe amplification product by the combined 
value of the control probes within the sample, this in order to compensate for 
differences in PCR efficiency of the individual samples. For hypermethylation 
analysis this 'relative peak value' or so-called ‘probe fraction’ of the ligation-
digestion sample is divided by the ‘relative peak value’ of the corresponding 
ligation sample, resulting in a so-called ‘methylation-ratio’ (M-ratio). Aberrant 
methylation was scored when the calculated M-ratio was > 0.25. The ME001 kit 
included the following genes: PTEN, CD44, GSTP1, ATM, IGSF4, CDKN1B, 
CHFR, BRCA2, CDH13, HIC1, BRCA1, TP73, TIMP3, CASP8, FHIT, MLH1 (2 
probes, MLH1a and MLH1 b), RASSF (2 probes, RASSF1a and RASSF1b), 
RARB, VHL, APC, ESR1, CDKN2A, CDKN2B, and DAPK1. And the ME002 kit 
included the following genes: PTEN, MGMT (2 probes, MGMT-a and MGMT-b), 
CD44, WT1, GSTP1, ATM-a, IGSF4-a, STK11, CHFR, BRCA2, RB1 (2 probes, 
RB1-a and RB1-b), THBS1, ASC, CDH13, TP53, BRCA1, TP73, GATA5, RARB, 
VHL, ESR1, PAX5A, CDKN2A, and PAX6.  
 
Statistical analysis 
The Wilcoxon-Mann-Whitney test was used to compare the age of the patients 
and changes in copy numbers or number of hypermethylated genes in tumours 
of patients with FAP vs. those of patients with sporadic cancer. Fisher’s exact 
test was used to examine differences between FAP-related and sporadic 
carcinomas in the frequencies of chromosomal copy number changes and 
percentage carcinomas showing methylation. The chi-square test was used for 
the association between copy numbers or methylation and histopathological 
characteristics. P < 0.05 was considered to be statistically significant (SPSS 
12.0.1 for Windows 2003, SPSS Inc, Chicago, USA). 
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Results 
 
Histological evaluation of the FAP-related tumours 
The histopathological characteristics of the five FAP-related and ten sporadic 
carcinomas are summarised in Table 1. All FAP-related carcinomas were 
adenocarcinomas with moderate-to-poor differentiation. One carcinoma was 
located in the ampullary region. Three carcinomas showed a circumscriptive 
growth pattern and two carcinomas a diffuse growth pattern. There was none to 
little peritumoural inflammation in four FAP-related carcinomas. Moderate-to-
extensive intratumoural inflammation was observed in two carcinomas and 
fibroblastic reaction was present in three carcinomas. In the majority of 
carcinomas invasion through the bowel wall was present (stage T3/T4). In three 
patients, lymph node metastases were present.  
 
 
Histological evaluation of the sporadic tumours 
Three carcinomas were located in the ampullary region. One sporadic tumour 
was a mucinous carcinoma. The adenocarcinomas were poorly (5/10), 
moderately (2/10) and well (2/10) differentiated. Circumscribed and diffuse 
growing carcinomas were observed in five and four of the patients, respectively. 
Peritumoural as well as intratumoural inflammation was moderate-to-extensive in 
four carcinomas. A fibroblastic reaction was present in nine carcinomas at a 
moderate-to-extensive rate. Most sporadic carcinomas (9/10) were in an 
advanced stage (T3/T4) and in three patients, lymph node metastases were 
observed. No differences in histopathological characteristics were observed 
between the FAP-related and sporadic carcinomas. 
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Comparative genomic hybridisation 
Chromosomal imbalances were detected in the majority of the FAP-related 
carcinomas (4/5). The mean number of changes was 3.8 (range 0–9). The 
mean number of gains (2.2; range 0-4) did not differ from the DNA copy 
number losses (1.6; range 0-4). For the sporadic carcinomas, 9 out of 10 
tumours showed DNA copy number changes with an average of 4.6 changes 
(range 0-10) per tumour. The number of chromosomal gains was significantly 
higher than the losses 3.4 (range, 0-8) versus 1.2 (range 0-5), respectively (p= 
0.03). The chromosomal gains and losses are listed in Table 2 whereas Figure 
1 shows a schematic presentation of the chromosomal imbalances detected in 
the FAP-related and sporadic carcinomas.  
 
In the FAP-related carcinomas, chromosomal gains were detected in regions 
on chromosome 7 (n = 1), 8 (n = 2), 11 (n = 1), 14 (n = 1), 17 (n = 2), 18 (n = 
1), 19 (n = 2) and 20 (n = 1) whereas losses were observed on chromosome 1 
(n = 1), 4 (n = 1), 10 (n = 1), 11 (n = 1), 15 (n = 2), 17 (n = 1) and 18 (n = 1).  
 
In the sporadic carcinomas, gains most frequently (30% of the tumours) 
involved chromosomes 8, 12, 13 and 20. For these chromosomes the 
common regions of overlap were 8q11-13, 8q24-qter, 12p, 12q11-q21, 13q, 
and 20q. Clear copy number gains (ratio > 1.4) involved 13q, 12p and 5p11-
13. High copy number amplifications (ratio > 1.6) were seen on 8q24-qter and 
20q. Genetic losses were observed in regions on chromosome 2 (n = 1), 6 (n 
= 2), 8 (n = 1), 9 (n = 2), 15 (n = 1), 17 (n = 2), 18 (n = 2) and 21 (n = 1).  
 
A significant difference in chromosomal imbalances between the FAP-related 
and sporadic carcinomas was seen on chromosome 12. In 6/10 of the 
sporadic carcinomas, gains in regions of this chromosome were observed, 
whereas no gains were detected in the FAP-related carcinomas (p = 0.04). 
Also for chromosome 13, genetic gains (even a clear copy) were seen in the 
sporadic carcinomas but not in the carcinomas of patients with FAP (p = 0.17).  
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Figure 1: Summary of all chromosomal imbalances detected by CGH in sporadic and  
familial adenomatous polyposis-related duodenal carcinomas. Lines on the left  
and right of the chromosomes indicate respectively losses (red) and gains (green). 
 A thin line indicates genetic aberrations crossing the 0.8 or 1.2 threshold, while clear  
copy changes crossing the 0.6 and 1.4 are indicated by a thick line (dark green). High  
copy changes, indicated by a ratio lager than 1.6 are indicated by an additional spot on  
a line (dark green). 
 
 
FAP related tumours (n=5) 
Sporadic related tumours (n=10) 
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Table 2: Chromosomal imbalances as identified by CGH present in sporadic and 
 familial adenomatous polyposis-related tumours. 
 
 
ID 
 
 
CGH gains 
 
CGH losses 
 
 
Number 
of  
changes 
 
 
F1 
 
 
7q21-qter, 14q, 17q11-23, 18q11-12 
 
10q, 15q, 17p, 18q12-qter 
 
8 
F2 
 
8q23-qter, 11q11-13, 17q11-21, 19, 20 1p11-32, 4, 11q14-qter, 15q 9 
F3 
 
  0 
F4 
 
8  1 
F5 
 
19q32-qter  1 
S1 
 
6p11-12, 12q14-21, 13q, 15q24-qter 2q21-24, 21 6 
S2 
 
12q13-15, 20  2 
S3 
 
7pter-q22, 8q (8q24-qter high copy), 
13q (clear copy), 22 
 
8p, 9p, 15q, 17p, 18 9 
S4 
 
8q, 13q 9p, 17q23-qter 4 
S5 
 
  0 
S6 
 
1q23-qter, 5p, 16p, 19, 20q  5 
S7 
 
12p (clear copy), 17 18p 3 
S8 
 
12  1 
S9 
 
3p11-14, 6p11-21, 12q13-15, 12p, 14q12-21, 
15q24-qter, 18p, 20q (high copy) 
 
6p21-pter, 6q 10 
S10 
 
8q11-13, 8q23-qter, 5p11-13 (clear copy), 
12q14-15. 17q22-qter, 20q 
 6 
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Methylation–specific multiplex ligation-dependent probe amplification  
For both immunoglobulin superfamily genes member 4 (IGSF4) and TIMP 
metallopeptidase inhibitor 3 (TIMP3), hypermethylation was found in 3/5 FAP-
related carcinomas and 1/10 of the sporadic carcinomas (p = 0.08). Estrogen 
receptor 1 (ESR1) showed hypermethylation in four FAP-related carcinomas  
and in five sporadic carcinomas (p = 0.29). Two FAP-related carcinomas and 
two sporadic carcinomas showed hypermethylation in the adenomatous 
polysis coli (APC) and in H-cadherin (CDH13) genes (p = 0.41). A significant 
difference was observed between the FAP-related and sporadic carcinomas 
for the methylation of the paired box gene 6 (PAX6). Hypermethylation of 
PAX6 was observed in 3/5 FAP-related carcinomas versus no 
hypermethylation in the sporadic carcinomas (p=0.02) (see Figure 2). 
Hypermethylation of glutathione S-transferase Pi (GSTP) and mutL homolog 1 
(MLH1) was observed in one sporadic tumour. In one FAP-related tumour, 
hypermethylation of checkpoint with forkhead and ring finger domains (CHFR) 
and retinoblastoma 1 (RB1 b) was seen. The average number of 
hypermethylated genes was 4 ± 3 in FAP-related carcinomas versus 1 ± 1 in 
the sporadic carcinomas (p= 0.08). The following probes performed less 
reliable when using DNA isolated from formalin-fixed and paraffin-embedded 
tissue and are therefore excluded from further analysis: CDKN2B (ME001), 
MGMT, WT1, ASC, STK11, GATA5, ESR1, PAX5A and CHFR (all from 
ME002). 
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Discussion 
The genetic pathways leading to the development and progression of small 
bowel carcinomas are not well characterised. Sporadic carcinomas develop 
infrequently in the duodenum, while it is the main site for malignant extra-
colonic manifestations in patients with FAP. This study compares 
chromosomal and methylation alterations in duodenal FAP-related and 
sporadic carcinomas. In order to reveal similarities or differences in the 
pathways leading to these cancers, the data is also compared to literature 
data on colorectal and gastric cancer. 
 
We observed hypermethylation in several well-known tumour suppressor 
genes in the sporadic duodenal carcinomas. In accordance with the data in 
Figure 2: Percentage of sporadic and familial adenomatous polyposis-related  
duodenal carcinomas showing hypermethylation in the genes IGSF4, TIMP3,  
ESR1, APC, CDH13 and PAX6. 
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our study, a similar frequency of hypermethylation of TIMP3 (10%) was seen 
in colorectal carcinomas 34, 35. In contrast, a higher frequency of 
hypermethylation was found in colorectal carcinomas for APC (± 50% vs. 20% 
in our study) 34, 35 and for CDH13 (65% vs. 20% in our study) 36. In addition, 
frequent hypermethylation of the genes CDKN2A 37, 38 and RASSF1A 39, 40 was 
found in colorectal tumours, in contrast, no hypermethylation was found in our 
study. Almost no hypermethylation was found in the promotor region of the 
PAX6 gene in colorectal carcinomas 41. For gastric cancer, the frequencies of 
hypermethylation of APC and TIMP3 were higher compared to our findings (± 
78% and ± 43%, respectively). Similar to colorectal cancer, CDKN2A and 
RASSF1A are also frequently hypermethylated in gastric cancer in contrast to 
the duodenal carcinomas studied here 42. Although, the MS-MLPA and the 
conventional MS-PCR showed very similar results in our hands for the MGMT 
43
 gene, differences found in comparison with literature data may arise from 
the different methods.  
 
Several genomic imbalances in duodenal carcinomas were detected by CGH. 
Similar to what has been described for colorectal carcinomas; sporadic 
duodenal carcinomas showed frequent gains on chromosomes 8q, 12p, 13q 
and 20q. In contrast to sporadic colorectal cancer, only one loss at 18q was 
observed 44-47 in the duodenal carcinomas. In gastric carcinomas, again 
frequent gains involved 8q, 13q and 20q but only occasionally 12p 48, 49.  In 
contrast to both colorectal and gastric carcinomas, sporadic duodenal 
carcinomas often showed gains in the region 12q13-21. Interestingly, a 
difference was observed between sporadic and FAP-related carcinomas with 
respect to copy changes on chromosomes 12 and 13 as detected by CGH. 
Gains were only present in the sporadic carcinomas and not in the FAP-
related carcinomas. Chromosomal gains on chromosome 12p were also 
observed in pancreatic 50, 51 and gastric tumours 49. Recently, gains of 12p 
were shown to be late events in liver metastases of colorectal carcinomas, 
indicating their role in tumour progression 46. Likewise, gains of 12p were often 
observed in the advanced stages of a wide variety of tumours 46, 52, 53. In the 
current study, most carcinomas also presented at an advanced stage. 
However, since the tumour stage was comparable in both groups, this could 
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not explain the difference detected between sporadic and FAP-related 
carcinomas. Possible candidate genes on chromosome 12 include KRAS2, 
cyclinD2, MDM2 and WNT1. In addition, gains of 13q as observed here in 
sporadic duodenal tumours, were shown frequently in both colorectal 44, 45, 47, 
54
 and gastric carcinomas 48, 49.  Also a difference was observed in the 
hypermethylation status of the PAX6 gene between sporadic and FAP-related 
duodenal carcinomas. PAX6 is a highly conserved transcription factor, which 
plays an important role in the normal embryological development 55. 
Furthermore, this transcription factor is implicated in pancreatic and intestinal 
endocrine cell fate determination and in eye and brain development 56. 
However, the role of PAX6 in the development of intestinal carcinomas is less 
clear and also the difference in hypermethylation of PAX6 between FAP- and 
sporadic carcinomas is difficult to explain. Future research must further 
elucidate the exact role of PAX6 in the development of duodenal carcinomas. 
 
The mutations in the APC gene (located on chromosome 5q21-22) often found 
in patients with FAP lead to a disturbed function of the APC protein. The key 
tumour suppressor function of APC is to regulate the stability and cellular 
localisation of β-catenin 57. β-catenin is a bifunctional protein with a crucial role 
in cell-cell adhesion 58 and a signalling role in the Wnt pathway 59. Loss of 
functional APC leads to a disturbed Wnt signalling pathway, which is involved 
in many types of cancer 60 and aberrant activation of this pathway could 
possibly result in chromosomal instability as found in colon cancer 61. The 
genes of WNT1 and WNT10B, both members of the Wnt gene family and 
encoding for Wnt signalling proteins, are located in the chromosome 12q13 
region 62. Interestingly, in three sporadic carcinomas gains are found in this 
region. Given the importance of Wnt signalling in tumour formation, this may 
suggest that the chromosomal imbalances on chromosome 12 in the sporadic 
carcinomas are associated with Wnt signalling abnormalities. One has to 
realise that Wnt signalling is already disturbed in FAP-related carcinomas, 
which may explain the absence of chromosomal aberrations in this region of 
chromosome 12 here. So although different aberrations are detected in FAP-
related (APC mutations) and sporadic (+12q) carcinomas, their effects may be 
similar.  
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For FAP-related carcinomas, there are only karyotyping studies of colonic 
adenomas 63, colonic carcinomas 64 and desmoid tumours 65.  In comparison 
to CGH, a disadvantage of karyotyping is that it requires the culture of fresh 
tumour cells, which can only be achieved for some of the (malignant) tumours 
and which may introduce culture artifacts such as clonal selection 24. Since 
macro-dissected tumour tissue was used in this study, almost only tumour 
DNA was used for the CGH, thus increasing the accuracy of the 
measurements. However, carcinomas used in this study were routinely 
processed, formalin-fixed and paraffin-embedded. DNA isolated from paraffin-
embedded tissue is often degraded, with the bulk of the DNA showing a 
fragmented size. This could complicate the nick translation for the CGH and 
may lead to inferior results when compared to results obtained by CGH after 
using frozen tissues. Therefore, some chromosomal imbalances could have 
been left undetected in the paraffin-imbedded tumours investigated here, 
especially in the older specimens.  
 
The karyotyping study of desmoid tumours in patients with FAP mainly 
showed a defect on chromosome 5q, where the APC gene is located. 65. The 
FAP-related adenocarcinomas investigated here showed no abnormalities in 
this region. However, small deletions present in the APC gene could be 
undetected by CGH. Interestingly, we found hypermethylation of the APC 
promoter region in two FAP-related carcinomas, suggesting biallelic 
inactivation of the APC gene. To our knowledge, in the only study described 
so far which investigates a colon carcinoma of a patient with FAP, no 
abnormalities on chromosome 12 were observed and that is in accordance 
with our results 64. Sporadic colon carcinomas show gains of 12p in 
approximately 30% of the cases 44.  
 
Both sporadic and FAP-related carcinomas showed genetic gains on 
chromosome 8 (especially 8q). Diep et al. 46 suggested that gains of 8q could 
be involved in establishing distant colorectal metastases. Gains of 20q, which 
may be an early change in both primary colorectal carcinomas and their liver 
metastases, were also seen in sporadic as well as FAP-related carcinomas. 
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Furthermore, the frequency of gains of 20q was reported to increase with 
Dukes’ stages, emphasising their role in tumour progression as well 46, 54.  In 
addition, frequent gains of 20q have been reported in other tumours, including 
gastric adenocarcinomas 66. 
 
The current study showed no differences in chromosomal imbalances between 
tumours in the ampullary region and more distally located carcinomas, 
probably due to small numbers. In accordance with Chang et al. 21, several 
gains were found in sporadic tumours located in the ampullary region, such as 
on chromosomes 1q, 3p, 12p, 14q, 18p and 20q. In contrast to Blaker et al. 20, 
who reported frequent losses of 18q in sporadic small bowel 
adenocarcinomas, only one case of loss of chromosome 18 and one loss of 
chromosome 18p were observed in this study. The study of Blaker et al. 20 
however, included only four duodenal carcinomas, of which two tumours 
showed loss of chromosome 18 (q).  The two only studies describing 
hypermethylation of promoter regions of genes in small bowel carcinomas also 
showed both similarities and differences to our study. Brücher et al. 22 
demonstrated the same frequency in hypermethylation of APC, however 
differences were observed for the prevalence of hypermethylation of MLH1 
and CDKN2A. These differences may have been caused by our smaller study 
population. In comparison with results of Kim et al. 23, the same high 
frequency of hypermethylation was found here for EST1, although MLH1 and 
CDKN2A also differed from our study.  
 
In summary, the chromosomal and methylation alterations of 15 duodenal 
carcinomas were analysed in this study. The results suggest that gains on 
chromosomes 8, 17 and 19, and losses on chromosome 15 might play a role 
in the development and/or progression of FAP-related carcinomas (n=5). In 
the sporadic carcinomas (n=10), frequent gains were seen on chromosomes 
8, 12, 13 and 20. These findings are similar to what has been described for 
sporadic colorectal and gastric carcinomas. In contrast to results in sporadic 
colorectal cancer, only once was a loss of 18q observed in sporadic duodenal 
carcinomas. Furthermore, in contrast to both colorectal and gastric 
carcinomas, sporadic duodenal tumours often showed gains in the region 
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12q13-21. In addition, although the numbers of carcinomas studied here are 
small, different patterns of chromosomal imbalance could be detected in 
sporadic versus FAP-related carcinomas. Gains on chromosome 12 were not 
observed at all in duodenal carcinomas of patients with FAP, suggesting that 
identification of the genes in 12q13-21 could lead to a better understanding of 
the carcinogenesis pathways in both sporadic as well as FAP-related 
duodenal carcinomas. Interestingly, APC mutations present in patients with 
FAP may have a similar effect on the Wnt signalling as gains of 12q in 
sporadic tumours, suggesting that even though the aberrations detected may 
differ, a similar pathway is affected. Furthermore, methylation of multiple CpG-
islands is present in both sporadic and FAP-related duodenal carcinomas 
whereas the methylation status of PAX6 seems to be different in FAP-related 
carcinomas compared to sporadic carcinomas. 
 
Chapter 5 (Epi-)genetic changes in duodenal carcinomas 
 
 111 
 
References 
 
1.   
http://www.ikcnet.nl/uploaded/FILES/Landelijk/cijfers/Incidentie%202003/A1%201989
-  2003.xls. 2006. 
2.  Neugut AI, Jacobson JS, Suh S, Mukherjee R, Arber N. The epidemiology of cancer 
of the small bowel. Cancer Epidemiol Biomarkers Prev 1998;7:243-251. 
3.  Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: 
presentation, prognostic factors, and outcome of 217 patients. Cancer 2004;101:518-
526. 
4.  Howe JR, Karnell LH, Menck HR, Scott-Conner C. The American College of 
Surgeons Commission on Cancer and the American Cancer Society. 
Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-
1995. Cancer 1999;86:2693-2706. 
5.  Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK. Upper gastrointestinal 
cancer in patients with familial adenomatous polyposis. Lancet 1989;2:783-785. 
6.  Persson PG, Karlen P, Bernell O, Leijonmarck CE, Brostrom O, Ahlbom A, Hellers G. 
Crohn's disease and cancer: a population-based cohort study. Gastroenterology 
1994;107:1675-1679. 
7.  Green PH, Fleischauer AT, Bhagat G, Goyal R, Jabri B, Neugut AI. Risk of 
malignancy in patients with celiac disease. Am J Med 2003;115:191-195. 
8.  Rodriguez-Bigas MA, Vasen HF, Lynch HT, Watson P, Myrhoj T, Jarvinen HJ, 
Mecklin JP, Macrae F, St John DJ, Bertario L, Fidalgo P, Madlensky L, Rozen P. 
Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal 
carcinoma. International Collaborative Group on HNPCC. Cancer 1998;83:240-244. 
9.  Bodmer WF, Bailey CJ, Bodmer J, Bussey HJ, Ellis A, Gorman P, Lucibello FC, 
Murday VA, Rider SH, Scambler P, . Localization of the gene for familial 
adenomatous polyposis on chromosome 5. Nature 1987;328:614-616. 
10.  Jagelman DG, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer in familial 
adenomatous polyposis. Lancet 1988;1:1149-1151. 
11.  Bulow S, Bjork J, Christensen IJ, Fausa O, Jarvinen H, Moesgaard F, Vasen HF. 
Duodenal adenomatosis in familial adenomatous polyposis. Gut 2004;53:381-386. 
12.  Groves CJ, Saunders BP, Spigelman AD, Phillips RK. Duodenal cancer in patients 
with familial adenomatous polyposis (FAP): results of a 10 year prospective study. 
Gut 2002;50:636-641. 
Chapter 5 (Epi-)genetic changes in duodenal carcinomas 
 
 112 
 
13.  Kadmon M, Tandara A, Herfarth C. Duodenal adenomatosis in familial adenomatous 
polyposis coli. A review of the literature and results from the Heidelberg Polyposis 
Register. Int J Colorectal Dis 2001;16:63-75. 
14.  Spigelman AD, Talbot IC, Penna C, Nugent KP, Phillips RK, Costello C, DeCosse JJ. 
Evidence for adenoma-carcinoma sequence in the duodenum of patients with familial 
adenomatous polyposis. The Leeds Castle Polyposis Group (Upper Gastrointestinal 
Committee). J Clin Pathol 1994;47:709-710. 
15.  Offerhaus GJ, Giardiello FM, Krush AJ, Booker SV, Tersmette AC, Kelley NC, 
Hamilton SR. The risk of upper gastrointestinal cancer in familial adenomatous 
polyposis. Gastroenterology 1992;102:1980-1982. 
16.  Arvanitis ML, Jagelman DG, Fazio VW, Lavery IC, McGannon E. Mortality in patients 
with familial adenomatous polyposis. Dis Colon Rectum 1990;33:639-642. 
17.  Gisselsson D. Chromosome instability in cancer: how, when, and why? Adv Cancer 
Res 2003;87:1-29. 
18.  Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and 
chromatin alterations in human tumours. J Pathol 2002;196:1-7. 
19.  Esteller M. Relevance of DNA methylation in the management of cancer. Lancet 
Oncol 2003;4:351-358. 
20.  Blaker H, von Herbay A, Penzel R, Gross S, Otto HF. Genetics of adenocarcinomas 
of the small intestine: frequent deletions at chromosome 18q and mutations of the 
SMAD4 gene. Oncogene 2002;21:158-164. 
21.  Chang MC, Chang YT, Tien YW, Sun CT, Wu MS, Lin JT. Distinct chromosomal 
aberrations of ampulla of Vater and pancreatic head cancers detected by laser 
capture microdissection and comparative genomic hybridization. Oncol Rep 
2005;14:867-872. 
22.  Brucher BL, Geddert H, Langner C, Hofler H, Fink U, Siewert JR, Sarbia M. 
Hypermethylation of hMLH1, HPP1, p14(ARF), p16(INK4A) and APC in primary 
adenocarcinomas of the small bowel. Int J Cancer 2006;119:1298-1302. 
23.  Kim SG, Chan AO, Wu TT, Issa JP, Hamilton SR, Rashid A. Epigenetic and genetic 
alterations in duodenal carcinomas are distinct from biliary and ampullary carcinomas. 
Gastroenterology 2003;124:1300-1310. 
24.  Jeuken JW, Sprenger SH, Wesseling P. Comparative genomic hybridization: practical 
guidelines. Diagn Mol Pathol 2002;11:193-203. 
25.  van Dijk MC, Rombout PD, Boots-Sprenger SH, Straatman H, Bernsen MR, Ruiter 
DJ, Jeuken JW. Multiplex ligation-dependent probe amplification for the detection of 
chromosomal gains and losses in formalin-fixed tissue. Diagn Mol Pathol 2005;14:9-
16. 
Chapter 5 (Epi-)genetic changes in duodenal carcinomas 
 
 113 
 
26.  Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten 
JP, Errami A. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG 
methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 
2005;33:e128. 
27.  Hamilton S, Aaltonen LA. World Health Organization Classification of Tumours: 
Pathology and Genetics of Tumours of the Digestive System. In: IARC, ed. 1st ed. 
Lyon: 2000. 
28.  Morson B, Sobin LH. Histological Typing of Intestinal Tumours: International 
Histological Classification of Tumours. In: WHO, ed. Geneva: 1976. 
29.  Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. 
Lancet 1987;1:1303-1306. 
30.  Jeuken JWM, Sprenger SHE, Wesseling P, Macville MVE, von Deimling A, Teepen 
HLJM, van Overbeeke JJ, Boerman RH. Identification of subgroups of high-grade 
oligodendroglial tumours by comparative genomic hybridization. J Neuropathol Exp 
Neurol 1999;58:606-612. 
31.  Jeuken JWM, Sprenger SHE, Boerman RH, von Deimling A, Teepen HLJM, van 
Overbeeke JJ, Wesseling P. Subtyping of oligo-astrocytic tumours by comparative 
genomic hybridisation. J Pathol 2001;194:81-87. 
32.  Jeuken JWM, Sprenger SHE, Vermeer H, Kappelle AC, Boerman RH, Wesseling P. 
Chromosomal imbalances in primary oligodendroglial tumours and their recurrences; 
clues for malignant progression as detected by CGH. J Neurosurg 2002;96:559-564. 
33.  Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative 
quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe 
amplification. Nucleic Acids Res 2002;30:e57. 
34.  Lee S, Hwang KS, Lee HJ, Kim JS, Kang GH. Aberrant CpG island hypermethylation 
of multiple genes in colorectal neoplasia. Lab Invest 2004;84:884-893. 
35.  Bai AH, Tong JH, To KF, Chan MW, Man EP, Lo KW, Lee JF, Sung JJ, Leung WK. 
Promoter hypermethylation of tumour-related genes in the progression of colorectal 
neoplasia. Int J Cancer 2004;112:846-853. 
36.  Xu XL, Yu J, Zhang HY, Sun MH, Gu J, Du X, Shi DR, Wang P, Yang ZH, Zhu JD. 
Methylation profile of the promoter CpG islands of 31 genes that may contribute to 
colorectal carcinogenesis. World J Gastroenterol 2004;10:3441-3454. 
37.  Agnese V, Corsale S, Calo V, Augello C, Bruno L, Calcara D, Crosta A, Rodolico V, 
Rinaldi G, Cicero G, Latteri F, Agrusa A, Morello V, Adamo V, Altavilla G, Di Fede G, 
Fiorentino E, Grassi N, Latteri MA, Valerio MR, Tomasino RM, Colucci G, Bazan V, 
Russo A. Significance of P16INK4A hypermethylation gene in primary head/neck and 
colorectal tumours: it is a specific tissue event? Results of a 3-year GOIM (Gruppo 
Chapter 5 (Epi-)genetic changes in duodenal carcinomas 
 
 114 
 
Oncologico dell'Italia Meridionale) prospective study. Ann Oncol 2006;17:vii137-
vii141. 
38.  Lee M, Sup HW, Kyoung KO, Hee SS, Sun CM, Lee SN, Koo H. Prognostic value of 
p16INK4a and p14ARF gene hypermethylation in human colon cancer. Pathol Res 
Pract 2006;202:415-424. 
39.  van Engeland M, Roemen GM, Brink M, Pachen MM, Weijenberg MP, de Bruine AP, 
Arends JW, van den Brandt PA, de Goeij AF, Herman JG. K-ras mutations and 
RASSF1A promoter methylation in colorectal cancer. Oncogene 2002;21:3792-3795. 
40.  Wagner KJ, Cooper WN, Grundy RG, Caldwell G, Jones C, Wadey RB, Morton D, 
Schofield PN, Reik W, Latif F, Maher ER. Frequent RASSF1A tumour suppressor 
gene promoter methylation in Wilms' tumour and colorectal cancer. Oncogene 
2002;21:7277-7282. 
41.  Salem CE, Markl ID, Bender CM, Gonzales FA, Jones PA, Liang G. PAX6 
methylation and ectopic expression in human tumour cells. Int J Cancer 2000;87:179-
185. 
42.  Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and 
gastric cancer. Cancer 2006;106:483-493. 
43.  Jeuken J, Cornelissen S, Vriezen M, Errami A, Sijben A, Boots-Sprenger S,  
Wesseling P. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, 
and quantitative detection of MGMT promoter hypermethylation in gliomas. Submitted 
2007. 
44.  Aragane H, Sakakura C, Nakanishi M, Yasuoka R, Fujita Y, Taniguchi H, Hagiwara A, 
Yamaguchi T, Abe T, Inazawa J, Yamagishi H. Chromosomal aberrations in 
colorectal cancers and liver metastases analyzed by comparative genomic 
hybridization. Int J Cancer 2001;94:623-629. 
45.  De Angelis PM, Clausen OP, Schjolberg A, Stokke T. Chromosomal gains and losses 
in primary colorectal carcinomas detected by CGH and their associations with tumour 
DNA ploidy, genotypes and phenotypes. Br J Cancer 1999;80:526-535. 
46.  Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, Lothe RA. The order of 
genetic events associated with colorectal cancer progression inferred from meta-
analysis of copy number changes. Genes Chromosomes Cancer 2006;45:31-41. 
47.  Jiang JK, Chen YJ, Lin CH, Yu IT, Lin JK. Genetic changes and clonality relationship 
between primary colorectal cancers and their pulmonary metastases--an analysis by 
comparative genomic hybridization. Genes Chromosomes Cancer 2005;43:25-36. 
48.  Kimura Y, Noguchi T, Kawahara K, Kashima K, Daa T, Yokoyama S. Genetic 
alterations in 102 primary gastric cancers by comparative genomic hybridization: gain 
Chapter 5 (Epi-)genetic changes in duodenal carcinomas 
 
 115 
 
of 20q and loss of 18q are associated with tumour progression. Mod Pathol 
2004;17:1328-1337. 
49.  Peng DF, Sugihara H, Mukaisho K, Tsubosa Y, Hattori T. Alterations of chromosomal 
copy number during progression of diffuse-type gastric carcinomas: metaphase- and 
array-based comparative genomic hybridization analyses of multiple samples from 
individual tumours. J Pathol 2003;201:439-450. 
50.  Schleger C, Arens N, Zentgraf H, Bleyl U, Verbeke C. Identification of frequent 
chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative 
genomic hybridization (CGH). J Pathol 2000;191:27-32. 
51.  Mahlamaki EH, Hoglund M, Gorunova L, Karhu R, Dawiskiba S, Andren-Sandberg A, 
Kallioniemi OP, Johansson B. Comparative genomic hybridization reveals frequent 
gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic 
cancer. Genes Chromosomes Cancer 1997;20:383-391. 
52.  Kwong D, Lam A, Guan X, Law S, Tai A, Wong J, Sham J. Chromosomal aberrations 
in esophageal squamous cell carcinoma among Chinese: gain of 12p predicts poor 
prognosis after surgery. Hum Pathol 2004;35:309-316. 
53.  Rosenberg C, Van Gurp RJ, Geelen E, Oosterhuis JW, Looijenga LH. 
Overrepresentation of the short arm of chromosome 12 is related to invasive growth 
of human testicular seminomas and nonseminomas. Oncogene 2000;19:5858-5862. 
54.  Hughes S, Williams RD, Webb E, Houlston RS. Meta-analysis and pooled re-analysis 
of copy number changes in colorectal cancer detected by comparative genomic 
hybridization. Anticancer Res 2006;26:3439-3444. 
55.  Stuart ET, Kioussi C, Gruss P. Mammalian Pax genes. Annu Rev Genet 
1994;28:219-236. 
56.  Schonhoff SE, Giel-Moloney M, Leiter AB. Minireview: Development and 
differentiation of gut endocrine cells. Endocrinology 2004;145:2639-2644. 
57.  Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-
catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130-1134. 
58.  Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion 
molecule uvomorulin associates with three independent proteins structurally related in 
different species. EMBO J 1989;8:1711-1717. 
59.  Funayama N, Fagotto F, McCrea P, Gumbiner BM. Embryonic axis induction by the 
armadillo repeat domain of beta-catenin: evidence for intracellular signalling. J Cell 
Biol 1995;128:959-968. 
60.  Behrens J. Control of beta-catenin signalling in tumour development. Ann N Y Acad 
Sci 2000;910:21-33. 
Chapter 5 (Epi-)genetic changes in duodenal carcinomas 
 
 116 
 
61.  Hadjihannas MV, Bruckner M, Jerchow B, Birchmeier W, Dietmaier W, Behrens J. 
Aberrant Wnt/beta-catenin signalling can induce chromosomal instability in colon 
cancer. Proc Natl Acad Sci U S A 2006;103:10747-10752. 
62.  Bui TD, Rankin J, Smith K, Huguet EL, Ruben S, Strachan T, Harris AL, Lindsay S. A 
novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast 
carcinomas. Oncogene 1997;14:1249-1253. 
63.  Griffin CA, Lazar S, Hamilton SR, Giardiello FM, Long P, Krush AJ, Booker SV. 
Cytogenetic analysis of intestinal polyps in polyposis syndromes: comparison with 
sporadic colorectal adenomas. Cancer Genet Cytogenet 1993;67:14-20. 
64.  Muleris M, Nordlinger B, Dutrillaux B. Cytogenetic characterization of a colon 
adenocarcinoma from a familial polyposis coli patient. Cancer Genet Cytogenet 
1989;38:249-253. 
65.  Yoshida MA, Ikeuchi T, Iwama T, Miyaki M, Mori T, Ushijima Y, Hara A, Miyakita M, 
Tonomura A. Chromosome changes in desmoid tumours developed in patients with 
familial adenomatous polyposis. Jpn J Cancer Res 1991;82:916-921. 
66.  Weiss MM, Snijders AM, Kuipers EJ, Ylstra B, Pinkel D, Meuwissen SG, van Diest 
PJ, Albertson DG, Meijer GA. Determination of amplicon boundaries at 20q13.2 in 
tissue samples of human gastric adenocarcinomas by high-resolution microarray 
comparative genomic hybridization. J Pathol 2003;200:320-326. 
Chapter 6 
 
 
 
 
 
 
Ursodeoxycholic acid intervention in  
patients with 
familial adenomatous polyposis:  
a pilot study. 
 
 
 
 
Marloes Berkhout 
Hennie M.J. Roelofs 
Pieter Friederich 
Annie van Schaik 
Marleen J.E.M. Gosens 
Brigitte Marian  
Beatrice L. Pool-Zobel 
J. Han. J.M. van Krieken 
Wilbert H.M. Peters 
Fokko M. Nagengast 
 
 
 
 
 
 
 
 
Translational Research 2007; in press. 
 
Chapter 6 UDC intervention in FAP 
 
 118 
 
 
 
 
 
 
 
 
 
 
 
 
Duodenal adenomas, especially those clustered in the peri-ampullary region, 
are the main pre-malignant extra-colonic manifestations in patients with 
familial adenomatous polyposis (FAP), which suggests a role of bile in this 
adenomatosis. Ursodeoxycholic acid (UDC), a bile acid with chemopreventive 
properties was tested in patients with FAP to find out whether UDC is able to 
reduce cytotoxicity or genotoxicity of duodenal bile or to reduce the 
cyclooxygenase-2 (COX-2) expression in the duodenum. A three-month 
unblinded intervention with UDC (up to 25 mg/kg body weight daily) was 
performed in 5 patients with FAP. Bile acids in duodenal bile were determined 
by gas chromatography. Cytotoxicity of bile was quantified by the WST-1 assay 
and genotoxicity was determined using the Comet assay. COX-2 expression in 
duodenal biopsies was determined immunohistochemically. This high dose of 
UDC was well tolerated and duodenal bile was highly enriched with UDC. 
Cytotoxicity of the heat inactivated post intervention bile was 2-fold lower 
compared to the pre-intervention bile (p = 0.043) and no difference in 
genotoxicity was observed. Duodenal COX-2 expression was non-significantly 
reduced (p = 0.125) after the intervention. UDC enrichment of bile in patients 
with FAP did lower the cytotoxicity of heat inactivated bile whereas duodenal 
COX-2 expression was non-significantly reduced. The results of this small pilot 
study warrant a more extensive study on chemoprevention with UDC in 
patients with FAP. 
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Introduction 
Familial adenomatous polyposis (FAP), caused by mutations in the 
Adenomatous Polyposis Coli (APC) gene, is characterised by the early onset 
of hundreds to thousands of adenomas throughout the large bowel 1, 2. Left 
untreated, there is nearly 100% progression to colorectal cancer by the age of 
35-40 years. Prophylactic colectomy is the recommended treatment to 
eliminate the risk of colorectal cancer. In addition, patients with FAP run the 
risk of developing extra-colonic manifestations and the duodenum is the main 
site for (pre-)malignant development 3, 4. The prevalence of the mainly peri-
ampullary located adenomas varies from 50% to over 90% 4-6. With a 
prevalence of 2-5%, duodenal carcinomas are now, together with desmoid 
tumours, the leading causes of cancer-related mortality in patients with FAP 5, 
7-10
. Since both incidence and severity of the duodenal adenomatosis 
increases with age, and since the FAP population is aging, the problems with 
respect to the development of duodenal adenomas and malignancies will 
further increase 9.  
 
The clustering of the duodenal adenomas around the Ampulla of Vater 
suggests that bile plays a role in the formation and/or progression of these 
adenomas. In the liver, the primary bile acids, cholic acid and 
chenodeoxycholic acid, are synthesised and conjugated with taurine or 
glycine. The conjugated bile acids are excreted into the gall bladder and 
released into the small intestine after stimulation of the gall bladder. Bile acids 
are re-absorbed into the terminal ileum and only 5 per cent of the bile acid 
pool enters the large intestine. Bacteria in the large intestine deconjugate the 
bile acids and are responsible for the 7- dehydroxylation of the primary bile 
acids into the secondary bile acids, deoxycholic acid and lithocholic acid from 
cholic acid and chenodeoxycholic acid, respectively. The circulating bile acid 
pool in healthy individuals is composed of about 35% cholic acid, 35% 
chenodeoxycholic acid, 25% deoxycholic acid and less than 5% lithocholic 
acid 11, 12. After colectomy however, the content of secondary bile acids in the 
circulating bile acid pool is significantly reduced in patients with FAP as well as 
in non-FAP patients 13. The secondary bile acids especially are known tumour 
promoters in the gastrointestinal tract 14-17. In contrast, ursodeoxycholic acid 
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(UDC), a tertiary bile acid hardly present in human bile, may act as a 
chemopreventive drug in patients at risk of colon cancer, as suggested by 
several pre-clinical studies 18, 19. Wali et al. 19 found an inhibiting effect of UDC 
on the induction of cyclooxygenase-2 (COX-2), a key enzyme in the regulation 
of cell proliferation, in an animal model of colonic carcinogenesis. More 
importantly, in patients with ulcerative colitis or primary sclerosing cholangitis, 
the risk of colorectal dysplasia or cancer was reduced by UDC 20. UDC 
treatment was also associated with a significant reduction in the recurrence of 
colorectal adenomas with high grade dysplasia in a large phase III clinical trial 
21
. Furthermore, a combination of UDC and sulindac was proven effective in 
the prevention of intestinal adenomas in a mouse model of FAP 22.  
 
Until now, the treatment of duodenal adenomas in FAP has been restricted to 
surgical intervention, with concomitant high morbidity and mortality 23 and 
therefore, new therapies, such as chemoprevention, would be preferable.  
   
This pilot study explores the possibility of ursodeoxycholic acid as a 
chemopreventive agent for duodenal adenomas/carcinomas in patients with 
FAP. We therefore performed a pilot intervention study with ursodeoxycholic 
acid in five patients with FAP to find out if ursodeoxycholic acid is tolerated. In 
addition, we studied the effects on bile acid composition, cytotoxicity and 
genotoxicity of duodenal bile, sampled before and after the intervention. We 
also studied whether the intervention influenced the duodenal COX-2 
expression levels. 
 
Materials & Methods  
 
Patients 
In this study, 5 patients (average age 42, range 33–50 years; 4 males / 1 
female) with FAP were included. Three patients had undergone sub-colectomy 
with an ileorectal anastomosis and the other two patients had a colectomy with 
an ileostomy. The patients had no history of liver disease, pancreatic disease 
or gall stones. Informed consent was given by the patients and the study was 
approved by the local medical ethical review committee.  
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Study design 
A three-month unblinded intervention with ursodeoxycholic acid was 
performed in 5 patients with FAP. Ursodeoxycholic acid was administered 
initially at 300 mg per day during the first week. During the second week, the 
dose was gradually increased to 600 mg per day, followed by two weeks at 
1200 mg per day. During weeks 5 –12, the patients received a daily dose of 25 
mg/kg body weight 24. After intravenous administration of 5 g CCK-8 
(Calbiochem-Novabiochem AG, Läufelfingen, Switzerland), duodenal bile and 
biopsies were collected twice during duodenoscopy with an Olympus TJF-
160R side-viewing endoscope; once before the start of the intervention and 
once one day after the end of the ursodeoxycholic acid intervention period.  
 
Bile acid analysis 
Composition and concentration of bile acids in the duodenal bile of the 
patients with FAP, obtained both before and after the intervention, were 
determined by gas chromatography essentially as previously described 25, 26 
with some minor modifications. In short, after enzymatic hydrolysis of duodenal 
bile with cholylglycine hydrolase, total deconjugated bile acids were extracted 
with C-18 bonded silica cartridges. After hydrolysis of esterified bile acids with 
1 M KOH  (60 C for 2 hrs), the unconjugated bile acids were separated from 
the neutral sterols by Lipidex DEAP chromatography and after methylation and 
silylation, bile acids were measured by capillary gas chromatography 
(Chrompack, CP9001 with column CP Sil 5CB, Varian Inc, Palo Alto, USA). 
 
Pancreatic enzymes 
To investigate the effect of the pancreatic enzymes on the cytotoxicity and 
genotoxicity assays, the duodenal bile was heat inactivated at 60 C for 30 
mins.  
 
Pancreatic enzyme activities 
The enzymatic assay of trypsin in the duodenal bile was performed by 
photospectrometry with 0.25 mM N-benzoyl-L-arginine ethyl ester as a 
substrate, according to the instructions of the manufacturer (Enzymatic assay 
of trypsin, Sigma, St Louis, USA). Amylase activity in duodenal bile was 
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determined by the routine Clinical Chemistry Laboratory, Radboud University 
Nijmegen Medical Centre, the Netherlands.  
 
Cell culture 
Two cell lines were used to quantify cytotoxicity or genotoxicity in this study: 
HT-29 (colonic adenocarcinoma cells; ATCC HTB-40) and LT97 (colonic 
adenoma cell line derived from a patient with FAP 27). Both cell lines were 
cultured in a humidified incubator (5% CO2) at 37˚C using the serum-free PC-1 
medium supplemented with 2 mM L-glutamine and a supplement provided by 
the manufacturer (Cambrex, Verviers, Belgium). The medium was changed 
every two days until cells reached 80% - 100% confluence.   
 
Cytotoxicity measurements   
After reaching confluence, the cells were seeded at a density of 15,000 cells 
/well in a flat-bottomed 96 wells plate (Costar, Corning Incorporated, Corning, 
NY, USA). The HT-29 cells were allowed to grow for 24 hrs, whereas the LT97 
cells needed 48 hrs with an additional medium change to form a cell 
monolayer in these plates. The medium was removed and the cells were 
incubated with 200 l test sample and controls. The PC-1 medium alone was 
used as a negative control and the PC-1 medium containing 3.2 mM 
unconjugated deoxycholic acid (Sigma, St Louis, USA) was used as a positive 
control for cytotoxicity. Wells without cells served as background correction for 
the measurements. Duodenal bile was diluted 20 times with PC-1 medium, 
sterilized by filtration on a low protein binding 0.2 m filter (Acrodisc, Gelman 
sciences, Michigan, USA), and added to the wells in the following dilutions: 20, 
40, 80, etc.until 20,480 times. Every dilution was measured in octuple. After 
incubating for 24 hrs, the medium was removed and new PC-1 medium 
containing 10% (v/v) proliferation reagent WST-1 (Roche, Penzber, Germany) 
was added to each well. In viable cells, WST-1 will be converted to formazan 
by mitochondrial activity. After two hours, the color intensity of the formazan 
formed was quantified in a microplate reader (Thermomax, Molecular Devices, 
Sopachem B.V., Wageningen, the Netherlands). The absorbance was 
measured against the background controls at a wavelength of 405 nm and a 
reference wavelength of 620 nm. The cell viability was expressed as the 
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percentage of absorption of test samples, compared with that of wells 
incubated with medium alone. Results are given as the dilution factors of the 
duodenal bile at which 50% of the cells survive. The mean value of a duplo 
experiment was used to calculate the overall mean of four independently 
reproduced experiments for each patient. For the group of patients, the results 
are given as the median with 25th and 75th percentiles. 
 
Genotoxicity measurements   
Genotoxicity was measured using the Comet assay. Since ursodeoxycholic 
acid enriched bile showed an effect on the cytotoxicity assay with the HT-29 
cells, this cell line was also used in the Comet assay. To exclude the role of 
pancreatic enzymes and to underline the possible effect of ursodeoxycholic 
acid enriched bile, the genotoxicity of heat inactivated duodenal bile was 
measured. After harvesting the cells, cell suspensions of 2x105 cells/ml were 
incubated with 10% (v/v) 0.1 mM hydrogen peroxide (positive control), 
phosphate-buffered saline (PBS) (negative control) or heat inactivated diluted 
duodenal bile for 30 mins at 37˚ C. The dilution of duodenal bile at which more 
than 90% cell viability was achieved in the cytotoxicity assay, was used in the 
comet assay. The cell pellets of 50 l of the incubated cell suspensions were 
distributed with 75 l of low melting point agarose on Comet slides (Trevigen 
Inc., Gaithersburg, USA), according to the instructions of the manufacturer. 
The slides were kept at 4˚ C for 30 mins and subsequently at 4 ˚ C for 60 mins 
in lysis buffer.  Next, all the slides were placed in an electrophorese chamber 
(Owl Separation Systems, Portsmouth, USA) with alkaline buffer (1 mM EDTA, 
300mM NaOH, pH 13) at 4 ˚C. After 30 mins, the current was switched on and 
electrophoresis was carried out at 25 V and 300 mA for 30 mins with the slides 
just covered. The slides were removed from the alkaline solution and washed 
three times for 5 mins at 4˚ C in neutralisation buffer (0.4 M Tris/ HCl, pH 7.5). 
Finally, the slides were placed in 100% ethanol for 10 mins at 4˚ C. The slides 
were allowed to air-dry overnight and were stored at 4˚ C until further analysis. 
All handling of the samples was performed under red light. The slides were 
stained with SYBR Green (2 g/ml; Trevigen Inc.) and evaluation was 
performed by microscopic analyses with Kinetic Imaging Komet software 5.5 
(Kinetic Imaging, Nottingham, UK). Fifty cells per slide were evaluated and the 
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percentage of fluorescence in the tail (TI, “tail intensity”) was scored. The 
mean value of a duplo experiment was used to calculate the overall mean of 
two independently performed experiments for each patient. For the groups, 
results are given as the median with 25th and 75th percentiles. 
 
Immunohistochemistry  
The paraffin–embedded biopsies were cut into 4 µm sections. These sections 
were de-paraffinised in xylene, rehydrated and incubated with 3% hydrogen 
peroxide/PBS to block endogenous peroxidase. Antigen retrieval was 
performed using microwave exposure for 10 mins in 10 mM citrate buffer (pH 
6.0). The slides were allowed to cool down for at least 90 mins. After pre-
incubation with 20% normal horse serum, sections were incubated overnight 
at 4˚ C with 1:200 diluted primary antibody against COX-2 (Cayman Chemical 
Company, Michigan USA) in PBS/1% Bovine Serum Albumin (BSA), followed 
by the incubations with a biotinylated secondary antibody and avidin-biotin-
peroxidase complex (Vector Laboratories Inc, Burlingame, USA) respectively. 
Finally, 3,3’-diaminobenzidene (DAB) was used as chromagen with 
haematoxylin counterstaining. Negative controls were constructed by omitting 
the primary antibody. The scoring of COX-2 staining was performed 
independently and in a blind manner by two of the authors (M.B and 
M.J.E.M.G). The following scoring criteria of the biopsies were formulated 
before the start of the analyses: 0, no staining; 1, weak cytoplasmatic and 
membranous staining (may contain strong staining in <10% of the cells); 2, 
moderate-to-strong staining in 10–90% of the cells; and 3, strong staining in 
>90% of the cells 28.  For the statistical analysis, scores 0-2 were categorised 
as “low expression” of COX-2 and score 3 as “high expression” of COX-2, see 
below. 
 
Statistical analysis 
The Wilcoxon matched-pairs signed-ranks test was used to examine 
differences in bile acid composition, cytotoxicity and genotoxicity of the 
duodenal bile, obtained before and after the intervention. The Mann-Whitney 
test was used for comparison of two unrelated parameters. The duodenal 
staining of COX-2 before and after the intervention was compared with the 
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McNemar test. P<0.05 was considered statistically significant. (SSPS 12.0.1 
for Windows 2003, SPSS Inc., Chicago, USA). 
 
Results 
 
Patients 
The high dose of ursodeoxycholic acid was tolerated well by four patients. One 
patient, taking the maximum dose, suffered from diarrhea and needed a dose 
reduction for a short period of time. After two days, this patient was able to 
continue with ursodeoxycholic acid at the dose of 25 mg/ kg body weight. No 
other side effects were reported by the patients. 
 
Bile acid composition of duodenal bile 
Figure 1 shows the bile acid composition of the duodenal bile of the patients 
with FAP, both before and after the intervention with ursodeoxycholic acid. 
The contents of the secondary bile acids, lithocholic acid and deoxycholic acid, 
were very low and did not differ before or after the intervention, whereas the 
levels of chenodeoxycholic acid and cholic acid were significantly lower after 
the intervention period (p = 0.043). The content of ursodeoxycholic acid was 
raised significantly from almost zero to 49% after the intervention period (p = 
0.043). The total pre-intervention bile acid concentration decreased from 26.3 
mmol/L to a post-intervention concentration of 8.4 mmol /L (p = 0.080), which 
correlated with lowered concentrations of bilirubin in the post-intervention 
duodenal bile (p < 0.0001). 
 
Pancreatic enzymes 
No differences were observed in the trypsin enzyme activity of duodenal bile 
before and after the intervention (48 (range 22-182) vs. 64 (range 27–254) 
units/mg protein, p = 0.500). After heat inactivation, the trypsin activity was 
significantly lower in duodenal bile obtained before and after intervention (both 
1 unit/mg protein, p < 0.001). 
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Amylase activity showed no difference in bile before and after the intervention 
(269,600 (range 5600-299,800) vs. 241,140 range (12,340- 527,000) units/L, p 
= 0.500). After heat inactivation, the amylase activity was not significantly 
lower, either before or after the intervention (72,400 vs. 109,300 units/L, p= 
0.210).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cytotoxicity of bile  
The cytotoxicity of duodenal bile obtained both before and after the 
ursodeoxycholic intervention period, measured by using the cell lines HT-29 
and LT97 was not different (see Figures 2 & 3).  
 
After heat inactivation, the cytotoxicity of the ursodeoxycholic acid enriched 
duodenal bile towards the HT-29 cells was approximately 2-fold lower when 
compared to the pre-intervention bile (median IC50 of 56 vs. IC50 of 121, p = 
Figure 1: Bile acid composition of duodenal bile from patients with FAP before and  
after ursodeoxycholic acid intervention. 
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0.043). Furthermore, the duodenal bile became less cytotoxic compared with 
the non-heat inactivated duodenal bile (see Figure 2). In the HT-29 cell test 
system, the cytotoxicity of the heat inactivated duodenal bile was 
approximately 7-fold lower after the intervention (median IC50 of 56, p = 
0.008) compared with the non-heat inactivated bile (IC50 of 413) (see Figure 
2).  Using the LT97 cells, after heat inactivation the cytotoxicity of post-
intervention bile was 15 times lower than the same bile before heat 
inactivation (median IC50 of 21 vs. IC50 of 308, p = 0.008p = 0.008) (see 
Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Cytotoxicity: scatter plots showing the dilutions of (heat inactivated) duodenal  
bile at which 50% of HT-29 cells survive (IC50), obtained before and after the  
ursodeoxycholic acid intervention. 
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Genotoxicity of bile 
There was no difference in the percentage of DNA in the tails of HT-29 cells 
treated with PBS or with duodenal bile before intervention (17.5% vs. 21.9%, 
respectively; p = 0.286) nor with the ursodeoxycholic acid enriched duodenal 
bile obtained after the intervention period (17.5% vs. 17.7%, respectively; p = 
0.841). No differences were observed in tail intensity after treatment with 
duodenal bile obtained before and after the intervention (21.9% vs. 17.7%, 
respectively; p = 0.715) (see Figure 4). There was a significantly higher 
amount of DNA in the tails of HT-29 cells incubated with hydrogen peroxide 
(positive control) compared with PBS (negative control) treated cells (89.6% 
vs. 17.5%, respectively; p = 0.009), demonstrating that the Comet assay is 
functioning properly. 
 
Figure 3: Cytotoxicity: scatter plots showing the dilutions of (heat inactivated) duodenal  
bile at which 50% of LT97 cells survive, obtained before and after the  
ursodeoxycholic acid  intervention. 
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Immunohistochemistry 
Typical examples of immunohistochemical staining of COX-2 before and after 
the intervention are depicted in Figure 5. Granular cytoplasmatic and 
membranous staining of COX-2 was observed in all normal duodenal 
specimens. Before the intervention, four of the five patients with FAP showed 
strong duodenal staining of COX-2 in more than 90% of the cells. After the 
intervention, all five patients showed moderate-to-strong staining in 10-90% of 
the cells (see Figure 6, p = 0.125 ).  
 
Figure 4: Genotoxicity: scatter plots showing the percentages of DNA in the tails of 
HT-29 cells, treated with heat inactivated duodenal bile, obtained before and after 
the ursodeoxycholic acid intervention. 
 
* Because of the unsuccesful Comet assay, the data of one patient was not available 
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Figure 5: Immunohistochemical staining for COX-2 in normal duodenal mucosa of patients  
with FAP, sampled before and after the intervention with ursodeoxycholic acid. A,  
Before intervention (original magnification X 200). B, After intervention (original magnification  
X 200). C, Before intervention (original magnification X 400). D, After intervention 
 (original magnification X 400). 
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Discussion  
Duodenal carcinomas and desmoid tumors are now the leading causes of 
cancer–related mortality in patients with FAP. Therefore the treatment of 
duodenal adenomas in patients with FAP remains a clinical challenge 5, 7-10. 
Surgical intervention is associated with high morbidity and mortality 23. 
Consequently, chemoprevention of adenomas and carcinomas would be 
highly desirable. This pilot study explores the possibility of using 
ursodeoxycholic acid as an agent to prevent duodenal adenomatosis and 
subsequent carcinogenesis in patients with FAP. 
  
This study shows that ursodeoxycholic acid is tolerated well by FAP patients 
whose colon has been removed. Moreover, the duodenal bile is highly 
enriched with this tertiary bile acid. The amount of ursodexycholic acid in the 
duodenal bile after the intervention as found in this study (up to 50%) 
corresponds to the enrichment of up to 41%, as reported in the duodenal bile 
of healthy volunteers after ursodeoxycholic acid intervention 29. Enrichment of 
bile with ursodeoxycholic acid however has not yet been described in a group 
of patients after colectomy with a disturbed enterohepatic circulation.  
 
Figure 6: Immunohistochemistry: scatter plots showing the duodenal COX-2 expression  
before and after the ursodeoxycholic acid intervention 
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The duodenal bile was highly cytotoxic towards the two cell lines used as test 
systems here, however no differences were observed in cytotoxicity of bile 
sampled before and after the ursodeoxycholic acid intervention. However, 
since trypsin present in the duodenal bile might disturb proper functioning of 
the cytotoxicity test and as trypsin is also used to release cells adhered to the 
plastic, heat inactivated bile was also tested. Heat inactivation of the trypsin in 
duodenal bile did indeed significantly lower the cytotoxicity and unmask the 
lower cytotoxicity of ursodeoxycholic acid-enriched heat inactivated bile, at 
least in the HT-29 cell test system. This also implies that pancreatic enzymes, 
and more especially trypsin, may play an important role in the cytotoxicity, 
either by being extremely cytotoxic to cells not protected by mucins, or by 
disturbing proper functioning of the cytotoxicity test by cell release from the 
plastic and subsequent loss of viable cells in the WST-1 assay. This has to be 
further investigated.  
 
In contrast to HT-29 cells, LT97 did not reveal any difference when treated 
with pre- or post-treatment bile. Overall, the LT97 cells were found to be less 
sensitive towards the cytotoxic effects of duodenal bile, heat inactivated or not. 
An explanation for this is not yet available. 
 
The lowering effect of the ursodeoxycholic acid-enriched bile on cytotoxicity 
might be explained by the decreased concentration of total bile acids in the 
post-intervention duodenal bile. It is known that ursodeoxycholic 
supplementation can lead to increased fasting and residual gall bladder 
volume 30. Furthermore, the pancreatic secretion of amylase can be reduced 
by ursodeoxycholic acid when given intraduodenally 31. In this study, there 
was no difference in the amylase activity before and after the intervention.  
 
Although the duodenal bile was cytotoxic to HT-29 cells, DNA damage was not 
generated in these cells by heat inactivated duodenal bile. These findings 
seem in contrast with earlier reports where bile acids were shown to generate 
damage of DNA in HT-29 cells 32, 33. However, these studies were carried out 
with deoxycholic acid, a secondary bile acid, which is formed in the large 
intestine by the bacterial 7- dehydroxylation of cholic acid. In this study, all 
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patients with FAP had undergone a colectomy, and therefore had low levels of 
deoxycholic acid and other secondary bile acids in their enterohepatic 
circulation (see Figure 1).  
 
In accordance with results of Brosens et al. 34, we found high expression of 
COX-2 in the normal duodenum of patients with FAP, sampled before the 
intervention with ursodeoxycholic acid. After the intervention, 4 of the 5 
patients showed a less intense duodenal staining of COX-2. Probably due to 
the small number of patients in this pilot study, this finding is not statistically 
significant. Therefore, further studies on lowering the high expression of COX-
2 present in the normal duodenum of these patients seems justified, especially 
since ursodeoxycholic acid is well tolerated and lowers cytotoxicity of bile.  
  
It is not clear from this study whether ursodeoxycholic acid prevents 
development or wheter it decelerates progression of adenomas. A double-
blind intervention with a larger study population should be carried out in order 
to elucidate this. In such at larger study, the intervention period should be 
lengthened and the number, size and grade of dysplasia of the duodenal 
adenomas should be taken as end points.  
 
Due to germline mutations, the normal duodenal epithelial cells of patients with 
FAP bear one allele with loss of the APC gene. As a consequence, the normal 
duodenum of these patients has shown a higher proliferation index 35, 36 , 
increased levels of COX-2 34 and loss of extracellular E-cadherin 37. In 
combination with the cytotoxic duodenal bile, these cellular abnormalities in 
the normal duodenal mucosa of patients with FAP might explain their high 
susceptibility to developing adenomas in the peri-ampullary region.   
 
In conclusion, this is the first intervention study with ursodeoxycholic acid in 
patients with FAP. Enrichment of bile with urosdeoxychlolic acid does show a 
positive effect on in vitro cytotoxicity and seems to lower the duodenal COX-2 
expression. Since pancreatic enzymes may also show considerable 
cytotoxicity, a double-blind controlled intervention study in patients with FAP 
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should be applied with a combination of ursodeoxycholic acid and inhibitors of 
pancreatic enzyme secretion and/or inhibitors of COX-2. 
Chapter 6 UDC intervention in FAP 
 
 135 
References 
 
 1.  Bodmer WF, Bailey CJ, Bodmer J, Bussey HJ, Ellis A, Gorman P, Lucibello FC, Murday 
VA, Rider SH, Scambler P et al. Localization of the gene for familial adenomatous 
polyposis on chromosome 5. Nature 1987;328:614-616. 
 2.  Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J. Familial adenomatous polyposis 
(FAP): frequency, penetrance, and mutation rate. Hum Mutat 1994;3:121-125. 
 3.  Offerhaus GJ, Giardiello FM, Krush AJ, Booker SV, Tersmette AC, Kelley NC, Hamilton 
SR. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. 
Gastroenterology 1992;102:1980-1982. 
 4.  Bertoni G, Sassatelli R, Nigrisoli E, Pennazio M, Tansini P, Arrigoni A, Ponz dL, Rossini 
FP, Bedogni G. High prevalence of adenomas and microadenomas of the duodenal 
papilla and periampullary region in patients with familial adenomatous polyposis. Eur J 
Gastroenterol Hepatol 1996;8:1201-1206. 
 5.  Kadmon M, Tandara A, Herfarth C. Duodenal adenomatosis in familial adenomatous 
polyposis coli. A review of the literature and results from the Heidelberg Polyposis 
Register. Int J Colorectal Dis 2001;16:63-75. 
 6.  Domizio P, Talbot IC, Spigelman AD, Williams CB, Phillips RK. Upper gastrointestinal 
pathology in familial adenomatous polyposis: results from a prospective study of 102 
patients. J Clin Pathol 1990;43:738-743. 
 7.  Spigelman AD, Talbot IC, Penna C, Nugent KP, Phillips RK, Costello C, DeCosse JJ. 
Evidence for adenoma-carcinoma sequence in the duodenum of patients with familial 
adenomatous polyposis. The Leeds Castle Polyposis Group (Upper Gastrointestinal 
Committee). J Clin Pathol 1994;47:709-710. 
 8.  Bulow S, Bjork J, Christensen IJ, Fausa O, Jarvinen H, Moesgaard F, Vasen HF. 
Duodenal adenomatosis in familial adenomatous polyposis. Gut 2004;53:381-386. 
 9.  Groves CJ, Saunders BP, Spigelman AD, Phillips RK. Duodenal cancer in patients with 
familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 
2002;50:636-641. 
 10.  Arvanitis ML, Jagelman DG, Fazio VW, Lavery IC, McGannon E. Mortality in patients 
with familial adenomatous polyposis. Dis Colon Rectum 1990;33:639-642. 
Chapter 6 UDC intervention in FAP 
 
 136 
 11.  Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal 
physiology and liver disease. Gastroenterology 2004;126:322-342. 
 12.  Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev 
Biochem 2003;72:137-174. 
 13.  Barker GM, Radley S, Bain I, Davis A, Lawson AM, Keighley MR, Neoptolemos JP. 
Biliary bile acid profiles in patients with familial adenomatous polyposis before and after 
colectomy. Br J Surg 1994;81:441-444. 
 14.  Williamson RC, Bauer FL, Ross JS, Watkins JB, Malt RA. Enhanced colonic 
carcinogenesis with azoxymethane in rats after pancreaticobiliary diversion to mid small 
bowel. Gastroenterology 1979;76:1386-1392. 
 15.  Debruyne PR, Bruyneel EA, Li X, Zimber A, Gespach C, Mareel MM. The role of bile 
acids in carcinogenesis. Mutat Res 2001;480-481:359-369. 
 16.  Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as 
carcinogens in human gastrointestinal cancers. Mutat Res 2005;589:47-65. 
 17.  Nagengast FM, Grubben MJ, van Munster I. Role of bile acids in colorectal 
carcinogenesis. Eur J Cancer 1995;31A:1067-1070. 
 18.  Khare S, Cerda S, Wali RK, von Lintig FC, Tretiakova M, Joseph L, Stoiber D, Cohen 
G, Nimmagadda K, Hart J, Sitrin MD, Boss GR, Bissonnette M. Ursodeoxycholic acid 
inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in 
colon cancer. Cancer Res 2003;63:3517-3523. 
 19.  Wali RK, Khare S, Tretiakova M, Cohen G, Nguyen L, Hart J, Wang J, Wen M, 
Ramaswamy A, Joseph L, Sitrin M, Brasitus T, Bissonnette M. Ursodeoxycholic acid 
and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon 
cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol Biomarkers Prev 
2002;11:1653-1662. 
 20.  Pardi DS, Loftus EV, Jr., Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a 
chemopreventive agent in patients with ulcerative colitis and primary sclerosing 
cholangitis. Gastroenterology 2003;124:889-893. 
 21.  Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen 
J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, 
Chapter 6 UDC intervention in FAP 
 
 137 
Lance P. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma 
recurrence. J Natl Cancer Inst 2005;97:846-853. 
 22.  Jacoby RF, Cole CE, Hawk ET, Lubet RA. Ursodeoxycholate/Sulindac combination 
treatment effectively prevents intestinal adenomas in a mouse model of polyposis. 
Gastroenterology 2004;127:838-844. 
 23.  Gallagher MC, Shankar A, Groves CJ, Russell RC, Phillips RK. Pylorus-preserving 
pancreaticoduodenectomy for advanced duodenal disease in familial adenomatous 
polyposis. Br J Surg 2004;91:1157-1164. 
 24.  Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of high-dose ursodeoxycholic 
acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 
2004;40:693-698. 
 25.  Tangerman A, van SA, van der Hoek EW. Analysis of conjugated and unconjugated 
bile acids in serum and jejunal fluid of normal subjects. Clin Chim Acta 1986;159:123-
132. 
 26.  Salemans JM, Nagengast FM, Tangerman A, van Schaik A, Hopman WP, de Haan AF, 
Jansen JB. Effect of ageing on postprandial conjugated and unconjugated serum bile 
acid levels in healthy subjects. Eur J Clin Invest 1993;23:192-198. 
 27.  Richter M, Jurek D, Wrba F, Kaserer K, Wurzer G, Karner-Hanusch J, Marian B. Cells 
obtained from colorectal microadenomas mirror early premalignant growth patterns in 
vitro. Eur J Cancer 2002;38:1937-1945. 
 28.  Buskens CJ, Van Rees BP, Sivula A, Reitsma JB, Haglund C, Bosma PJ, Offerhaus 
GJ, Van Lanschot JJ, Ristimaki A. Prognostic significance of elevated cyclooxygenase 
2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 
2002;122:1800-1807. 
 29.  Woollett LA, Buckley DD, Yao L, Jones PJ, Granholm NA, Tolley EA, Heubi JE. Effect 
of ursodeoxycholic acid on cholesterol absorption and metabolism in humans. J Lipid 
Res 2003;44:935-942. 
 30.  van Erpecum KJ, van Berge Henegouwen GP, Stolk MF, Hopman WP, Jansen JB, 
Lamers CB. Fasting gallbladder volume, postprandial emptying and cholecystokinin 
release in gallstone patients and normal subjects. J Hepatol 1992;14:194-202. 
Chapter 6 UDC intervention in FAP 
 
 138 
 31.  Neubrand MW, Dominguez-Munoz JE, Reichel C, Kampmann S, Eschmann K, von FM, 
Bregulla M, Malfertheiner P, Sauerbruch T. Effect of intraduodenal administration of 
ursodeoxycholic acid on interdigestive interaction between gallbladder motility, 
pancreatic secretion and endocrine activity. Digestion 2004;69:149-157. 
 32.  Glinghammar B, Inoue H, Rafter JJ. Deoxycholic acid causes DNA damage in colonic 
cells with subsequent induction of caspases, COX-2 promoter activity and the 
transcription factors NF-kB and AP-1. Carcinogenesis 2002;23:839-845. 
 33.  Booth LA, Gilmore IT, Bilton RF. Secondary bile acid induced DNA damage in HT29 
cells: are free radicals involved? Free Radic Res 1997;26:135-144. 
 34.  Brosens LA, Iacobuzio-Donahue CA, Keller JJ, Hustinx SR, Carvalho R, Morsink FH, 
Hylind LM, Offerhaus GJ, Giardiello FM, Goggins M. Increased cyclooxygenase-2 
expression in duodenal compared with colonic tissues in familial adenomatous 
polyposis and relationship to the -765G -> C COX-2 polymorphism. Clin Cancer Res 
2005;11:4090-4096. 
 35.  Biasco G, Cenacchi G, Nobili E, Pantaleo MA, Calabrese C, Di Febo G, Morselli LA, 
Miglioli M, Brandi G. Cell proliferation and ultrastructural changes of the duodenal 
mucosa of patients affected by familial adenomatous polyposis. Hum Pathol 
2004;35:622-626. 
 36.  Santucci R, Volpe L, Zannoni U, Paganelli GM, Poggi B, Calabrese C, Biasco G. Cell 
proliferation of the duodenal mucosa in patients affected by familial adenomatous 
polyposis. Gastroenterology 1997;113:1159-1162. 
 37.  Berkhout M, Gosens MJEM, Brouwer KM, Peters WHM, Nagengast FM, van Krieken 
JH, Nagtegaal ID. Loss of extracellular E-cadherin in the normal mucosa of duodenum 
and colon of patients with familial adenomatous polyposis. Hum Pathol 2006; 37: 1389-
1399. 
 
   
 
Summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
 
 140 
Summary 
  The high prevalence of duodenal adenomas in patients with FAP has been  
recognised for some time. The individual variety in age of onset and severity of 
the duodenal adenomatosis is large in patients with FAP. In contrast to the 
colorectal adenomatosis, the genotype-phenotype correlation as well as the 
exact mechanism underlying duodenal adenomatosis is much less clear for 
upper gastrointestinal manifestations in patients with FAP. Although 
duodenectomy is assumed to be an effective treatment, it is a complicated 
procedure with significant morbidity and even mortality. Moreover, after 
surgical intervention, the remaining small bowel mucosa at the choledojejunal 
anastomosis is at risk, since there are strong suggestions for a role of bile in 
FAP-associated small bowel adenomatosis. Prevention of adenoma formation 
by chemopreventive agents would be highly preferable in the management of 
the duodenal adenomatosis in patients with FAP. 
 
In Chapter 1, a general introduction is given for this thesis and its objectives 
are summarised as follows:  
1. to investigate factors that may influence the individual variety in 
duodenal adenomatosis in patients with FAP.  
2. to further elucidate the mechanisms underlying the development of 
duodenal adenomas and carcinomas in patients with FAP.  
3.  to explore the possibility of chemoprevention of duodenal 
adenomas/carcinomas in patients with FAP. 
 
In order to study interindividual variety in duodenal adenomatosis, we 
investigated in the first two chapters the role of the biotransformation 
(detoxification) enzyme families glutathione S-transferase (GST) and UDP-
glucuronosyltransferase (UGT) in the duodenum of FAP patients. These 
enzymes are important in the mucosal protection against potential mutagens 
and carcinogens. In Chapter 2, the duodenal detoxification capacity of 
patients with FAP was compared with that of control, matched for age and 
gender. GST and UGT enzyme activities and GST isoform levels were 
measured in both the normal duodenal mucosa of patients with FAP and that 
of controls. No differences were found in the detoxification enzyme levels 
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measured here. However, this study was performed on a limited number of 
patients and the assays cover only part of the GST and UGT isoenzymes 
present in the duodenum. We therefore performed a larger study, described in 
Chapter 3, where all GST and UGT genes of interest, covering all GST and 
UGT biotransformation enzymes present in the duodenum, were genotyped 
with respect to functional polymorphisms. A significant difference was found in 
the genotype distribution of UGT1A3. Patients with FAP more often have a 
genotype associated with a high UGT enzyme activity towards various 
flavonoids, which are constituents of fruits and vegetables. Consumption of 
these compounds is associated with a protection against gastrointestinal 
cancers. High UGT1A3 enzyme activity may result in a high rate of inactivating 
and excretion of flavonoids in patients with FAP compared to controls. As a 
consequence, the potential protective effect of flavonoids may be less 
pronounced in patients with FAP. Furthermore, UGT1A3 is also involved in 
steroid hormone metabolism. However, the polymorphisms investigated here 
had no predictive value for the severity of the duodenal adenomatosis in the 
patients with FAP. 
 
In order to elucidate the pathways leading to the development of duodenal 
adenomas and carcinomas in patients with FAP, we studied the normal 
mucosa as well as the changes that took place after adenoma formation. The 
distributions of E-cadherin, SMAD4 and -catenin in normal duodenal mucosa 
and adenomas in both FAP and non-FAP patients were studied as described 
in Chapter 4. Furthermore, staining of these parameters in the duodenum was 
compared to that in the colon. A significant loss of extracellular E-cadherin 
was observed in both duodenal- and colonic adenomas, as well as in normal 
tissue of patients with FAP. Loss of duodenal extracellular E-cadherin was 
associated with a younger age of the FAP patients at the moment of 
colectomy, suggesting a more severe course of the disease. Furthermore, 
nuclear localisation of -catenin was observed more often in duodenal FAP 
adenomas compared with non-FAP adenomas. Loss of nuclear SMAD4 was 
seen in the duodenum and even more in the colon of patients with FAP, as 
well as non-FAP patients. Loss of duodenal SMAD4 was correlated with a high 
Spigelman stage in patients with FAP.   
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Finally, we investigated the mechanism of development of adenocarcinomas 
in the duodenum of FAP patients by comparing the genetic makeup of both 
FAP-related and sporadic adenocarcinomas of the small bowel. In Chapter 5 
the chromosomal abnormalities and alterations in methylation of several genes 
in sporadic and FAP-related duodenal carcinomas were studied. 
Chromosomal imbalances were detected in the majority of both types of 
tumours. A significant difference in chromosomal imbalances between the 
FAP-related and sporadic tumours was seen on chromosome 12. In 60% of 
the sporadic tumours, gains in particular regions of chromosome 12 were 
observed versus none in the FAP-related tumours. Identification of the genes 
in those regions of chromosome 12 could reveal differences in tumour 
characteristics and lead to a better understanding of the carcinogenesis 
pathways leading to sporadic and FAP-related duodenal tumours. 
Hypermethylation was seen in IGSF4, TIMP3, ESR1, APC, CDH13 and PAX6. 
Hypermethylation of PAX6 was only observed in FAP-related tumours and not 
in sporadic tumours.  
 
Although duodenectomy is assumed to be an effective treatment in patients 
with FAP, it is a complicated procedure with significant morbidity and even 
mortality. Moreover, after surgical intervention, the remaining small bowel 
mucosa at the choledojejunal anastomosis is at risk. There are strong 
suggestions for a promoting role of bile in FAP-associated small bowel 
adenomatosis. Bile may be highly cytotoxic and may stimulate duodenal cell 
proliferation. Therefore, we wanted to study the effects of an intervention with 
ursodeoxycholic acid in patients with FAP. Ursodeoxycholic acid (UDC) is a 
less cytotoxic tertiary bile acid with chemopreventive potential in the treatment 
of several gastrointestinal manifestations. UDC (25mg/kg body weight daily) 
was given during three months to five patients with FAP and pre- and post- 
intervention bile was sampled from these patients (Chapter 6). Cytotoxicty of 
the UDC-enriched bile was approximately twice as low compared to the pre-
intervention bile, whereas duodenal COX-2 expression level was not 
significantly reduced. No differences in genotoxicity were observed between 
the pre- and post-intervention bile. The results of this small pilot study warrant 
a more extensive study on chemoprevention with UDC in patients with FAP. 
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Discussion 
This thesis describes investigations on several aspects of the development of 
adenomas and carcinomas in the duodenum of patients with FAP. Since FAP 
is a rare disease, most of the studies performed have included only a limited 
number of patients. Therefore, in future studies, a multi-centre approach 
should be pursued, leading to enlarged study populations and subsequently 
an increased power.  
 
Several findings in this thesis underline that mechanistical differences exist 
between the development of adenomas and carcinomas in the duodenum and 
the colon. In Chapter 2, no difference was found between the detoxification 
capacity in the duodenum of patients with FAP versus controls. In contrast, a 
lower detoxification capacity was observed in the colon of patients with FAP. 
Also the prevalence of adenomas or carcinomas and the age of onset of the 
disease differ between these two locations. Figure 2 of the introduction 
demonstrates that APC and K-ras mutations in duodenal adenomas and 
carcinomas occur relatively less frequent, whereas these mutations are 
commonly seen in colorectal cancers of patients with FAP.  
 
Mutations in the APC gene are not often found in sporadic small bowel 
carcinomas. However, sporadic duodenal tumours may also have a disturbed 
Wnt signalling pathway, possibly due to gains on chromosome 12, where the 
genes of the Wnt family are localised (Chapter 5).  
 
It is likely that the APC mutations, as often found in patients with FAP, lead to 
several cellular abnormalities as described in Figure 2 of the introduction. The 
presence of such cellular abnormalities in “normal” mucosa, in combination 
with the features of the bile, may explain the high rates in the malignant 
transformation observed in the peri-ampullary region of patients with FAP. 
Interestingly, results in Chapter 6 obtained with the duodenal bile, showed a 
possible role for UDC in the chemoprevention of duodenal adenomatosis. The 
patients with FAP reported little side effects from the high dose of UDC, which 
makes UDC a possible candidate to be applied in such studies. However the 
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exact role of the pancreatic enzymes, namely their high cytotoxicity in our test 
system, need to be further investigated.   
 
The non-significant reduction of cyclooxygenase-2 (COX-2) expression, as 
demonstrated in Chapter 6, has been shown before to be an important target 
for chemoprevention studies in patients with FAP. However, the use of specific 
and non-specific COX-2 inhibitors has been associated with upper abdominal 
bleedings and cardiovascular side effects. The patients with FAP reported little 
side effects from the high dose of UDC. Since there are many FAP patients 
with early duodenal adenomatosis, there is an urgent demand for 
chemoprevention. The lack of serious side effects makes UDC a possible 
candidate to be applied in such studies. 
 
Future perspectives 
The results with ursodeoxycholic acid (UDC) in the pilot study on patients with 
FAP are a good basis for future research. A multi-centre randomised double-
blind intervention study with UDC should be performed. Also combinations 
with UDC and other drugs should be explored e.g., specific COX-2 inhibitors 
like celecoxib, pancreas enzyme inhibitors or the flavonoids curcumin and 
quercetin, which were recently shown to have an inhibiting effect on ileal 
adenomas. In these intervention studies, regression of duodenal adenomas 
should be taken as primary end points.  
 
Future research to identity genes that are located in the regions of 
chromosome 12, which differ between sporadic and FAP-related duodenal 
carcinomas, would be interesting to further elucidate mechanistical differences 
between both tumours. Furthermore, a comparison could be made with 
respect to the hypermethylation profiles of FAP-related duodenal and 
colorectal tumours to investigate differences between these two sites. The 
relatively small studies on FAP-related duodenal tumours as performed here, 
should be extended including carcinomas of all parts of the small intestine, as 
well as tumour specimens of other high-risk patients.   
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Conclusions 
In conclusion, we believe that the chemoprevention of the duodenal 
adenomatosis in patients with FAP will become of great importance. 
Knowledge of duodenal adenomatosis is essential for the management and 
the treatment of these adenomas. This thesis provides new insights into the 
development of adenomas and carcinomas in the duodenum of patients with 
FAP. Furthermore, first results with an ursodeoxycholic acid intervention in 
patients with FAP seem promising and can hopefully provide, eventually in 
combination with other agents, a powerful chemopreventive treatment regimen 
in the future. 
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Samenvatting 
Familiaire adenomateuze polyposis (FAP) wordt veroorzaakt door mutaties in 
het adenomateuze polyposis coli (APC) gen. De ziekte kenmerkt zich door de 
ontwikkeling van honderden adenomen (poliepen) in de dikke darm. Wanneer 
de dikke darm niet preventief wordt verwijderd, is de kans op het ontwikkelen 
van dikke darmkanker bijna 100%. Ook de ontwikkeling van adenomen in de 
dunne darm (in het bijzonder het duodenum) van FAP patiënten is een groot 
probleem. Deze problematiek zal steeds meer toenemen, omdat FAP 
patiënten steeds ouder worden als gevolg van de preventieve verwijdering van 
de dikke darm. Hierdoor neemt de kans op duodenum adenomen en 
vervolgens het ontstaan van duodenum kanker aanzienlijk toe.  
 
Er is echter een grote variatie tussen FAP patiënten qua mate van de 
adenoomvorming en de leeftijd, waarop deze duodenum adenomen ontstaan. 
De plaats van de mutatie binnen het APC gen is geassocieerd met de mate 
van de ontwikkeling van adenomen in de dikke darm, maar deze relatie is 
minder duidelijk in het duodenum. Over het mechanisme van de ontwikkeling 
van adenomen in de dunne darm is weinig bekend. Het verwijderen van het 
duodenum is een effectieve behandeling voor het voorkomen van duodenum 
kanker, deze zware operatie gaat echter gepaard met een hoge morbiditeit en 
mortaliteit. Gezien het feit dat gal een rol lijkt te spelen in de ontwikkeling van 
duodenum adenomen, zou het resterende dunne darm segment (jejunum) na 
de operatie ook weer risico kunnen lopen op maligne transformatie. Daarom 
zou het een groot voordeel zijn om de duodenum adenomen van FAP 
patiënten chemopreventief te kunnen behandelen. 
 
In Hoofdstuk 1 wordt een algemene inleiding gegeven en worden de doelen 
van dit proefschrift als volgt samengevat:  
1. onderzoek naar mogelijke factoren die de variatie in de ontwikkeling 
van duodenum adenomen in FAP patiënten beïnvloeden. 
2. onderzoek naar de mechanismen die verantwoordelijk zijn voor de 
ontwikkeling van duodenum adenomen in FAP patiënten. 
3. onderzoek naar de mogelijkheden van chemopreventie van duodenum 
adenomen/ carcinomen in FAP patiënten.  
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Om de individuele variatie in de ontwikkeling van de duodenum adenomen te 
onderzoeken, worden in de eerste twee hoofdstukken de ontgiftingsenzymen 
glutathion S-transferasen (GST) and UDP-glucuronosyltransferasen (UGT) in 
het duodenum van FAP patiënten onderzocht. Deze enzymen zijn betrokken 
bij bescherming van de mucosa tegen potentiële mutagenen en carcinogenen. 
In Hoofdstuk 2 wordt de ontgiftingscapaciteit van het duodenum van FAP 
patiënten vergeleken met die van proefpersonen zonder FAP. Naast de GST 
en UGT enzymactiviteit zijn verder zijn ook vier GST isovormen 
gekwantificeerd in beide groepen. Er wordt geen verschil gevonden tussen 
FAP duodenum en controle duodenum, wat betreft de gemeten 
ontgifitingsenzymen. Het aantal FAP patiënten was echter relatief laag, terwijl 
ook maar een deel van de GSTs en UGTs is bepaald door de hier gebruikte 
methoden. We hebben daarom in Hoofdstuk 3 van een grotere groep FAP 
patiënten het genotype bestudeerd van alle belangrijke isovormen van de GST 
en UGT ontgiftingsenzymen, die aanwezig zijn in het duodenum. Er werd een 
significant verschil gevonden in de verdeling van het UGT1A3 genotype. De 
FAP patiënten hebben vaker het UGT1A3 genotype, dat geassocieerd is met 
een verhoogde enzymactivieit ten opzichte van flavonoïden. Flavonoïden 
komen voor in groente en fruit en ze lijken een beschermende werking te 
hebben tegen de ontwikkeling van verschillende kankers van het 
maagdarmkanaal. Als gevolg van het snelle genotype worden de flavonoïden 
sneller geïnactiveerd in FAP patiënten. Dit zou er toe kunnen bijdragen dat 
deze patiënten minder baat hebben bij de beschermende werking van 
flavonoïden. Verder zijn de UGT1A3 enzymen ook betrokken bij de steroïd 
hormoon huishouding. Deze onderzochte polymorfismen blijken echter geen 
voorspellende waarde voor de ontwikkeling van duodenum adenomen te 
hebben. 
 
Om het mechanisme van de ontwikkeling van adenomen en carcinomen in het 
duodenum van FAP patiënten te bestuderen, hebben we bepaalde 
eigenschappen van de normale mucosa vergeleken met die van adenomen. In 
Hoofdstuk 4 is er gekeken naar de aankleuring van E-cadherine, -catenine 
en SMAD4 in normaal en adenomateus duodenum weefsel van FAP en niet-
FAP patiënten. Ook zijn de aankleuringspatronen in het duodenum vergeleken 
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met de dikke darm. Er is een significant verlies gevonden van extracellulair E-
cadherine in adenomen en normaal weefsel van zowel het duodenum als de 
dikke darm van patiënten met FAP. Dit verlies is geassocieerd met een 
(jongere) leeftijd, waarop de colectomie is uitgevoerd, wat op een ernstiger 
fenotype zou kunnen duiden. -catenine bevindt zich vaker in de celkernen in 
FAP adenomen vergeleken met niet-FAP adenomen. In zowel FAP als niet-
FAP patiënten werd een verlies van nucleair SMAD4 gevonden in het 
duodenum en zelfs nog meer in de dikke darm. In het duodenum was dit 
verlies van SMAD4 geassocieerd met een hoger Spigelman stadium, m.a.w. 
een meer ernstigere vorm van duodenum adenomen. 
 
Als laatste hebben we gekeken naar de ontwikkeling van carcinomen, door de 
genetische opmaak van sporadische duodenumcarcinomen te vergelijken met 
die van FAP-gerelateerde carcinomen. Daarom zijn in Hoofdstuk 5 
chromosomale afwijking en veranderingen in de methylering van verschillende 
genen bestudeerd, in zowel sporadische als FAP-gerelateerde 
duodenumcarcinomen. In de meeste tumoren werden chromosomale 
afwijkingen gevonden. Vooral interessant is het significante verschil tussen 
sporadische en FAP-gerelateerde carcinomen met betrekking tot chromosoom 
12. In 60% van de sporadische carcinomen werd een amplificatie gevonden in 
bepaalde gebieden op chromosoom 12, terwijl in de FAP-gerelateerde 
carcinomen deze afwijkingen nooit werden gevonden. Het identificeren van de 
genen, die zich in deze gebieden bevinden, zou daarom tot meer kennis 
kunnen leiden over de ontwikkeling van zowel sporadische als FAP-
gerelateerde carcinomen. Ook werd hypermethylatie van de genen IGSF4, 
TIMP3, ESR1, APC, CDH13 en PAX6 in de duodenumcarcinomen gevonden. 
Hypermethylatie van het gen PAX6 werd alleen gezien in de FAP-gerelateerde 
carcinomen.  
 
Gal lijkt een rol te spelen bij de formatie van adenomen in het duodenum van 
FAP patiënten, onder meer omdat deze adenomen vooral rondom de papil 
van Vater (galafvloed) geconcentreerd zijn. Het veranderen van de 
galsamenstelling (minder cytotoxisch maken) is een mogelijke vorm van 
chemopreventie. Ursodeoxycholzuur (UDC) is een weinig cytotoxisch tertiair 
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galzuur met chemopreventieve eigenschappen. Daarom hebben we in 
Hoofdstuk 6 onderzocht of een hoge dosis van UDC wordt verdragen door 
FAP patiënten, die geen dikke darm meer hebben. Gedurende 3 maanden zijn 
vijf patiënten behandeld met UDC (25 mg/kg eenmaal daags). De cytotoxiciteit 
en genotoxiciteit zijn gemeten van de gal, die voor en na de interventieperiode 
verzameld is. Uit deze studie blijkt dat UDC goed wordt verdragen door FAP 
patiënten en dat hun gal aanzienlijk is verrijkt met dit tertiaire galzuur. Na hitte 
inactivatie van de pancreasenzymen, die ook aanwezig zijn in duodenum gal, 
bleek de cytotoxiciteit van de gal na de interventie significant lager dan voor 
de interventie. Ook bleek de cyclooxygenase-2 (COX-2) expressie, een 
sleutelenzym voor de regulering van de celdeling, verminderd na de UDC 
interventie (niet-significant). De genotoxiciteit bleek niet verschillend tussen de 
gal van voor en na de UDC interventie. De resultaten van deze kleine pilot 
studie zijn interessant genoeg om UDC te testen als een chemopreventief 
middel in een grotere groep FAP patiënten. 
 
Discussie 
In dit proefschrift worden verschillende studies beschreven met betrekking tot 
de ontwikkeling van adenomen en carcinomen in het duodenum van FAP 
patiënten. FAP is een zeldzame aandoening, in Nederland zijn ongeveer 600 
patiënten bekend. Dit is meteen de reden dat de studies in dit proefschrift vaak 
op een klein aantal patiënten zijn gebaseerd. Toekomstig onderzoek m.b.t. 
FAP patiënten zou daarom ook gebaat zijn bij een multi-center aanpak, 
hierdoor zouden grotere patiënten populaties bestudeerd kunnen worden, 
waardoor de statistische power vergroot zou worden.  
  
Meerdere bevindingen uit dit proefschrift wijzen op een verschillend 
mechanisme van adenoomvorming in het duodenum ten opzichte van dat in 
de dikke darm. In Hoofdstuk 2 werd geen verschil gevonden in de 
ontgiftingscapaciteit van het duodenum van FAP patiënten ten opzichte van 
controles, terwijl dat eerder wel in de dikke darm werd gevonden. Verder is er 
ook een verschil tussen deze twee locaties in de prevalentie van adenomen 
en carcinomen en de leeftijd waarop de adenoomvorming begint. Figuur 2 uit 
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de Introductie laat zien dat APC en K-ras mutaties minder vaak voorkomen in 
het duodenum van FAP patiënten in vergelijking met de dikke darm. 
 
APC mutaties worden minder vaak gevonden in sporadische dunne darm 
carcinomen. Mogelijk hebben sporadische duodenum carcinomen echter toch 
een verstoring in de Wnt signaalroute door de gevonden amplificaties in de 
regio’s op chromosoom 12, waar de genen van het WNT signaalroute zich 
bevinden (Hoofdstuk 5). 
 
Het is aannemelijk dat de APC mutaties, zoals die vaak in FAP patiënten 
gevonden worden, leiden tot de cellulaire afwijkingen, zoals beschreven in 
Figuur 2 van de introductie. Vooral de afwijkingen die zich al in “normale” 
mucosa bevinden, zouden in combinatie met meer cytotoxische gal, een 
verklaring kunnen zijn voor het hoge risico van FAP patiënten op een maligne 
transformatie in het gebied rond de papil van Vater. Uit Hoofdstuk 6 blijkt 
echter ook dat de pancreasenzymen uit duodenumgal een hoge cytotoxiciteit 
vertonen met onze meetmethode. Onduidelijk is daarom nog in hoeverre deze 
pancreasenzymen cytotoxisch zijn in vivo en daarom lijkt het zinvol om de rol 
van pancreasenzymen in de ontwikkeling van adenomen verder uit te zoeken. 
 
De niet-significante vermindering van COX-2 expressie in het duodenum, 
zoals te zien in Hoofdstuk 6, kan ook een belangrijk aangrijpingspunt zijn voor 
chemopreventie studies bij FAP patiënten. Het gebruik van specifieke en 
aspecifieke COX-2 remmers is echter geassocieerd met een hoger risico op 
bloedingen in het maagdarmkanaal en ook op cardiovasculaire bijwerkingen. 
Het gebruik van een hoge dosis van UDC leidde echter tot weinig bijwerkingen 
bij de FAP patiënten. Er zijn veel FAP patiënten met een beginnende vorm 
van adenoomvorming, waardoor een chemopreventief middel erg gewenst is. 
UDC zou, eventueel in combinatie met andere geneesmiddelen, een goede 
kandidaat kunnen zijn voor chemopreventie studies in FAP patiënten.  
 
Toekomstig onderzoek 
De resultaten van de pilot studie met UDC bij FAP patiënten zijn een goede 
basis voor toekomstig onderzoek. Daarom zou een multi-center, 
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gerandomiseerde dubbel-geblindeerde interventie studie moeten worden 
uitgevoerd, waarin verschillende combinaties geneesmiddelen samen met 
UDC zouden moeten worden getest: bijv. de specifieke COX-2 remmer 
celecoxib, remmers van pancreasenzymen of de flavonoïden curcumine en/of 
quercitine. Deze flavonoïden hebben recent een remming van de 
adenoomgroei in het ileum laten zien. In deze interventie studies zou de 
regressie van duodenum adenomen als primair eindpunt moeten worden 
genomen. 
  
Verder onderzoek naar de verschillen in genen op chromosoom 12, zoals te 
vinden in sporadische en FAP-gerelateerde duodenumcarcinomen, zou het 
mechanisme achter de carcinoomvorming meer kunnen verhelderen. Omdat 
hypermethylering van genen een belangrijke rol kan spelen in het onstaan van 
carcinomen, zou een meer uitgebreide vergelijking moeten worden gemaakt 
tussen de hypermethyleringsprofielen van dunne darm en dikke darm 
carcinomen. De relatief kleine studies van FAP-gerelateerde 
duodenumcarcinomen zoals beschreven in dit proefschrift, zouden uitgebreid 
moeten worden met carcinomen van alle delen van de dunne darm en ook 
met tumoren van andere patiënten groepen, die een verhoogd risico hebben 
op het ontstaan van dunne darm kanker. 
 
Conclusies 
Adenoom- en carcinoomvorming in het duodenum van FAP patiënten zal met 
het toenemen van de leeftijd van deze patiënten een steeds groter probleem 
worden. Kennis over het mechanisme van deze adenoom- en 
carcinoomvorming is essentieel voor de behandeling van deze tumoren. Dit 
proefschrift geeft nieuwe inzichten in de ontwikkeling van adenomen en 
carcinomen in het duodenum van FAP patiënten. Chemopreventie zou de 
behandeling van de toekomst kunnen worden en de eerste resultaten van de 
ursodeoxycholzuur interventie in FAP patiënten lijken veelbelovend. 
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